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KURZZUSAMMENFASSUNG 
Aromatische [
18
F]Fluoraminosäuren sind als vielversprechende Radiodiagnostika für die 
Positronen-Emissions-Tomographie entwickelt worden. Eine breitere Anwendung dieser radio-
fluorierten Verbindungen ist jedoch aufgrund der bisher notwendigen aufwändigen Radiochemie 
eingeschränkt. In dieser Arbeit wurde eine vereinfachte, dreistufige Radiosynthese von 2-[
18
F]Fluor-L-
phenylalanin (2-[
18
F]Fphe), 2-[
18
F]Fluor-L-tyrosin (2-[
18
F]Ftyr), 6-[
18
F]Fluor-L-m-tyrosin (6-
[
18
F]Fmtyr) und 6-[
18
F]Fluor-L-DOPA (6-[
18
F]FDOPA) entwickelt. Dazu wurden entsprechende 
Vorläufer durch einen nukleophilen Isotopenaustausch
 18
F-fluoriert, die entweder durch Entfernen der 
aktivierenden Formylgruppe mit Rh(PPh3)3Cl oder durch deren Umwandlung mittels Baeyer-Villiger 
Oxidation und anschließend durch saure Hydrolyse in die entsprechenden aromatischen 
[
18
F]Fluoraminosäuren überführt wurden. 
Zwei effiziente synthetische Ansätze wurden für die Synthese von hoch funktionalisierten Fluor-
benzaldehyden und -ketonen entwickelt, die als Vorläufer benutzt wurden. Die Verbindungen (2S,5S)-
tert-Butyl-2-tert-butyl-5-(2-fluor-5-formylbenzyl)-3-methyl-4-oxoimidazolidin-1-carboxylat (1a), (2S, 
5S)-tert-Butyl-5-(5-acetyl-2-fluorbenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidin-1-carboxylat (1c), 
(2S,5S)-Benzyl-2-tert-butyl-5-(2-fluor-5-formylbenzyl)-3-methyl-4-oxoimidazolidin-1-carboxylat 
(1d), 4-Fluor-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)me-thyl)benzaldehyd 
(1e) und 1-(4-Fluor-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)phenyl)-
ethanon (1f) konnten in sechs Schritten und in einer Gesamtausbeute von 41%, 48%, 37%, 27% und 
32% hergestellt werden. (2S,5S)-tert-Butyl-5-(4-(benzyloxy)-2-fluor-5-formylbenzyl)-2-tert-butyl-3-
methyl-4-oxoimidazolidin-1-carboxylat (1b) wurde in zehn Schritten mit einem Gesamtausbeute von 
19% synthetisiert, während die Verbindungen (2S,5S)-tert-Butyl-5-(5-(3,5-bis(trifluormethyl)-benzo-
yl)-2-fluorbenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidin-1-carboxylat (1g) und (2S,5S)-tert-butyl-
tert-butyl-5-(2-fluor-5-(2,2,2-trifluoracetyl)benzyl)-3-methyl-4-oxoimidazolidin-1-carboxylat (1h) 
durch ein neues dreistufiges Verfahren in Ausbeuten von 54 % und 40 % erhalten wurden. Alle 
Verbindungen wiesen eine hohe Diasteromerenreinheit von > 99% auf. 
Die Vorläufer 1a, 1d und 1e wurden unter Anwendung einer Decarbonylierungsreaktion für die 
Synthese von 2-[
18
F]Fphe eingesetzt, während 1b für die von 2-[
18
F]Ftyr verwendet wurde. Die 
Radiosynthesen konnten entweder unter konventioneller Erhitzung oder über Mikrowellenheizung 
durchgeführt werden. Konventionelle Heizung erbrachte die gewünschten Produkte 2-[
18
F]Fphe und 2-
[
18
F]Ftyr in radiochemischen Ausbeuten (RCA) von 43% und in 49%, während RCA von 34% und 
43% über Mikrowellenheizung erzielt wurden. Mit der letzten Methode konnten jedoch 38 min der 
Gesamtsyntheseszeit gespart und somit vergleichbare Produktaktivitäten erhalten werden. Der 
Enantiomerenüberschuß für 2-[
18
F]Fphe war 88%, während im Fall von 2-[
18
F]Ftyr 92% erreicht 
wurden. 
6-[
18
F]Fmtyr wurde aus dem Seebach-Vorläufer 1c in 13 % Gesamt-RCA mit hoher Enan-
tiomerenreinheit von > 93% gewonnen. Eine vergleichbare Gesamt-RCA von 11 % an 6-[
18
F]Fmtyr 
wurde mit Schöllkopf-Vorläufer 1f erzielt, während die Enantiomerenreinheit in diesem Fall nur bei 
87 % lag. Über den 
18
F-für-
19
F Austausch an den Vorläufern 1g und 1h konnten relativ hohe RCA 
erzielt werden, hingegen nur niedrigere bei der Baeyer-Villiger Oxidation. So wurde 6-[
18
F]Fmtyr 
ausgehend von 1g und von 1h mit einer Gesamt-RCA von nur 6% und 13% gewonnen. Die 
Enantiomerenreinheit des Endprodukts unter Verwendung beider Vorläufer war jedoch > 98%. 
Die auf einer früheren Arbeit basierende nukleophile Radiosynthese von 6-[
18
F]FDOPA mittels 
Isotopenaustausch konnte durch Anpassung vieler Parameter weiter optimiert werden, so dass ca. 40% 
RCA bei einer hohen Enantiomerenreinheit von > 96% erzielt werden konnte. Die spezifische 
Aktivität der hier unter Entwicklungsbedingungen dargestellten [
18
F]Fluoraminosäuren war mit der 
durch elektrophile Methoden erreichten vergleichbar. Außerdem konnte in ersten Untersuchungenden 
demonstriert werden, dass die Automatisierung der dreistufigen Radiosynthese grundsätzlich 
durchführbar ist, jedoch weitere technische Entwicklungen erforderlich sind.   
  
  
ABSTRACT 
Aromatic [
18
F]fluoroamino acids have earlier been developed as promising probes for diagnostics 
using PET. However, a wider use of these radiofluorinated compounds has been limited due to 
radiosynthetic constraints. The work here presents an amenable three-step radiosynthesis pathway for 
the preparation of 2-[
18
F]fluoro-L-phenylalanine (2-[
18
F]Fphe), 2-[
18
F]fluoro-L-tyrosine (2-[
18
F]Ftyr), 
6-[
18
F]fluoro-L-m-tyrosine (6-[
18
F]Fmtyr) and 6-[
18
F]fluoro-L-DOPA (6-[
18
F]FDOPA). For this, 
corresponding precursors were 
18
F-fluorinated by nucleophilic isotopic exchange, followed by either 
removal of an activating formyl group with Rh(PPh3)3Cl or its conversion by Baeyer-Villiger 
oxidation, respectively, and subsequent hydrolysis of protecting groups in acidic medium.  
Two efficient synthetic approaches were developed for the preparation of highly functionalized 
fluoro-benzaldehydes and -ketones which were used as labeling precursors. The compounds (2S,5S)-
tert-butyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (1a), 
(2S,5S)-tert-butyl 5-(5-acetyl-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate 
(1c), (2S,5S)-benzyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-4-oxoimidazolidine-1-carbo-
xylate (1d), 4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)me-thyl)benzal-
dehyde (1e) and 1-(4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)me-
thyl)phenyl)ethanone (1f), could be prepared in six steps and overall yields of 41%, 48%, 37%, 27%, 
and 32%, respectively. (2S,5S)-tert-Butyl 5-(4-(benzyloxy)-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-
methyl-4-oxoimidazolidine-1-carboxylate (1b) was prepared in ten steps with an overall yield of 19% 
while compounds (2S,5S)-tert-butyl 5-(5-(3,5-bis(trifluoromethyl)-benzoyl)-2-fluorobenzyl)-2-tert-
butyl-3-methyl-4-oxoimidazolidine-1-carboxylate (1g) and (2S,5S)-tert-butyl 2-tert-butyl-5-(2-fluoro-
5-(2,2,2-trifluoroacetyl)benzyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (1h) were synthesized by 
a novel three-step procedure in 54% and 40%, respectively. All compounds were obtained with high 
diasteromeric purity of > 99%. 
Corresponding precursors 1a, 1d, and 1e were used for the radiosynthesis of 2-[
18
F]Fphe while 1b 
was employed for 2-[
18
F]Ftyr making use of a decarbonylation reaction. The radiosyntheses were 
performed either under conventional or microwave heating. The conventional heated reactions yielded 
the desired products 2-[
18
F]Fphe and 2-[
18
F]Ftyr in 43% and 49% whereas 34% and 43% RCY, 
respectively, were obtained when microwave heating was applied. However, 38 min of total 
preparation time were saved with the latter method, thus providing similar amounts of product activity. 
The enantiomeric excess achieved for 2-[
18
F]Fphe was 88% while in the case of 2-[
18
F]Ftyr 92% was 
obtained.  
6-[
18
F]Fmtyr was prepared from the Seebach-precursor 1c in 13% overall RCY with a high 
enantiomeric purity of > 93%. A comparable overall RCY of 11% of 6-[
18
F]Fmtyr was achieved with 
the Schöllkopf-precursor 1f while the enantiomeric purity in this case was only 87%. Precursors 1g 
and 1h showed a relative high RCY of the 
18
F-for-
19
F substitution, but a low one in the Baeyer-Villiger 
oxidation. Thus from 1g and 1h, 6-[
18
F]Fmtyr was obtained with an overall RCY of only 6% and 13%, 
respectively. However, the enantiomeric purity of the product using both precursors was > 98%.  
Based on earlier attempts the nucleophilic radiosynthesis of 6-[
18
F]FDOPA by isotopic exchange 
could also be optimized by changing many parameters from the previous work providing ca. 40% 
RCY and a high enantiomeric purity of > 96%. The specific activity of the tracers prepared here under 
developmental conditions was as high as that achieved by electrophilic methods. Furthermore, in 
preliminary studies it could be demonstrated that the automation of the three-step radiochemical 
synthesis developed here is principally feasible but requires further technical maturation. 
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1 INTRODUCTION 
1.1 Basic aspects of positron emission tomography  
Positron emission tomography (PET) is a non-invasive molecular imaging technique that 
has the ability to monitor physiologic processes in living beings. PET relies on the use of 
exogenous radioactive probes (radiotracers) which emit a detectable photon signal. Imaging 
techniques such as magnetic resonance imaging (MRI), X-rays, or ultrasound (US) provide 
valuable information on anatomy (namely, structural imaging), but give limited or no 
information at all on metabolic or molecular events. Therefore, for the in vivo detection of 
diseases in patients, these imaging methods are restricted to those malfunctions associated 
with structural abnormalities.  
A positron emitter is an unstable atom bearing an excess of protons in its nucleus. The 
nucleus gets stabilized by the conversion of one proton in a neutron under emission of a 
positron and a neutrino (Scheme 1). The emitted positron (β+) is slowed down in the tissue by 
collisions. After thermalization at the end of the track a positronium, a hydrogen-like atom, is 
formed by the positron and an electron. The positron and electron are antiparticles, so they 
annihilate each other. In the annihilation process, two γ photons of 511 keV are generated 
(annihilation radiation), these photons travel in opposite direction forming 180° angle. 
Contrary to the β+-emission, and because of their penetration power, these two γ photons can 
travel outside the body where scintillation crystals can detect them. If two photons arrive at 
opposite detectors within a certain coincidence time, they will be registered as a valid event 
and the position where the annihilation took place can be located on the line between the 
detectors (Figure 1). This is one major advantage of PET because noise from incidental 
radiation is minimized. The spatial resolution of the images is high since it is just limited by 
the distance the positron needs to become thermalized. This is only few millimeters for 
suitable positron emitters.
1
  
18
F                
18
O + β+ + υ 
Scheme 1:  Decay of fluorine-18 by positron emission 
Uncertainties based on adsorption and scattering radiation effects can be avoided by 
applying an attenuation correction, which is developed by an accurate independent 
transmission measurement. For this purpose a 
68
Ge source is generally used before the real 
2 
tracer is injected. By this procedure, the distribution of radioactivity in the object tissues can 
be precisely quantified,
2
 which is the most important advantage of this methodology and 
justifies the application of corpuscular emitters in the living body.  
 
Figure 1: Schematic representation of the principle of PET.
 3
 
In order to gain quantitative medicinal relevant information from the distribution of the 
radioisotope in the body, the temporal and local change of the radiotracer has to be combined 
with a suitable bio-mathematical compartment model describing the pharmacokinetic 
behavior of the pharmaceutical.
4
 In a typical molecular assay, a positron-labeled probe is 
injected intravenously, and PET scans provide measures of the tissue concentration of the 
probe and labeled products over time. These data are combined with a measure of the time 
course of the plasma probe concentration, representing its delivery to tissue, and processed 
with a compartmental model containing equations describing the temporal change in the 
individual compartments, transport and reaction processes the probe undergoes. The result is 
an image of the rate of the process under study.  
Since some of the positron-emitting radionuclides are elements found in biomolecules 
(for example, C, N, and O) it is possible to label compounds of interest authentically, i.e. 
without a change of composition or structure interfering with their biological activity. Table 1 
lists the most commonly used short-lived positron emitters, typically used nuclear reactions 
for its production, and its main physical-chemistry characteristics.
3
 It can be noticed that the 
half-lives are quite small which is also an additional advantage since the patients are exposed 
to relatively low radiation doses and studies can be repeated in short time intervals if needed. 
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PET radionuclides can be produced with the help of a particle accelerator, generally a 
cyclotron. Radionuclides generated by this way show in general a high specific activity if 
stable material of the radionuclide produced is excluded. The term specific activity refers to 
the ratio of the amount of activity per mass of material. High specific activities allow to work 
with samples whose mass is so small that it can be neglected. Because of that it is possible to 
evaluate a biological process without disturbing it. Furthermore, toxicological and/or 
immunological effects are not an issue. 
Table 1: Commonly used radionuclides in PET, their half-lives, production reactions, 
target materials, products and decay products
3
 
Radionuclide T1/2 (min) Nucl. Reaction Target Product Decay product 
11
C 20.4 
14N(p,α)11C N2(+O2) 
N2(+H2) 
[
11
C]CO2 
[
11
C]CH4 
11
B 
13
N 9.97 
16O(p,α)13N H2O 
H2O + EtOH 
[
13
N]NOx 
[
13
N]NH3 
13
C 
15
O 2.04 
15
N(d,n)
15
O N2(+O2) [
15
O]O2 
15
N 
18
F 110 
20Ne(d,α)18F 
18
O(p,n)
18
F 
Ne(+F2) 
[
18
O]H2O 
[
18
O]O2(+F2)  
[
18
F]F2 
[
18
F]F
- 
[
18
F]F2
 
18
O 
 
 The short half-live of the above mentioned radionuclides requires the development of 
rapid synthetic methods for introducing them into the molecule of interest. The labeled 
compound has to be synthesized, purified, analyzed, and formulated usually within minutes. 
A timescale of roughly three isotope half-lives is loosely the limit for the total synthesis time 
allowed in order to obtain enough radiolabeled material for administration to a person 
undergoing the PET scan. Radiotracers should be designed in such a way that they arrive 
unchanged at the place of interest and provide a detailed picture of the targeted molecular 
structure or biological processes under study. Probes are synthesized with very low mass so as 
not to exert mass effects on the biological processes measured. Common tissue concentrations 
of PET probes are in the range of pico- to femtomoles per gram.
5
 A number of modern PET 
facilities house cyclotrons (for radioisotope production), radiosynthetic laboratories, and PET 
scanners under one roof to allow efficient production and provision of short-lived PET probes 
to the scanner. 
4 
A further development in scanner technology has been the integration of PET with 
anatomical imaging techniques such as CT and MRI into one device. The combined PET/CT 
and PET/MRI techniques allow matching of functional information on the PET image to the 
detailed anatomical images from CT or MRI scans (Figure 2). 
 
Figure 2: Images of the brain obtained using magnetic resonance tomography (left) and 
positron emission tomography (right) upon injection of [
18
F]FDG which are 
combined in a fusion picture (middle). Image: Forschungszentrum Jülich
6
 
PET has been widely used in oncology
7,8
 for the diagnosis of tumors by looking at the 
accumulation and metabolism of certain PET probes within the tumor. In the field of 
cardiology,
9,10,11
 PET has been developed as a clinical tool for myocardial perfusion imaging 
as a means of characterizing and diagnosing coronary heart disease. In neurology,
12,13,14
 have 
been employed for the characterization of early stages of neurological disorders (such as 
Alzheimer‟s and Parkinson‟s disease), abnormal neurotransmitter activity, movement 
disorders, stroke, epilepsy, and neurooncology. It is expected that PET -as an in vivo 
pharmacological imaging tool- will play an increasingly important role in drug 
development.
15,16,17
 It is anticipated that PET studies will improve the selection of potential 
drug candidates at an earlier stage of development, give a proof of principle or a greater 
understanding of a drugs mechanism of action, and an aid in guiding dose selection.
3
 
1.2 18F-Radiofluorination of organic molecules 
Fluorine-18 is the most often used radionuclide for diagnostics with PET. The relatively 
long half-life of 
18
F (T1/2 = 109.8 min) possess less constraints on synthesis time and permits 
longer imaging protocols to investigate processes of slower tracer kinetics up to about 6 h.
18
 
The low kinetic energy of the positron particle emitted by the 
18
F during nuclear decay, with a 
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maximum energy of 650 keV (mean energy of 250 keV), and a maximum range in water of 
2.4 mm (mean range 0.3 mm) prior to annihilation, translates into a high spatial image 
resolution.
19
 The relatively long half-life of fluorine-18 also permits the distribution of 
18
F-
radiopharmaceuticals to clinical services located within a few hours of transport.  
Most of the established synthetic methods for radiofluorination of organic molecules 
follow the general concepts of fluoro-organic chemistry like electrophilic and nucleophilic 
substitution. The short half-live, non-equimolar reactions with 
18
F-reagents in the nanomolar 
range, and the limited availability of those reagents on a no-carrier-added (n.c.a.) scale, often 
limit labeling possibilities and require special techniques like labeling through secondary 
compounds. In addition, recently even an enzymatic fluorination method has been reported in 
order to achieve fast and specific labeling.
20
  
1.2.1 Electrophilic fluorination 
Direct electrophilic substitution is a strategy that has been established for the labeling of 
compounds with unsaturated bonds. The most common chemical form of the radioactive 
starting material is [
18
F]F2. Nowadays, [
18
F]F2 is generally produced in two steps by the 
18
O(n,p)
18
F nuclear reaction on 
18
O2 in gaseous form followed by the addition of carrier F2.
21
 
The addition of carrier leads to a low specific activity of the labeled products, furthermore, the 
maximum radiochemical yield (RCY) that can theoretically be obtained is 50% since only one 
atom of [
18
F]F2 reacts with the labeling precursor. Due to the high reactivity of molecular 
fluoride, reactions should be performed at low temperatures in order to reduce the formation 
of undesired side reactions. Other electrophilic reagents formed from [
18
F]F2 with a somewhat 
lower reactivity, like [
18
F]CH3COOF and [
18
F]XeF2, have been also employed. Moreover, the 
electrophilic pathway is limited to relatively low amounts of radioactive product at elevated 
cost. Furthermore, the methodology for the generation of electrophilic radiofluorination 
species is not established in every PET centre. 
In order increase the regioselectivity in arenes, demetallation reactions of organometallic 
precursors were introduced. Suitable organometallic precursors are aryltrimethyltin, 
aryltrimethylgermanium and aryltrimethylsilicon compounds.
22,23
 Experiments performed on 
a series of p-substituted phenyl derivatives (CH3O-, CH3-, H-, F-, Br-, CF3-, O2N-), showed a 
decrease in the fluorodemetallation yield in the order Sn > Ge > Si, and with rings containing 
electron-withdrawing groups (Scheme 2). It was also observed that the only side-products 
which were formed from the corresponding metallated anisyl- and toluyl-compounds were 2-
6 
fluoroanisole (< 16%) and benzylfluoride (< 5.5%). Moreover, no direct hydrogen 
substitution was observed with the other substrates.  
M(CH3)3
R
18F
R
[18F]F2
[18F]CH3CO2F
R= OCH3, CH3, H, F, Br, CF3, NO2
M= Si, Ge, Sn
 
Scheme 2:   Electrophilic radiosynthesis of [
18
F]fluoroarenes via [
18
F]fluorodemetallation 
reactions
23 
1.2.2 Nucleophilic substitution 
Nucleophilic substitution with [
18
F]fluoride is considered the most attractive method for 
the synthesis of 
18
F-labeled radiopharmaceuticals, since [
18
F]fluoride is rather easily available 
with both, high activity and specific activity through the 
18
O(p,n)
18
F reaction on 
18
O-enriched 
water using a cyclotron. The [
18
F]fluoride obtained in aqueous solution is poorly reactive due 
to high hydratation, for this reason, further treatment of the radioactive solution is necessary 
in order to enhance its reactivity.  
The first step consist on the separation of the [
18
F]fluoride from the relatively expensive 
18
O-enriched water and solubilization in an organic solvent. This is generally achieved by 
adsorption of [
18
F]fluoride onto an ion exchange resin allowing the recovery of the 
18
O-
enriched water, followed by elution of the radioactive species with a small volume of an 
aqueous weak base. The water is then removed by azeotropic evaporation with acetonitrile. 
Alternatively the [
18
F]fluoride can electrochemically be isolated from the 
18
O-enriched target 
water on an electrode in an electrochemical cell.
24
 Rinsing of the electrode with a dry organic 
solvent is enough for drying and the [
18
F]fluoride is then released into an aprotic reaction 
medium by inversion of the voltage in the cell. 
Although alkali metal fluorides have traditionally been used for nucleophilic substitution, 
fluorination with these reagents is known to proceed only with strong activation and under 
vigorous conditions due to their limited solubility in organic solvents and low nucleophilicity. 
As an alternative, a “naked” fluoride ion, which is not solvated by bulky cations or solvent 
molecules, is usually used to improve these reactions. This is achieved using a phase transfer 
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catalyst (PTC) as anion activator in dipolar aprotic solvents. The most commonly employed 
anion activator system is the combination of the aminopolyether Kryptofix 2.2.2 as PTC and 
potassium carbonate as base. This system was originally developed for the radiosynthesis of 
17-[
18
F]fluoroheptadecanoic acid
25
 and then directly transferred with great success to the 
radiosynthesis of 2-[
18
F]fluorodeoxyglucose (FDG).
26
 For base sensitive molecules 
tetrabutylammonium hydrogencarbonate or Kryptofix 2.2.2 in combination with a potassium 
oxalate/carbonate mixture have effectively been used.
27,28,29
 The basic features of the principal 
radiofluorination methods have been already reviewed.
30
 
Radiofluorination by substitution can be performed both on aliphatic (SN2) and aromatic 
compounds (SNAr). The typical method for introducing [
18
F]fluoride at a specific site of an 
aliphatic molecule is the nucleophilic displacement of the corresponding halides (Br, I) and 
sulphonyl esters such as triflate, mesylate, tosylate or nosylate. Typical media for 
18
F-
fluorination involve dipolar aprotic solvents, with acetonitrile the most used one, at 
temperatures around 80 °C. The basic character of the reaction mixture can play a role in 
possible competitive elimination reactions. Recently, Kim et al.
31
 demonstrated the use of 
protic solvents with a very low pKb value, such as tertiary alcohols, for the routine production 
of 
18
F-tracers via nucleophilic reactions. 
On the other hand, common leaving groups for SNAr are F, NO2 and NMe3
+
, with a pre-
requisite of activation of the arene by electron withdrawing groups at the ortho or para 
position to the leaving group, such as carbonyl, CF3, NO2 or cyanide. Aromatic nucleophilic 
18
F-fluorination reactions require higher temperatures than with aliphatic compounds. 
Therefore, solvents with higher boiling points like dimethylformamide
 
(DMF) and 
dimethylsulfoxide (DMSO) are preferred. The application of this labeling methodology for 
the 
18
F-fluorination of complex molecules has recently been reviewed by Ermert and 
Coenen.
32
  
As mentioned above, synthetic methods for the preparation of [
18
F]fluoroaromatic 
compounds rely on the use of activated aryl groups. This, however, limits the range of 
[
18
F]fluoroaromatic compounds available from simple one-step methods to those arenes 
which bare electron-withdrawing substituents. Direct nucleophilic 
18
F-fluorination of electron 
rich arenes for producing n.c.a. radiopharmaceuticals requires the generation of an 
electrophilic center.
33
 The use of iodonium salts is an extremely useful alternative to achieve 
this goal even with electron-donating substituents in good RCY. The first use of iodonium 
8 
salts as a general route for the n.c.a. synthesis of non-activated [
18
F]fluoroaromatic 
compounds with high specific activity was reported by Pike and Aigbirhio.
34
  
The regioselectivity of this reaction was found to be controlled electronically as well as 
sterically e.g. by bulky ortho substituents (ortho effect). The ortho effect can be a dominant 
factor for the site of the preferential nucleophilic attack where the electron-rich ring is 
fluorinated. Ortho-substituted aryl fluorides can be selectively produced by using 
unsymmetric diaryl iodonium salts. The use of heteroaromatic iodonium salts containing the 
electron-rich 2-thienyl ring has been reported as efficient for completely directing the 
nucleophilic 
18
F-substitution to the less electron-rich aryl ring (Scheme 3).
35
 
I+ S
R
X-
[K222]18F
18F
R
+
SI
R= 2-OCH3, 3-OCH3, 4-OCH3, 4-CH3, 4-OBn, H, 4-I, 4-Br, 4-Cl
X= Br, I, OTs, OTf  
Scheme 3:  Nucleophilic substitution of heteroaromatic aryliodonium salts
35 
1.2.3 Labeling through secondary compounds 
Not all fluorine-containing target radiotracers are amenable to direct single-step labeling 
with [
18
F]fluoride ion; this is especially true for electron-rich arenes and for macromolecules. 
A useful strategy for obtaining 
18
F-labeled tracers is to prepare secondary compound (a 
labeling agent) from [
18
F]fluoride and use it for the introduction of fluorine-18 into the target. 
Such labeling agents may be aliphatic or aromatic and the targets complex molecules with 
low molecular weight or macromolecules.  
An important class of labeling agents are the functionalized straight chain aliphatic 
[
18
F]fluorides, prepared from the reaction of [
18
F]fluoride ion with α,ω-bifunctional agents 
(Scheme 4).
36,37,38
 The most widely used are the short chain [
18
F]ω-fluoroalkyl agents, 
especially [
18
F]fluoromethyl bromide,
39,40
 and 2-[
18
F]fluoroethyl tosylate (Scheme 4).
41,42 
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TsO
OTs
[K222]18F 18F
OTs
CH2Br2
[K222]18F CH2Br
18F
ACN
ACN  
Scheme 4:  Radiosynthesis of [
18
F]fluoromethyl bromide
39
 and 2-[
18
F]fluoroethyl tosylate
41 
 [
18
F]Fluoromethyl bromide can be prepared from dibromomethane and purified by vapor 
phase transfer (in carrier nitrogen) through several Sep-Pak columns, before reaction with a 
precursor to obtain the target tracer by O- or S-alkylation (N-fluoromethyl compounds are 
generally unstable). The overall RCYs of these processes tend to be low [
18
F]Fluoromethyl 
bromide may also be converted into a more reactive labeling agent, [
18
F]fluoromethyl triflate, 
by passage over heated silver triflate.
43
 
2-[
18
F]Fluoroethyl tosylate has been successfully applied to the syntheses of several 
radiotracers. This labeling agent is rather more reactive than the alternative [
18
F]fluoroethyl 
bromide and may be produced and used in situ.
44
 The [
18
F]fluoroalkylating agents are 
generally applied to the labeling of small molecules. In other hand, labeling agents for 
18
F-
fluoroamidation
45
 and 
18
F-fluoroacylation
46
 may be prepared similarly and are generally 
applied to the labeling of peptides and proteins under mild conditions in aqueous solutions 
(Scheme 5). 
TsO
NHBoc
1. [K222]18F
    DMSO
18F
NH3
+
2. TFA
-O2CCF3
O
R2R1
X
O
O
R2R1
18F
O
[K222]18F
ACN
X= Cl, Br, OTs
R1= H, CH3
R2= CH3, CH2CH3  
Scheme 5:  Radiosynthesis of intermediate labeling agents for 
18
F-fluoroamidation
45
 and 
18
F-fluoroacylation
46 
 o- or p-[
18
F]Fluorobenzaldehydes may be produced quite efficiently in one step by 
aromatic nucleophilic substitution in the corresponding benzaldehyde bearing a good leaving 
10 
group, such as NO2 or Me3N
+
.
47,48
 These aldehydes are very useful secondary compounds, 
since they can often be the first step in built-up syntheses of radiotracers. As depicted in 
Scheme 6, they may also serve as entries into other useful labeling agents such as the 
corresponding [
18
F]fluorobenzyl halides, through their reduction and halogenation. Further, 
reductive decarbonylation leads to the corresponding [
18
F]fluorophenyl compounds. A review 
regarding this labeling methodology has recently been published.
49
  
X
CHO
[K222]18F
18F
CHO
NaBH4
18F
CH2OH
SOBr2
18F
CH2Br
X= +N(CH3)3, NO2
18F
Rh(PPh3)3Cl
 
Scheme 6:  Radiosynthesis of o- or p-[
18
F]fluorobenzaldehydes and derivatives as labeling 
agents
47 
Other [
18
F]fluoroarenes have also proven very versatile to serve as labeling agents. An 
example is p-[
18
F]fluorobromobenzene,
50,51
 which is e.g. efficiently produced by the reaction 
of bis(p-bromophenyl)iodonium bromide or its 2-thienyl analog with [
18
F]fluoride ion 
(Scheme 7). This may be further converted into the useful synthon p-
[
18
F]fluorophenyllithium.  
I+ S [K222]18F
18F
+
SI
Br
Br
Br-
DMF
18F
Li
BuLi
 
Scheme 7:  Radiosynthesis of p-[
18
F]fluorobromobenzene and p-[
18
F]fluorophenyllithium
51
 
“Click” chemistry, which utilizes Huisgen 1,3-dipolar cycloaddition of terminal alkynes 
and azides to form 1,2,3-triazoles, has recently also been adopted for the preparation of 
[
18
F]fluoropeptides (Scheme 8).
52,53
 The reaction requires a Cu
I
 catalyst, proceeds under mild 
conditions in aqueous media and requires virtually no protection of other functional groups. 
The use of the non-radioactive component of the reaction in excess compensates for moderate 
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reactivity. Thus, many labeling reactions can be completed within 20 min in moderate to high 
radiochemical yields.  
18F
n
N3 peptide
O
N
N
N
18F
peptide
O
TsO
[K222]18F
ACNn
n
CuI, Na ascorbate
DIEA
n= 1-3
peptide
O
N
N
N
18F
peptide
TsO
N3
[K222]18F
ACN CuSO2, Na ascorbate
Phosphate buffer
18F
N3
O
 
Scheme 8:  The two alternative onsets for Huisgen´s 1,3-dipolar cycloaddition for the pre-
paration of [
18
F]fluoropeptides
52,53
 
1.2.4 Enzymatic fluorination 
Fluorinase enzyme, from the bacterium Streptomyces cattleya, is a recent alternative 
method for the direct introduction of fluorine-18 into organic molecules. Developments by 
O'Hagan et al.
54,55
 on the isolation and over-expression of the fluorination enzyme have led to 
its utilization for highly selective formation of C-F bonds and its application in 
18
F-
radiolabeling. Initial reports using the fluorinase enzyme gave a low RYC of 1%, but 
provided the proof-of-principle.
20
 The introduction of a coupled-enzyme strategy brought a 
major improvement, with [
18
F]-5′-fluoro-5′-deoxyadenine ([18F]5′-FDA) being synthesized in 
95% RCY within two hours.
56
 Although the incubation times for these enzymatic reactions 
are rather long (2-4 h) rapid evolutionary techniques are expected to improve such enzymes 
and greatly enhance the reaction rates. The major limitation to this technique is the specificity 
of the fluorinase enzyme, which restricts its use as a general fluorination method. However, it 
is possible to label a range of derivatives using additional enzyme coupled systems and 
hydrolysis reactions. Enzymatic methods of radiolabeled compounds are particularly 
attractive because of their high chemo-, and enantio-specificity and the formation of few side 
products, which will simplify purification.  
12 
1.3 Amino acids 
Amino acids serve many other essential functions in cells that are necessary for life but 
they mainly represent the building blocks of proteins. For this, they are linked together by 
peptide bonds to form the basic structure of proteins. However, owing to the many “side 
groups” that are part of the amino acids other sorts of bonds, e.g. disulfide and hydrogen 
bridges, may form between different amino acid units. These additional bonds twist and turn 
the protein into convoluted shapes that are unique to the protein and essential to its ability of 
performing certain functions in living organisms.
57
  
The 20 amino acids commonly found in proteins are called “standard amino acids”. All of 
them, except proline, have as common characteristics a free carboxylic acid and a free 
unsubstituted amino group attached to the α carbon atom. Figure 3 depicts their general 
structural formula. Due to the chiral center amino acids are D- or L-stereoisomers, except for 
glycine, which has none, and threonine and isoleucine, which each have two chiral centers. 
Generally, amino acids found in cellular proteins are L-stereoisomers. 
COOHR
NH2
H
 
Figure 3: General structure of α-L-amino acids 
Various ways of classifying the amino acids have been described, of which the most 
commonly used is based on the polarity of the R group. This leads to four classes of amino 
acids: 
(1) Non-polar or hydrophobic R group: They have an equal number of amino and 
carboxyl groups and are neutral. These amino acids are hydrophobic and have no charge on 
the R group. The amino acids belonging to this group are alanine, valine, leucine, isoleucine, 
phenylalanine, glycine, tryptophan, methionine and proline. 
(2) Neutral, uncharged, polar R group: These amino acids also do not have any charge on 
the R group but participate in hydrogen bonding of protein structure. The amino acids in this 
group are serine, threonine, tyrosine, cysteine, glutamine and aspargine. 
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(3) Positively charged R group: Polar amino acids with positive charge have more amino 
groups as compared to carboxyl groups making it basic. These are lysine, arginine and 
histidine. 
(4) Negatively charged R groups: Polar amino acids with negative charge have more 
carboxyl groups than amino groups making them acidic. They are classified as dicarboxylic 
mono-amino acids. These are aspartic acid and glutamic acid. 
1.4 Amino acid transport across the cell membrane 
Amino acid transport across the membrane of cells has been extensively described by 
Pisitti and co-workers.
58
 Although all amino acids can diffuse into cells, the main transport of 
amino acids into cells occurs through carrier mediated processes. The activity of the specific 
carrier is based on both binding affinity and the capacity of the carrier. The latter can also be 
expressed as the number of functional carriers per cell. Thus, an increase of amino acid 
transport into the cell can be due to either an increased affinity or an increased amount of 
carriers or a combination of both besides to an increased offer, i.e. concentration in the blood. 
Three principal transport systems account for much of the amino acid uptake by 
mammalian cells (Figure 4). System A is Na
+
 dependent. It transports most neutral amino 
acids and is often inhibited by the presence of intracellular substrates of this system, i.e. the 
presence of a certain intracellular amino acid inhibits the uptake into the cell of additional 
similar extracellular amino acids. System ASC is also Na
+
 dependent and mainly acts as a 
carrier for the neutral amino acids, but with this carrier system the presence of neutral amino 
acids in the interior of the cell leads to stimulation of the transport of more amino acids into it. 
The affinity of the carrier protein increases once a sodium ion binds to the transporter. 
Subsequently, the amino acid will bind to the activated carrier forming an amino 
acid/sodium/co-transporter complex. A conformational change on the structure of this 
complex delivers both the amino acid and the sodium ion into the cell. The binding of the 
sodium ion is promoted by the electric potential of the membrane. This gradient is maintained 
by the glucose-dependent sodium/potassium adenosine triphosphatase ion transporter. Thus 
transporters A and ASC are energy consuming. Efflux of amino acids is unlikely to occur 
because of the inwardly directed sodium electrochemical gradient. 
Amino acid transport by the sodium-independent transporter L is mainly dependent on 
the concentrations of the amino acid outside and inside the cell. The direction of the transport 
14 
is determined by this gradient. However, an amino acid can be transported against this 
gradient by a mechanism known as countertransport. This comprises the efflux by system L of 
another amino acid, whose gradient has been established by one (or more) of the sodium-
dependent transport systems. The sodium-independent system L has a specificity for the 
branched and aromatic non-polar amino acids and uptake is subject to trans-stimulation by the 
intracellular substrates of this system. In general, the systems A and ASC are responsible for 
transport of the neutral amino acids, whereas system L transports the aromatic and the 
branched chain amino acids.  
 
Figure 4: Schematic depiction of major amino acid transporter systems. The system A 
transporter cotransports one extracellular amino acid (AA) with one Na
+
 into the 
cell. The system L transporter exchanges one AA from the extracellular 
compartment with one AA from the intracellular compartment and does not 
require Na
+
. The system ASC transporter cotransports one extracellular AA with 
one Na
+
 into the cell while transporting one intracellular AA out of the cell. The 
intracellular amino acid pool gradient is maintained by active transport by system 
A as well as further concentrative amino acid transporters. The sodium ion (Na
+
) 
gradient is maintained by the Na
+
, K
+
-ATPase
 59
 
1.5 Tumor imaging with radiolabeled amino acids 
Visualization of tumors with radiolabeled amino acids is based on surplus accumulation 
of the radiotracer in the diseased cell. The amino acid uptake is often increased in malignant 
tissue.
60,61
 Tumor cells require amino acids for energy production, protein synthesis and cell 
duplication. Malignant tumors are characterized by a hypermetabolic state: not only glucose 
metabolism but also protein synthesis and amino acid transport are often enhanced in cancer 
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cells. Both A- and L-type amino acid transports have been shown to be up-regulated in tumor 
cells as compared with normal tissue.
62
 Especially analogues of phenylalanine and tyrosine 
have proven to be useful for tumor imaging.
63
 
Several studies have described the application of radiolabeled amino acids or analogues 
for measurement of the protein synthesis rate (PSR) or solely the amino acid transport. For 
some applications, the use of amino acids analogues represents an advantage as compared to 
FDG. For instance, amino acids may help in imaging areas in which FDG imaging is limited, 
such as the brain (because of high background FDG uptake), or in differentiating tumorous 
from inflammatory lesions (because of high FDG uptake in macrophages, e.g., after 
radiotherapy).  
It has been suggested that amino acid transport may be more important for tumor imaging 
than the incorporation of amino acids into proteins.
64,65
 The fraction of radiolabeled amino 
acid that is incorporated into proteins during the time of a PET study is small as compared to 
the total amount that is taken up by the cell. Therefore, it is unlikely that the incorporated 
fraction substantially contributes to the scintigraphic visualization of the tumor lesion. 
Consequently non-metabolisable synthetic amino acid analogues for the quantification of the 
amino acid transport rate have been developed.
64,66,67,68
 With these analogues, release of 
radiolabeled metabolites from the cells back into the circulation does not occur. This enables 
quantification of the amino acid transport with relatively simple kinetic modeling. Moreover, 
amino acid transport is a relatively rapid process and, therefore, tumor imaging based on 
amino acid transport can be performed within 20 min post injection, whereas imaging of the 
rather slow PSR would require imaging for much extended times post injection. Thus, two 
kinds of amino acid-based PET tumor imaging can be distinguished: (1) that one based solely 
on amino acid transport and (2) that one based on amino acid transport and protein 
incorporation, i.e. also measuring the PSR.
69,70 
1.6 Synthesis of catecholamines from aromatic amino acids  
Phenylalanine is the starting material for the synthesis of tyrosine in mammals. 
Conversion of phenylalanine into tyrosine is catalyzed by the enzyme phenylalanine 
hydroxylase (PH) which introduces a hydroxyl group in the position 4 of the aromatic ring of 
phenylalanine. Tyrosine again acts as precursor in the biosynthesis of catecholamines (CA). 
Dihydroxyphenylethylamine (dopamine, DA), norepinephrine (NE), and epinephrine (EP) are 
synthesized in the adrenal medulla and in adrenergic neurons in the central nervous system. 
16 
Biosynthesis of CA involves five enzymatic steps as shown in Scheme 9: phenylalanine is 
converted by PH in tyrosine; tyrosine hydroxylase (TH) catalyzes the conversion of tyrosine 
to dihydroxyphenylalanine (DOPA); DOPA is converted to DA by aromatic L-amino acid 
decarboxylase (AADC); dopamine β-hydroxylase (DBH) catalyzes the enzymatic reaction of 
DA to NE, and EP is synthesized from NE by phenylethanolamine N-methyltransferase 
(PNMT).
71
 
COOH
HO
NH2
COOH
HO
NH2
OH
HO
NH2
OH
HO
NH2
OH
OH
HO
HN
OH
OH
Tyrosine hydroxylase Aromatic L-amino acid decarboxylase
DOPA decarboxylase
Dopamine -hydroxylase
Phenylethanolamine
N-methyltransferase
L-Tyrosine
L-DOPA
Dopamine
Norepinephrine
Epinephrine
O2, Tetrahydro-
biopterine
H2O, Dihydro-
biopterine
CO2
O2, Ascorbic 
Acid
H2O, Dehydro-
ascorbic acid
S-adenosyl-
methionine
Homocysteine
CH3
COOH
NH2
Phenylalanine hydroxylase
L-Phenylalanine
 
Scheme 9:  Synthesis of catecholamines from phenylalanine
71
 
DA is produced in several areas of the brain, including the substantia nigra and the 
ventral tegmental area (VTA). The VTA is the origin of the dopaminergic cell bodies of the 
mesocorticolimbic DA system and is widely implicated in the drug and natural reward 
circuitry of the brain. In the terminal ends of neurons, DA is packed after synthesis into 
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vesicles, which are then released into the synapse in response to a presynaptic electrochemical 
action potential.  
DA neurons are mainly present in the VTA of the midbrain, the substantia nigra, pars 
compacta, and the arcuate nucleus of the hypothalamus. DA has many functions in the brain, 
including important roles in behavior and cognition, voluntary movement, motivation, 
punishment and reward, inhibition of prolactin production (involved in lactation and sexual 
gratification), sleep, mood, attention, working memory, and learning.  
Two major degradation pathways for DA exist. In most areas of the brain, including the 
basal ganglia, DA is either inactivated by reuptake via the DA transporter (DAT) or by the 
enzymatic breakdown by monoamine oxidase (MAOA and MAOB) into 3,4-
dihydroxyphenylacetic acid. In the prefrontal cortex, however, there are very few DA 
transporter proteins, and DA is instead inactivated by reuptake via the NE transporter, 
presumably on neighboring NE neurons, rather than through enzymatic breakdown by 
catechol-O-methyl transferase (COMT) into 3-methoxytyramine. 
1.7 Parkinson´s disease 
Parkinson‟s disease (PD) is a progressive neurological disorder characterized by a large 
number of motor and non-motor features that can impact on function of the patient to a 
variable degree. Because there is no definitive physiological test for the diagnosis of PD, the 
disease must be diagnosed based on clinical criteria. Rest tremor, bradykinesia, rigidity and 
loss of postural reflexes are generally considered the cardinal signs of PD.
72
 The primary 
symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia. 
Normally this involves insufficient formation and thus action of dopamine produced in the 
dopaminergic neurons of the midbrain (specifically the substantia nigra). 
The pathological hallmark of PD is cell loss within the substantia nigra particularly 
affecting the ventral component of the pars compacta. By the time of death, this region of the 
brain has lost 50-70% of its neurons compared with the same region in unaffected individuals. 
The earliest documented pathological changes in PD have been observed in the medulla 
oblongata/pontine tegmentum and olfactory bulb. In these early stages patients are pre-
symptomatic. As the disease advances the substantia nigra, areas of the midbrain and basal 
forebrain become involved. Finally, pathological changes appear in the neocortex.
73
 
18 
The standard symptomatic therapy of PD for more than 30 years has been DOPA. As it 
was mentioned before, this is the precursor of DA which is deficient in PD. DOPA is readily 
converted into dopamine by AADC. To reduce peripheral metabolism of DOPA, the drug is 
combined with a peripheral dopa decarboxylase inhibitor (i.e. carbidopa or benserazide). This 
increases the amount of DOPA that crosses the blood-brain barrier.
74
 
1.8 [18F]Fluoroaromatic amino acids 
Many amino acids have been radiolabeled to study their potential imaging characteristics. 
These radiolabeled amino acids differ in ease of synthesis, biodistribution and formation of 
metabolites in vivo. To date, the most frequently used amino acid tracers for tumor diagnosis 
are [
11
C-methyl]-L-methionine (MET) for PET and 3-[
123
I]iodo--methyl-L-tyrosine (IMT) 
for single photon emission computed tomography (SPECT).
75
 Due to the short physical half-
life of the 
11
C-label (20.4 min), MET PET remains restricted to a few PET centers with a 
cyclotron on site and could not be established in routine clinical practice despite of its 
compatibility with amino acid uptake kinetics and convincing first clinical results. IMT 
SPECT offers a more widespread application, but the spatial resolution of SPECT is 
considerably lower than that of PET.
76
 Therefore, a number of attempts have been undertaken 
to label amino acids with fluorine-18.  
1.8.1 6-[18F]Fluoro-3,4-dihydroxy-L-phenylalanine  
3,4-Dihydroxy-6-[
18
F]fluoro-L-phenylalanine (6-[
18
F]FDOPA) is a fluorinated analogue 
of the naturally-occurring L-3,4-dihydroxyphenylalanine (L-DOPA). It has been used 
extensively for evaluation of the dopaminergic system in the brain, particularly in Parkinson´s 
disease, as it is a substrate for the enzyme aromatic amino acid decarboxylase (AADC), 
normally found in high abundance in dopaminergic neurons. For this reason, under normal 
physiological conditions there is high uptake and retention of 6-[
18
F]FDOPA in the substantia 
nigra and the striatum. Additionally, 6-[
18
F]FDOPA also shows high uptake in 
neuroendocrine tumors (NET)
77
 and some other tumors, such as cerebral gliomas, which may 
exhibit an increased accumulation due to amino acid transport.
78
 The brain uptake of 6-
[
18
F]FDOPA in animal and humans can be decreased by other system L substrates such as L-
phenylalanine, consistent with a 6-[
18
F]FDOPA transport via system L.
79
 However, 
accumulation of the radiotracer in non-NETs, except for cerebral gliomas, is less predictable, 
and the role of 6-[
18
F]FDOPA seems to be limited.  
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Figure 5: PET and MRI of PD-patient and control. (a) Control subjects shows high uptake 
of 6-[
18
F]FDOPA (highest value in white) in the striatum. (b) Subject with 
Parkinson's disease where the uptake is unilaterally reduced (up to 70% below 
normal). (c) Analysis showing the difference in uptake between a and b (yellow 
represents the largest statistical difference and red the smallest one). The 
statistical map (c) is rendered over the corresponding MRI scan for anatomical 
localization.
80
  
The first reported radiosynthesis of 6-[
18
F]FDOPA is already 30 years old. It was 
performed through direct electrophilic labeling of 3-methoxy-L-DOPA ethyl ester using 
[
18
F]XeF2 as fluorinating agent and hydrogen fluoride as solvent followed by the cleavage of 
the methyl group with hydrobromic acid. Scheme 10 depicts the synthetic approach. This 
procedure achieved the desired amino acid in 1% radiochemical yield (RCY).
81
 Using the 
same precursor but [
18
F]acetyl hypofluorite as fluorinating agent the RYC was improved to 
4%.
82
  
COOEt
NH2
HO
OMe
COOH
NH2
HO
OH
1) [18F]XeF2
2) HBr
18F
 
Scheme 10: First reported electrophilic synthesis of 6-[
18
F]FDOPA
81
 
Several reports dealing with the direct electrophilic labeling of “naked” L-DOPA in 
different solvent systems were afterwards published. These experiments provided the desired 
compound in 3-8% RCY.
83,84,85
 The major drawback of these procedures was the occurrence 
of all the others probable regioisomers which were not easy to separate from the 6-
[
18
F]FDOPA requiring complicate and time consuming HPLC procedures. 
20 
Further labeling attempts consisted in the labeling of other protected L-DOPA 
derivatives. Some of them had relative success, like the labeling of (S)-2-amino-3-(4-hydroxy-
3-(pivaloyloxy)phenyl)propanoic acid which delivered the desired amino acid in 17% RCY 
after 60 min (Scheme 11).
86
  
COOH
NH2
O
OH
COOH
NH2
HO
OH
1) [18F]CH3COOF
2) HCl
O
18F
 
Scheme 11: Most efficient direct electrophilic synthesis of 6-[
18
F]FDOPA
86
 
However, as mentioned before, the use of direct electrophilic substitution is limited due 
to the low regioselectivity of the reaction. Efforts were focused to improve it by the use of a 
leaving group in the position 6 of the aromatic ring facilitating the regioselective introduction 
of the radioactive fluoride atom. The first regioselective synthesis of 6-[
18
F]FDOPA following 
this approach was achieved via fluorodesilylation of 6-trimethylsilyl-3,4-dimethoxy-L-
DOPA-ethylester. The precursor was labeled with [
18
F]F2 in a mixture of freon-11/CCl4, 
subsequent hydrolysis with concentrated HBr followed by chromatographic purification 
yielding the radiotracer with a RCY of 8% in 60 min.
87
 An improvement of the RYC was 
achieved when fluorodemercuration was performed instead of a fluorodesilylation. Here, the 
precursor (4,5-dimethoxy-2-((S)-3-methoxy-3-oxo-2-(2,2,2-trifluoroacetamido)propyl)phen-
yl)(oxo)(2,2,2-trifluoroacetyl) mercury was labeled at room temperature with [
18
F]CH3COOF 
in dichloromethane followed by cleavage of the protecting groups with hydrobromic acid. 
After chromatographic purification the 6-[
18
F]FDOPA was obtained in a total time of 50 
min.
88
 The disadvantage of this procedure is the use of mercury derivative since the heavy 
metal is toxic. 
In 1992 Namavari and co-workers published the synthesis that until now is the best 
alternative for the preparation of 6-[
18
F]FDOPA via electrophilic substitution (Scheme 12). 
Toxic mercury was replaced by tin and the desired amino acid was obtained in 17% RCY.
89
 
de Vries et. al. adapted the fluorodestannylation method described by Namavari and 
coworkers and developed a simple, fully automated synthesis module for the routine clinical 
production of 6-[
18
F]FDOPA.
90
 This was prepared with both, high radiochemical yield 33 ± 
4 %, and radiochemical purity > 99% in 45 min synthesis time. CFCl3 was found to be a 
better solvent for the fluorodestannylation reaction than CHCl3 or acetonitrile. Also in CFCl3, 
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[
18
F]F2 was a superior fluorinating agent over [
18
F]acetyl hypofluorite. However, CFCl3 is not 
anymore available. 
COOEt
NHCHO
(H3C)3COOCO
OCOOC(CH3)3
Sn
COOH
NH2
HO
OH
1) [18F]XeF2
2) HBr
18F
 
Scheme 12:  Regioselective synthesis of 6-[
18
F]FDOPA by electrophilic 
fluorodestannylation
89
 
Nucleophilic approaches for the radiosynthesis of 6-[
18
F]FDOPA started with substitution 
by [
18
F]fluoride on small benzaldehyde derivatives with subsequent build-up reactions.
91
 The 
first nucleophilic synthesis of 6-[
18
F]FDOPA was based on the nucleophilic displacement of a 
nitro group of two commercially available substrates, 3,4-dimethoxy-2-nitrobenzaldehyde 
(nitroveratraldehyde) or 6-nitropiperonal by [
18
F]fluoride.
92
 Fluorination was conducted in 
presence of the aminopolyether Kryptofix 222 and potassium carbonate in DMSO. The 
condensation of the fluorinated aldehydes with phenyloxazolone and the subsequent 
hydrolysis with HI/P gave only a mixture of 6-(D, L) isomers after purification by HPLC. The 
racemic mixture was resolved on an analytical scale chiral column. The method, which 
requires 100 min (EOB) to be complete, produces 6-[
18
F]FDOPA with 10% RCY, 
enantiomeric purity > 99%, and a specific activity of 44.4 GBq/µmol. Despite of formation of 
a racemic mixture this method was automated producing the desired L-amino acid after chiral 
HPLC in 2 h, with a RCY of 3-5%.
93
 Further extensive efforts have been focused in the 
improvement of the nucleophilic substitution.
94,95,96
  
In order to avoid the formation of racemates the introduction of a chiral group was 
envisioned. The general procedure relies on a built-up synthesis depicted in Scheme 13. After 
the 
18
F-labeling step, the aldehyde functionality is reduced to the benzyl alcohol and 
afterwards converted to the benzyl halide derivative. The benzyl halide (generally bromide) is 
subsequently coupled to either a chiral auxiliary or to a prochiral auxiliary by chiral phase 
transfer alkylation. The last step consists in the hydrolysis of the protecting groups in acid 
medium.  
The use of the glycine derivatives [(+)-2-hydroxypinanyl-3-idene]glycine tert-butyl ester 
and the analogous ethyl ester as chiral inductors provided the desired L-isomer in 75%. 
22 
Alkylation of the Schiff base was carried out with the lithium salt of 2,2,6,6-
tetramethylpiperidine as base in anhydrous THF at -78°C. Following hydrolysis of the 
protecting groups with hydroxylamine and HI, the L-amino acid was obtained in 75% (e.e. 
50%) with a 10% RCY within 120 min.
 97,98
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Scheme 13: General scheme of the nucleophilic built-up radiosynthesis of 6-[
18
F]FDOPA 
In 1993 Lemaire and coworkers
99
 reported the synthesis of 6-[
18
F]FDOPA using two 
different chiral inductors. 2-[
18
F]Fluoro-4,5-dimethoxybenzyl bromide was added to the 
lithium enolates of 1-(S)-(-)camphor imine of tert-butyl glycinate and (S)-(-)-1-Boc-2-tert-
butyl-3-methyl-4-imidazolidinone ((S)-Boc-BMI). After hydrolysis with HI and HPLC 
purification, the L-isomer of 6-[
18
F]FDOPA was isolated in 5-10% RCY. The e.e. using the 
first chiral auxiliary was 83%, while 96% e.e. was obtained when the second one was used. 
The overall synthesis time was of 110 min.  
3,5,6,7,8,8a-Hexahydro-7,7,8a-trimethyl-[6S-(6α,8α,8αβ)]-6,8-methano-2H-1,4-benzoxa-
zino-2-one was investigated as chiral auxiliary. This procedure is slightly different to the 
previously described. A synthetic step is saved by direct condensation of the auxiliary with 
3,4-dimethoxy-2-[
18
F]fluorobenzaldehyde or 6-[
18
F]fluoropiperonal in the presence of NaH 
providing the corresponding 3-[(2-[
18
F]fluorophenyl)methylene]-3,5,6,7,8,8a-hexahydro-
7,7,8a-trimethyl-[6S-(3Z,3α,6α,8α,8αβ)]-6,8-methano-2H-1,4-benzoxazin-2-one derivatives 
as a single stereoisomer. L-Selectride® promoted hydrogenation of the olefinic double bond 
of these derivatives, in presence of tertbutyl alcohol, generated the corresponding 3-[(2-
[
18
F]fluorophenyl)methyl]-3,5,6,7,8,8a-hexahydro-7,7,8a-trimethyl-[3S-(3α,6α,8α,8αβ)]-6,8-
methano-2H-1,4-benzoxazin-2-one derivatives. Deprotection yielded 6-[
18
F]FDOPA in 3% 
RCY, with an e.e. > 90% in a total synthesis time of 125 min. 
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Another four-step synthesis and for long time the most successful among the nucleophilic 
built-up synthesis was reported by Lemaire and coworkers in 1993.
100
 Trimethylammonium 
veratraldehyde triflate was used as precursor for the asymmetric synthesis of 6-[
18
F]FDOPA. 
Diiodosilane was used to prepare the corresponding [
18
F]fluorobenzyliodide. Akylation of (S)-
Boc-BMI with this electrophilic agent, hydrolysis and purification by preparative HPLC 
provided 6-[
18
F]FDOPA ready for human injection whit 23% RCY. The enantiomeric purity 
and the specific activity were above 96% and 37 GBq/µmol, respectively. The synthesis 
procedure was completed within 90 min (Scheme 14). 
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Scheme 14: Enantioselective nucleophilic built-up synthesis of n.c.a. 6-[
18
F]FDOPA
100 
Further developments involved the use of phase-transfer chiral catalysts for the coupling 
of glycine derivatives with the benzyl bromide instead of the coupling with a chiral auxiliary 
(Scheme 14). A chiral quaternary ammonium salt derived from a Cinchona alkaloid served as 
phase-transfer catalyst for the enantioselective alkylation of a glycine derivative. The active 
methylene group of this Schiff-base substrate was deprotonated with cesium hydroxide and 
alkylated by the 2-[
18
F]fluoro-4,5-dimethoxybenzyl halide (X = Br, I). The reaction proceeded 
with high yield (> 90%) at 0 °C or r.t. in solvents such as toluene or dichloromethane. After 
labelling, the labeled [
18
F]fluoroveratraldehyde was trapped on a C18 cartridge and then 
converted on the cartridge into the corresponding benzyl halide derivatives by addition of 
aqueous sodium borohydride and gaseous hydrobromic or hydroiodic acid. Hydrolysis and 
purification by preparative HPLC gave 6-[
18
F]FDOPA with 25-30% RCY (e.e. > 95%) within 
a synthesis time of 100 min.
101
 A slightly modified automated synthesis using the concept 
described before has recently been reported. Using a home-made automatic synthesizer 
24 
[
18
F]FDOPA was produced with RCY of 20% within 120 min. Radiochemical purity and e.e. 
were both ≥ 95%. The specific activity obtained was approximately 50 GBq/mmol.102 
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Scheme 15: Most efficient nucleophilic built-up synthesis of n.c.a. 6-[
18
F]FDOPA
101
 
This approach yields the desired radiotracer at the no-carrier-added level and allowed 
large-scale productions with good chemical, radiochemical and enantiomerical purity. 
However, the built-up synthesis is still difficult to automate due to its complexity. 
Independently of the previously described approaches a direct nucleophilic isotopic 
exchange reaction on a formyl-activated masked aromatic amino acid derivative was studied 
for improving the efficiency of the nucleophilic preparation of 6-[
18
F]FDOPA. Here, the 
required carbon skeleton and the chiral center with the desired configuration were constructed 
before introduction of the [
18
F]fluoride ion by use of a chiral auxiliary. The precursor 
undergoes an isotopic exchange with [
18
F]fluoride followed by a Baeyer-Villiger oxidation 
and subsequent hydrolysis. In a first attempt the 2-(benzyloxy)-4-fluoro-5-(((2S,5R)-5-
isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)benzaldehyde was used as starting 
material as depicted in Scheme 16.
103
 Although this approach was suggested a long time ago 
upon first radiosynthesis of corresponding [
18
F]fluoroaldehydes as one general possibility of 
their use no attempts for its realization were made so far.
104
 
                                                                   25 INTRODUCTION 
 
F
O
BnO
18F
O
BnO
18F
O
BnO
18F
OH
HO
COOH
NH2
O
m-CPBA HBr
N
N
OMe
OMe
N
N
OMe
OMe
N
N
OMe
OMe
[K222]18F
 
Scheme 16:  Three-step c.a. synthesis of 6-[
18
F]FDOPA by isotopic exchange using 2-
(benzyloxy)-4-fluoro-5-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyra-
zin-2-yl)methyl)benzaldehyde as labeling precursor
103 
Although the radiochemical yield of this procedure was similar to the n.c.a. built-up 
radiosynthesis reported by Lemaire, the e.e. was only 70%.  
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Scheme 17:  Three-step c.a. synthesis of 6-[
18
F]FDOPA by isotopic exchange using (2S,5S)-
tert-butyl-5-(4-benzyloxy-2-fluoro-formylbenzyl)-2-tert-butyl-3-methyl-4-oxo-
imidazolidine-1-carboxylate as labeling precursor
105 
26 
Recently, using (2S,5S)-tert-butyl-5-(4-benzyloxy-2-fluoro-formylbenzyl)-2-tert-butyl-3-
methyl-4-oxoimidazolidine-1-carboxylate as precursor, the synthesis of 6-[
18
F]F-DOPA was 
achieved with an acceptable radiochemical yield of 22 % and a high e.e of > 96%. (Scheme 
17).
105
 In spite of that, this method also presented some drawbacks, e.g. the synthesis of the 
labeling precursor could only be accomplished in eleven steps delivering a low yield of about 
1%, thus limiting the optimization studies of the radiosynthesis. The formation of unidentified 
radioactive side-products during the isotopic exchange reaction was also reported, what 
requires further attention. In addition, the RCY of the hydrolysis step, although already 
acceptable, should be improved. This radiochemical approach will be discussed in more detail 
in Chapter 3 along the work presented here.  
1.8.2 Radiosynthesis of 2-[18F]fluoro-L-phenylalanine and 2-[18F]fluoro-L-tyrosine 
2-[
18
F]Fluoro-L-phenylalanine (2-[
18
F]Fphe) has proven to be a useful radiopharma-
ceutical for the study of neutral amino acid transport at the blood brain barrier in vivo in 
humans.
106
 On the other hand, 2-[
18
F]fluoro-L-tyrosine (2-[
18
F]Ftyr), unlike other halogenated 
amino acids, is almost quantitatively incorporated into proteins lending it as interesting tracer 
for imaging of protein synthesis in vivo.
107
 Since the accumulation of 2-[
18
F]Fphe and 2-
[
18
F]Ftyr enables to distinguish tumors from normal tissue, positron emission tomography 
studies of their uptake are of clinical value for the diagnosis of brain tumors.
108,109,110
 Both 
radiotracers have been prepared by direct electrophilic synthesis with [
18
F]F2 and 
[
18
F]CH3COOF on phenylalanine and tyrosine, respectively, as well as on O-acetylated 
tyrosine. However, their radiochemical yield and positional isomeric purity were limited and 
demanded careful HPLC-separation (Scheme 18).
111
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Scheme 18:  Direct electrophilic synthesis of 2-[
18
F]Fphe and 2-[
18
F]Ftyr using the respective 
“naked” amino acid as starting material111 
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As described above for 6-[
18
F]FDOPA, here again radiofluorodemetallation and specially 
radiofluorodestannylation have been found most efficient labeling methods in order to achieve 
aromatic [
18
F]fluoroamino acids in routine production. In the case of 2-[
18
F]Ftyr, O,N-di-Boc-
2-triethylstannyl-tyrosine ethyl ester has proven to a be suitable precursor for its radio-
synthesis leading to an improved RCY of 21%.
112
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Scheme 19: Regioselective synthesis of 2-[
18
F]Ftyr by electrophilic fluorodestannylation
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In the other hand, 2-[
18
F]Ftyr has also been prepared in n.c.a. form in a multistep 
synthesis in similar way as 6-[
18
F]FDOPA in five steps starting by nucleophilic 
18
F-
substitution of a small aldehyde as depicted in Scheme 20.
113
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Scheme 20: Build-up nucleophilic synthesis of n.c.a. 2-[
18
F]Ftyr
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Again here, the problem with this synthetic approach is that despite the final product 
meets the quality control requirements and can be produced in amounts high enough for 
routine use in medical practice, the radiosynthesis is cumbersome to automate which hitherto 
limits a wider use of the radiotracer. 
28 
1.8.3 Radiosynthesis of 6-[18F]fluoro-L-m-tyrosine 
6-[
18
F]Fluoro-L-m-tyrosine (6-[
18
F]Fmtyr) has been employed as 6-[
18
F]FDOPA-
analogous imaging agent of the dopaminergic function in the brain by measuring the activity 
of the enzyme AADC in both animals as well as in humans using positron emission 
tomography (PET).
114
 Historically the tracer of choice for such studies has been 6-
[
18
F]FDOPA.
115
 However, 6-[
18
F]FDOPA is metabolized in the periphery and central nervous 
system by the enzyme catecholamine O-methyltransferase (COMT) producing O-MeDOPA. 
This is also able to cross bidirectionally the blood-brain-barrier thus compromising the quality 
of the clinical image as well as making its quantitative analysis more complicated. Contrary to 
6-[
18
F]FDOPA, 6-[
18
F]Fmtyr is not a substrate for COMT. Therefore the only radioactive 
species in the brain is the molecule of interest, providing a better signal/noise ratio and a clear 
diagnostic image while reducing the need for complex multicompartmental kinetic 
modeling.
116,117,118
  
 
Figure 6: Distribution of radioactivity 90 min after the injection of 6-[
18
F]FDOPA (left) or 
6-[
18
F]Fmtyr (right) in a patient with Parkinson's disease
119
  
Recently several studies illustrate the capacity of 6-[
18
F]Fmtyr for the assessment of the 
integrity of the presynaptic dopamine system. Studies dealing with the relationship of eating 
behavior and the dopamine synthesis capacity,
120
 relationship of striatal dopamine synthesis 
capacity to age and cognition,
121
 and for the evaluation of the effectiveness of gene therapy in 
primate models of PD
122
 and PD patients
123
 have been published. 
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Regarding the radiosynthesis of 6-[
18
F]Fmtyr, DeJesus and coworkers reported its 
synthesis via direct electrophilic fluorination of L-m-tyrosine with [
18
F]AcOF.
124,125
 The 
radiochemical yield was 71 ± 5% (n = 3; decay correction based on [
18
F]AcOF activity) after 
purification. The specific activity was 3.7-7.4 GBq/mmol (3.7-7.4 MBq)/mmol). 
Due to the success of the fluorodemetallation approach 6-[
18
F]Fmtyr has also been 
synthesized in two steps by electrophilic fluorodestannylation. Namavari and coworkers
126
 
reported the synthesis and 
18
F-fluorination of N-trifluoroacetyl-3-acetyloxy-6-trimethyl-
stannyl-L-phenylalanine ethyl ester followed by exhaustive deprotection of the acid, amine 
and phenol functionalities. The 6-[
18
F]Fmtyr was obtained more than 99% chemically and 
radiochemically pure. The total synthesis time took 60 min, and the radiochemical yield was 
17% of the 
18
F activity recovered from the target.
 
 
Scheme 21 depicts the synthesis of 6-[
18
F]Fmtyr reported by VanBrocklin and coworkers. 
A new di-Boc protected precursor, i.e. N-tert-butoxycarbonyl-3- tert-butoxycarbonyloxy-6-
trimethylstannyl-L-phenylalanine ethyl ester was employed, for the electrophilic 
fluorination.
127
 This precursor was synthesized from L-m-tyrosine in four steps with an 
overall yield of 26-27%. This procedure saves 3 synthetic steps for the synthesis of the 
precursor compared with the synthesis of that reported by Namavari et.al.
126
 The enatiomeric 
purity was > 95%. Decay-corrected radiochemical yields (n >6) for a two-pot method and 
one-pot method were 26 ± 3% and 25 ± 6%, respectively. For both methods, the chemical and 
radiochemical purities were > 96%, and the range of specific activities of 6-[
18
F]Fmtyr was 
28-74 MBq/μmol.  
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Scheme 21: Regioselective synthesis of 6-[
18
F]Fmtyr by electrophilic fluorodestannylation
127
 
An alternative procedure was reported Mulholland and coworkers for the radiosynthesis 
of this molecule (Scheme 22).
128
 The labeling precursor in this case was a benzophenone 
derivative, in which the amino acid function is already included. Contrary to the previously 
presented 6-[
18
F]FDOPA precursors for isotopic exchange nucleophilic radiofluorination (see 
Scheme 16 and 17), here the protected amino and carboxylic acid functional groups do not 
30 
form part of a cyclic compound. Unfortunately, the data related neither to RCY nor an 
enantiomeric purity was reported. 
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Scheme 22:  N.c.a. nucleophilic synthesis of 6-[
18
F]Fmtyr using (S)-4-(3,5-bis(trifluorome-
thyl)benzoyl)-2-(2-(tert-butoxycarbonylamino)-3-methoxy-3-oxo-propyl)-
N,N,N-trimethylbenzenaminium triflate as labeling precursor
128
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2 AIMS AND SCOPE  
In nuclear medicine diagnosis 
18
F-labeled aromatic amino acids are widely employed as 
radiopharmaceuticals for in vivo imaging using PET. Up to now, routine preparation of 
[
18
F]fluorophenyl amino acids is carried out via electrophilic labeling, preferably through 
fluorodestannylation reactions. The electrophilic approach is applicable because many of 
these compounds have a low toxicity and consequently they can be used in carrier-added 
form. However, since elemental [
18
F]fluorine is needed, these methods are limited to low 
amounts of activity at high costs. On the other hand, present nucleophilic syntheses using the 
advantage of large scale production of [
18
F]fluoride result either in insufficient enantiomeric 
purity or in a need of built-up syntheses that are difficult to automate 
Recently a new nucleophilic isotopic exchange approach was developed allowing the 
radiosynthesis of 6-[
18
F]fluoro-L-DOPA in three steps following the sequence 
18
F-for-
19
F 
exchange, Baeyer-Villiger oxidation, and hydrolysis using (2S,5S)-tert-butyl 5-(4-(benzylo-
xy)-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate as pre-
cursor. However, the lack of an efficient synthesis of the labeling precursor has restricted the 
optimization of the radiosynthesis and broader application. 
Therefore, the first objective here is to develop an efficient synthesis of the labeling 
precursor. Further goals include the optimization of every radiosynthetic step, involving the 
identification of side products and their mechanism of formation during the radiofluorination 
reaction. Furthermore, the study of the influence of the oxidizing agent on the Bayer-Villiger 
oxidation and the effect of the temperature and kind of mineral acid on the radiochemical 
yield of the hydrolysis reaction demand further exploration. 
 As an alternative a modified procedure in which a decarbonylation reaction should be 
performed instead of the Baeyer-Villiger oxidation in order to achieve the preparation of 2-
[
18
F]fluoro-L-tyrosine starting from the same precursor. Similarly a group of analogous 
fluoro-benzaldehyde precursors are envisaged for the radiosynthesis of 2-[
18
F]fluoro-L-
phenylalanine following this decarbonylation route. Following three derivatives were 
selected: (2S,5S)-tert-butyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-4-oxoimidazo-
lidine-1-carboxylate, (2S,5S)-benzyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-4-ox-
oimidazolidine-1-carboxylate and 4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihy-
dropyrazin-2-yl)methyl)benzaldehyde. Those will also enable to study the influence of the 
protecting group in the imidazolidinone ring and the kind of chiral auxiliary on the 
32 
radiochemical yield and the enantiomeric purity of the final product. The radiosynthetic 
procedure should be performed using both, conventional heating (oil bath) and microwave 
heating in order to compare the effect of the heating source on radiochemical yields and 
reaction times. 
In the frame of the planned work, it is also intended to prepare 6-[
18
F]fluoro-L-m-tyrosine 
using the oxidative pathway. Since fluoro-benzaldehydes which are not substituted with 
electron-donating groups are poorly directing their conversion into the respective phenol 
derivatives through Baeyer-Villiger oxidation, a series of fluoro-benzophenones will be 
synthesized to properly direct the reaction to the desired compound. This new series of 
precursors consists of (2S,5S)-tert-butyl 5-(5-acetyl-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-
oxoimidazolidine-1-carboxylate, 1-(4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihy-
dropyrazin-2-yl)methyl)phenyl)ethanone, (2S,5S)-tert-butyl 5-(5-(3,5-bis(trifluoromethyl)ben-
zoyl)-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate and (2S,5S)-
tert-butyl 2-tert-butyl-5-(2-fluoro-5-(2,2,2-trifluoroacetyl)benzyl)-3-methyl-4-oxoimidazolidi-
ne-1-carboxylate. With them it will be possible to study the effect of the activating group on 
the radiochemical yield of isotopic exchange reaction and the influence of the chiral group on 
the enantiomeric purity of the 6-[
18
F]fluoro-L-m-tyrosine. 
A major aim of the work present here is to achieve a deeper understanding regarding the 
isotopic exchange reaction on highly functionalized 4-fluoro-benzaldehyde and -benzo-
phenone derivatives. To that end, an exhaustive study on this reaction is planned. 
Experimental parameters including concentration and kind of [
18
F]fluoride anion activator, 
temperature, power of the microwave, reaction time, and nature of the carbonyl-activating 
group should be examined in order to determine their effect on the radiochemical yield and 
their role in the formation of further radiofluorinated non-wanted side products. 
Radioanalytical methods based on thin layer and high performance liquid chromatography 
using standard compounds must be developed in order to determine the radiochemical yields 
of products and side-products, their identity as well as radiochemical and enantiomerical 
purity. 
Finally, it is planned to transfer the elaborated three-step radiosynthesis of 6-[
18
F]fluoro-
L-DOPA into an commercially available remote-controlled synthesis module. In order to 
achieve this goal the SynChrom R&D device of Raytest GmbH controlled by GINA 
SynChrom software will be used. 
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3 RESULTS AND DISCUSSIONS 
3.1 Synthesis of precursors for the radiosynthesis of [18F]fluorophenylamino 
acids 
Preparation of suitable precursors for the radiosynthesis of aromatic [
18
F]fluorophenyl-
amino acids represent a major challenge for the development of these labeled compounds. As 
mentioned in the introduction of this work, most of the nucleophilic radiofluorinations of 
aromatic rings start with small aldehydes derivatives as labeling precursors. This is 
undesirable since the introduction of the radioactive fluorine atom at the beginning of the 
procedure leaves the construction of the enantioselective amino acid functionalities as part of 
the radiochemical pathway and generally these reactions are complex, multi-step procedures 
and consequently difficult to automate. 
Due to the high electron density of the ring with the amino acids of interest, the precursor 
should contain an activating, electron withdrawing group located in ortho or para position 
relative to the leaving group. Additionally, in the ideal precursor, the L-amino acid function is 
already built in.  
3.1.1 Earlier syntheses of precursors for the radiosynthesis of [18F]fluorophenyl-
amino acids 
The synthetic route pursued by Tierling et al.
103
 to attain this goal included the 
construction of the carbon skeleton of the phenylamino acid using the Schöllkopf‟s reagent 
(Scheme 23). By this way the chiral center with the desired configuration is built first, leaving 
the introduction of the activating formyl group for the last step. The disadvantage of this 
strategy is that the aromatic ring is not enough functionalized to allow an easy introduction of 
the activating formyl group. Moreover, the conditions of the reaction for the introduction of 
the formyl group are too harsh and probably led to decomposition of both starting material 
and products causing low yields.  
On the other hand, Kuroda and coworkers
129
 developed the synthesis of a labeling 
precursor choosing an imidazolidinone derivative as the masked amino acid functionality and 
iodide as the leaving group. The four-step synthesis starting from 3-iodoanisole furnishes the 
desired product with an overall yield of 18%. It is curious that, from the two chloromethyl 
groups in the first intermediate compound, the one adjacent to iodine is more reactive than the 
34 
other. However, in this procedure an appropriate substitution on the aromatic ring before the 
introduction of the chiral auxiliary led to a smooth conversion of the alcohol into the formyl 
group. Unfortunately, no 
18
F-labeling results with this precursor have been reported so far.  
HO F
O
BnO F
O
BnO F
OH
BnO F
Br
BnO F
N
N
O
O
BnBr
KF
NaBH4
SOBr2
Py
N
N
O
O
Li
Cl2HCOCH3
SnCl4
BnO F
N
N
O
O
O
 
Scheme 23: Synthesis of “Schöllkopf”-precursor for the radiosynthesis of 6-[18F]FDOPA by 
isotopic exchange according to Tierling et al.
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Scheme 24:  Synthesis of “Seebach”-precursor for the radiosynthesis of 6-[18F]FDOPA 
according to Kuroda et al.
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A further synthesis concept of Wagner et al.
105
 integrates the advantages of the both 
concepts previously described. In the following paragraphs Wagner´s approach will be 
presented in detail for the example of the precursor 1a and how a new and more efficient 
synthetic route was built here on these fundaments. 
Compound 1a was originally envisioned as potential precursor for the synthesis of 6-
[
18
F]Fmtyr,
130
 due to its similarity with the 6-[
18
F]FDOPA precursor, however, with a lower 
complexity, it became an important model compound. The optimized synthetic procedure for 
1a was supposed to be transferable to that of the 6-[
18
F]FDOPA precursor 1b. 
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Scheme 25: Synthesis of 1a, precursor for the radiosynthesis 6-[
18
F]Fmtyr by Wagner
130
  
The eight-step procedure starts with the reduction of the carbonyl function of 3-bromo-4-
fluorbenzaldehyde followed by the protection of the resulting alcohol as the 
tetrahydropyranylether (THP) derivative. Lithiation of the protected alcohol and quenching of 
the organometallic species with DMF yielded the o-fluorobenzaldehyde derivative 5. The 
benzaldehyde was then reduced to the benzylalcohol with NaBH4 and brominated with 
36 
CBr4/PPh3. Sequential treatment of the Seebach reagent ((S)-Boc-BMI) with lithium 
diisopropylamide and then with benzylbromide 7 led to the compound 8. Acid deprotection of 
the THP group followed by a Swern oxidation of the resulting alcohol yield the precursor 1a 
(Scheme 25). 
Although the precursor could be achieved using the described pathway, the overall yield 
was relatively low. The main cause was the low yields obtained in the formylation, 
bromination and alkylation steps which were lower than 30% for each of those.  
3.1.2 Improvements of the existing synthetic procedure for precursors 1a and 1b 
Improvement of the synthesis of precursor 1a 
One of the goals of the present work was to optimize this synthetic pathway. To that 
purpose, a systematic study of these three critical reactions was performed.  
According with the report of Wagner,
130
 the formylation step yielded in average 26% of 
the desired product. This is a “one-pot two-step” reaction, starting with the formation of the 
lithiated species by the Br-for-Li exchange reaction. Then DMF is added and the reaction 
mixture warmed to room temperature. The TLC analysis of the crude reaction mixture besides 
a new spot belonging to the formylated product, showed a second one, which, due to the Rf 
value was presumed to be non-reacted starting material 4. After chromatographic purification 
the supposed starting material was analyzed by 
1
H-NMR. The analysis showed that this 
compound was the non-brominated derivative 11 and not 4 as assumed. This side compound 
is most probably generated by the hydrolysis of the organo-lithium species as depicted in 
Scheme 26.  
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Scheme 26:  Side reaction of the formylation of 4 by lithiation yielding the non-brominated 
compound 11 
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In order to avoid this side reaction, the water-free conditions were improved. Under 
strictly water-free conditions, the desired product 5 was obtained with a yield of 79%. This 
yield is in agreement with those previously reported for analogous compounds.
131
 
Once the problems with the formylation were solved, the efforts were directed toward the 
optimization of the bromination reaction. Again here the yield was lower than 30%. The 
conversion of the benzylalcohol to the benzylbromide was earlier performed by Wagner et 
al.
105
 using the Appel reaction.
132
 This is a method for halogenation of alkylalcohols under 
mild conditions; however it can also be used for the bromination of benzylalcohols. The 
mechanism of the reaction involves the formation of a phosphonium salt pair 12. 
Deprotonation of the alcohol, forming bromoform, yields an alkoxide ion pair. The 
nucleophilic displacement of the bromide by the alkoxide yields intermediate 14. The bromide 
anion reacts by an SN2 process forming the desired bromide 7 and triphenylphosphine oxide 
15. The formation of the stable oxide is the driving force of the reaction.
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Scheme 27:  Mechanisms of the Appel reaction for conversion of benzylalcohols into 
benzylbromides
132
 
The reaction time and the temperature used by Wagner
130
 were 0.5 h and 0 C 
respectively. Under these conditions a complex mixture of products was obtained. In a first 
attempt to improve the yield, the temperature was increased to r.t. The experiment was not 
successful; a mixture of products with bigger complexity as before was obtained while the 
yield of the desired compound dropped to just 20%. Then, the conditions suggested by 
38 
Kocienski et al.
 133
 were applied. This time the reaction was cooled down to 0 C, the 
triphenylphosphine was added portion wise and after the last addition the mixture was stirred 
for additional 5 min before quenching. The use of Kocienski experimental modification 
produced compound 7 in yields ranging from 51% to 64%. Additionally, exclusively the 
desired compound was formed, which facilitated the purification step. Despite the acceptable 
yield obtained in its preparation, the bromobenzyl derivative shows a further disadvantage, 
the compound is thermally unstable; particularly when a solution of it in chloroform of ethyl 
acetate was heated above 40 °C. 
The next step of the optimization procedure was the alkylation of the benzylbromide 7 
with the lithium enolate of the chiral auxiliary (S)-(-)-1-BOC-2-tert-butyl-3-methyl-4-
imidazolidinone (Seebach‟s reagent) which before was producing compound 8 in low yield. It 
was observed that the conversion of the starting material, i.e. Seebach´s reagent, was very low 
and it could be recovered after chromatographic purification. The method, as well as in the 
case of formylation, is a “one-pot two-step” reaction which involved the formation of a 
nucleophilic species followed by quenching with an electrophile. Scheme 19 depicts both the 
formation of the Seebach´s enolate and its deactivation due to protonation. In order to increase 
the yield same measures to avoid moisture in the reaction medium were taken. Freshly 
prepared lithium diisopropylamide (LDA), product of the reaction of diisopropylamine and 
BuLi at -78 °C during 15 min, was used to generate the enolate derivative of Seebach 
reagent.
134
 The use of commercially available LDA in contrast leads to poor yields (20-30 %). 
On the other hand, the synthesis of LDA at -78 °C provides better alkylation yields compared 
with LDA prepared at 0 °C. Under these conditions the yield of the coupling compound could 
be improved to 70%. 
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Scheme 28: Formation and side reaction of the enolate 17 with H
+
. 
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Improvement of the synthesis of precursor 1b 
Once the low yield reaction steps were optimized, the interest focused on the synthesis of 
the 6-[
18
F]FDOPA precursor 1b. Scheme 29 depicts the synthesis of the benzylalcohol 22 to 
be used as starting compound for the analogous synthesis (see Scheme 25, comp. 3). The 
procedure starts with the bromination of 4-fluorosalicylic acid in ethanolic basic medium, 
followed by esterification with trimethylsilyldiazomethane (TMSDAM)/methanol. The 
phenol function was then protected as benzylether and finally the ester was reduced to the 
benzylalcohol with LiAlH4, however, after the last reaction small amounts of the 
debrominated benzyl alcohol were also detected. 
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Scheme 29: Synthesis of the benzylalcohol 22 from 4-fluorosalicylic acid 
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Scheme 30: Synthesis of the aldehyde 24 
After the benzylalcohol was prepared, the intention was to follow the synthetic pathway 
as described by Wagner et al.
105
 for compound 1a. The alcohol 22 was protected without 
problems as tetrahydropyranylether (Scheme 30). However, the formylation reaction, 
although conducted under the optimized conditions, generated a complex mixture of products 
from where the desired compound was difficult to isolate. The yield of product 24 was 20%. 
Among others, the presence of different isomers of the desired product was observed which 
40 
demonstrates that the reaction was not regiospecific. After this drawback, efforts were 
focused to find an alternative milder and regioselective reaction. 
3.1.3 New synthetic pathways for the preparation of labeling precursors 
Synthesis of the precursor 1a via a dioxalane approach 
Further experiments were performed in order to increase the efficiency of the synthesis of 
compound 1a by shortening the number of steps involved. Although the sequence oxidation–
THP protection as well as THP deprotection-reduction proceeds smoothly to afford the 
desired compounds in good yields, it also presents some drawbacks. First, the purification 
step of the protected alcohol 5 is complicate because of the desired compound and an impurity 
run closely together in the chromatography. Second, the deprotection reaction is time 
consuming; the reaction must be stirred overnight to afford the alcohol 9. Finally in order to 
guarantee a high conversion yield of the alcohol to the carbonyl, fresh oxalyl chloride is 
needed. Otherwise the activation of the DMSO is not effective and a mixture of the desired 
carbonyl compound and the starting material is obtained.  
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Scheme 31: Alternative synthesis of precursor 1a via a dioxalane approach 
Protection of the carbonyl group as the acetal derivative saves two synthetic steps. The 
acetal was prepared by condensation of 1,2-ethylene glycol with 3-bromo-4-
fluorbenzaldehyde using toluene as solvent. Formylation via Br-Li exchange followed by 
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addition of DMF and subsequent reduction of the o-fluorobenzaldehyde 26 yielded the 
benzylalcohol 27 with a combined yield of 50% (Scheme 31).  
Wagner explored also this strategy but was unsuccessful in achieving the bromobenzyl 
derivative 28; however, the previous result obtained in this work for the Appel reaction 
encouraged us to try the conversion. Compound 28 was obtained with a yield of 64%. 
However, besides 28 the unprotected bromobenzylaldehyde was formed. The use of CBr4 and 
PPh3 has been pointed out as reagents for the hydrolysis of acetals.
135
 In addition the 
bromobenzyl derivative 28, analogously to compound 7, evidenced thermal instability. 
After coupling with Seebach reagent, the deprotection of the acetal was performed using 
the procedure proposed by Sun and coworkers.
136
 The precursor 1a was obtained in a yield of 
94% after deprotection of 29 using catalytic amounts of I2 in acetone under reflux conditions. 
A substrate exchange mechanism is proposed for this reaction. It is presumed that the 
deprotection initially involves a polarization of carbonyl group in acetone by molecular 
iodine. The possible mechanism is shown in the Scheme 32.  
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Scheme 32: Proposed mechanism for the removal of the acetal protecting group 
Synthesis of precursors 1a, 1b, 1c, and 1d via a dithiolane approach 
Due to the success of the six-step approach for the synthesis of compound 1a, it was 
decided to transfer this methodology to the preparation of the compound 1b as well as to the 
novel (2S,5S)-tert-butyl-5-(5-acetyl-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidi-
ne-1-carboxylate 1c, a promising precursor for the radiosynthesis of 6-[
18
F]Fmtyr.  
It was previously discussed that the use of the 1,3-dioxolane derivative showed moderate 
lability during the bromination reaction and besides of that, product 28 was not stable. In 
42 
order to prevent the incidense of these side reactions the protecting group was changed to the 
more stable 1,3-dithiolane.  
3-bromo-4-fluorobenzaldehyde 2a, 2-(benzyloxy)-5-bromo-4-fluorobenzaldehyde 2b, 
and 1-(3-bromo-4-fluorophenyl)ethanone 2c were used as starting materials for precursors 1a, 
1b and 1c, respectively. The first and third are commercially available. The aldehyde 2b was 
prepared as shown in scheme 24.  
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Scheme 33: Synthesis of 2-(benzyloxy)-5-bromo-4-fluorobenzaldehyde 2b 
4-Fluorosalicylic acid was brominated in basic alcoholic medium using molecular 
bromine. The reaction produced the desired 3-bromo-4-fluoro-salicylic acid 30 in a yield of 
82%. Benzylation of 31 with benzyl bromide in basic media yielded the compound 32 in 77%. 
The ester functionality of 32 was then reduced to the alcohol 22 with 92% yield using 2.1 
equivalents of DIBAL-H. The first intention was to reduce the ester just to the corresponding 
aldehyde, however, after several trials using one equivalent of the reducing agent at different 
temperatures the result was always a mixture of 1:1 of the starting material and the benzyl 
alcohol derivative 22. Red-Al-pyrrolidine, which has been earlier successfully employed in 
this kind of reduction,
137 
produced similar results. Analogously as with compound 21 again 
here, the reduction of the ester to the alcohol using LiAlH4, generates a mixture of the desired 
alcohol 22 plus the debrominated alcohol. However, oxidation of alcohol 22 with Dess-Martin 
periodinane (DMP) in dichloromethane at room temperature optimally provides exclusively 
the aldehyde 2b in a yield of 92%.
138
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Scheme 34 resumes the general synthetic pathway for 1a, 1b and 1c. As mentioned 
before, in the first step the carbonyl function was protected as 1,3-dithiolane derivative using 
the procedure described by Firouzabadi and coworkers.
139
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Scheme 34: General synthetic pathway to precursors 1a,b,c 
Due to the unsatisfactory results obtained for the formylation of 23, compound 33b was 
selected as substrate in order to find an alternative to the Br-for-Li exchange. Compound 33b 
was reacted with Li2Cu(CN)Me2; a milder reagent than BuLi that has been used for the 
halogen-for-copper exchange reaction on aromatic aldehydes. In order to improve the 
homologation reaction, ethyl chloroformate was preferred as electrophile over DMF due to its 
higher electrophilic character (Scheme 35).  
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Scheme 35: Acylation reaction of 33b with ethyl chloroformate 
The reactions were performed following the procedure described by Kondo and 
coworkers.
140
 When the Br-for-Cu exchange reaction was carried out at -40 ºC for 30 min the 
desired product 34b was obtained in 15% yield. In spite of the low yield a positive aspect was 
that only the desired product was formed (Table 3, entry 1). Since the reaction showed the 
44 
desired regioselectivity, efforts were oriented to find optimal conditions for the conversion of 
compound 33b. In a second attempt, the reaction time was extended to 1 h, but the desired 
compound was isolated again with a low yield only. When the exchange was conducted at r.t. 
no formation of the product was detected by TLC of the crude reaction mixture. This is 
probably due to decomposition of the organometallic complex because of the high 
temperature (Table 2, entries 2-3). An alternative copper reagent is Neopent2CuLi, which has 
earlier been successfully used for the Br-for-Cu exchange reaction with diethyl 2-
bromoterephthalate.
141
 When Neopent2CuLi was reacted with 33b at r.t. for 1 h and 
subsequently treated with ethyl chloroformate the desired product 34b was obtained with a 
yield of 5% (Table 3, entry 4). The formation of lithiumcuprates through Br-for-Cu exchange 
proved to be regioselective, however, the conversion and therefore the yield of the desired 
compound were low. Generally, the exchange I-for-Cu is preferred over the Br-Cu exchange 
since iodine is a better leaving group than bromine for this kind of reactions. Based on these 
results a different option had to be explored since Li-for-Br exchange using sec-BuLi proved 
to be too reactive, while the Br-for-Cu exchange was too mild.  
Table 2: Optimization of the reaction conditions for the acylation of 33b with ethyl 
chloroformate 
Entry Reagent Time h Temp °C Yield % 
1 Li2Cu(CN)Me2 0.5 -40 15 
2 Li2Cu(CN)Me2 1 0 5 
3 Li2Cu(CN)Me2 0.5 r.t. 0 
4 Neopent2CuLi 1 r.t. 5 
5 i-PrMgCl.LiCl 1 0 54 
6 i-PrMgCl.LiCl 1 r.t. 30 
7 i-Pr2MgCl.LiCl 1 0 77 
Krasovskiy and coworkers reported that i-PrMgCl·LiCl can be used for high yield 
preparations of functionalized arylmagnesium reagents starting from aryl bromides.
142
 The 
best yield (54%) using this reagent was obtained when the Br-for-Mg exchange reaction was 
carried out at 0 ºC for 1 h (Table 2, entry 6). The addition of dioxane to a solution of i-
PrMgCl·LiCl in THF displaces the anionic Schlenk equilibrium forming 
diisopropylmagnesium chloride lithium chloride complex (i-Pr2MgCl·LiCl), this complex has 
shown exceptional reactivity for the conversion of aryl bromides into the corresponding 
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Grignard reagents.
143
 Using i-Pr2MgCl·LiCl under the conditions described before, compound 
11 was achieved in 77% yield (Table 2, entry 7). Attempts to prepare the benzyl alcohol 12 
directly by means of coupling of organo-magnesium species with para-formaldehyde pro-
vided the desired compound in poor yields of 10–20%. 
Reduction of 34 with LiAlH4 provided the benzyl alcohol 35 with around 92% yield after 
1 h at room temperature. The conversion of the benzyl alcohol to the benzyl bromide was 
performed using the Appel reaction with good yields.
144
 The stability of this group of benzyl 
bromides has been a problematic issue. Although the dioxalane protecting group should 
impart more stability, immediate decomposition was also observed when solutions of the 
benzyl bromide in dichloromethane or ethyl acetate were heated over room temperature. In 
order to avoid this problem, the reaction solvent CH2Cl2 was partially evaporated under vacuo 
without application of external heating. 
After optimization, the alkylated product 37 was obtained in a yield range of 75-89 %. 
Deprotection of the 1,3-dithiolane following the procedure described by Languille and 
coworkers using Dess-Martin periodinane (DMP) regenerates the carbonyl functionality to 
afford the desired series of compounds 1 with yields of around 80%.
145
 However, when 
commercial available DMP was used the reaction takes 3 h to be completed while with freshly 
prepared DMP only 0.5-1 h was required. Further experiments showed that the use of 
commercially available [bis(trifluoroacetoxy)iodo]benzene (BTI) generates the desired 
compounds 1 within 10 min in 91-93% yield.
146
 
In summary, the synthesis of 1b has been optimized. The 10 steps procedure achieved the 
desired compound with an overall yield of 19%. In addition, the derivatives 1a and 1c have 
been synthetized in 6 steps with overall yields of 41% and 48%, respectively. Table 3 lists the 
yields of the reaction steps to fluorobenzyloxoimidazolidinone derivatives 1a, 1b and 1c. 
Using the same synthetic strategy, and with the aim of studying the steric effect of bulky 
protecting groups over the RCY and the enantiomeric purity of 2-[
18
F]Fphe, a precursor was 
prepared bearing a benzyloxycarbonyl protecting group instead of a tert-butoxycarbonyl 
(Boc) in position 1 of the imidazolidinone system. Scheme 36 depicts the synthesis of 1d. For 
this purpose compound 36a was coupled with the lithium enolate of the (S)-benzyl 2-tert-
butyl-4-oxoimidazolidine-1-carboxylate ((S)-Z-BMI) in 78% yield and afterwards deprotected 
with BTI in order to get the desired compound in 90%.  
46 
Table 3: Yields of the reaction steps to fluorobenzyloxoimidazolidinone derivatives 1a, 1b 
and 1c 
Compound a (%) b (%) c (%) 
33 97 96 95 
34 81 77 81 
35 91 90 91 
36 74 74 84 
37 84 75 89 
1 93 92 91 
Overall yield 41 34
a
 48 
a
Including the synthesis of 2b the overall yield for 1b is 19 %. 
 
Scheme 36: Synthesis of precursor 1d from compound 36a 
Synthesis of Schöllkopf-precursors 1e and 1f via a dioxalane approach 
The previously developed synthetic approach provided not only the envisioned precursors 
1 but also constitutes the basis for the preparation of other interesting derivatives. Compounds 
bearing Schöllkopf´s chiral auxiliary are also of interest since the hydrolysis can be achieved 
using milder conditions than those needed for Seebach´s derivatives. Moreover, this kind of 
labeling precursors has not been fully evaluated yet due to the lack of a reliable synthetic 
procedure. 
The alkylation of the benzyl bromides 36a and 36c with Schöllkopf‟s derivatives 
generates the compounds 37e and 37f, respectively (Scheme 37).  
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Scheme 37: Alkylation of compounds 36 with Schöllkopf´s chiral auxiliary 
Attempts to cleavage the 1,3-dithiolane protecting group of 37f using DMP, as it was 
described above for Seebach´s derivatives, were unsuccessful. Although the spot 
corresponding to the desired compound 1f was seen in the TLC analysis of the reaction 
mixture after 10 min, it disappears with the advance of the time before the starting material is 
consumed. It seems that under these oxidative conditions the decomposition of the 
bislactimether occurs faster than the cleavage of the 1,3-dithiolane functionality. Further 
experiments following different procedures described in the literature were performed in order 
to achieve the desired deprotection. The reaction conditions and results are summarized in 
Table 4.  
Table 4: Conditions and yields for the cleavage of the 1,3-dithiolane functionality of 37e  
Entry Solvent Reagent
ref 
Temp ºC Time min. Yield % 
1 CH2Cl2 DMP
145 
r.t. 40 0
 
2 DMSO I2
147
 100 50 0
 
3 EtOH:H2O AgNO3
148
 50 20 0
 
4 ACN:H2O (3:1) KBr, Oxone
149
 r.t. 60 0
 
5 ACN:H2O (3:1) KBr, Oxone
149 
r.t. 20 2 
6 CH2Cl2 NBS+DMSO
150 
r.t. 20 0
 
7 CH2Cl2 m-CPBA+TFA
151
 r.t 30 0
 
8 ACN:H2O (9:1) BTI
146 
r.t. 10 70 
  
The best results were achieved when BTI was used. The desired compound 1f was 
isolated in 70% within 10 min reaction time. Analogously the aldehyde 1e was produced with 
48 
76% yield (Scheme 38). These results were the reason why BTI was also tried for the 
deprotection of the precursors bearing Seebach´s chiral auxiliary.  
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Scheme 38: Cleavage of the 1,3-dithiolane functionality of 37e and 37f with BTI 
Synthesis of fluorophenone derivatives of Seebach-precursors 1g and 1h via a Grignard 
approach 
As described before the synthesis of the precursor 1c was performed starting from the 
commercially available 4-fluoro-3-bromoacetophenone in a six-step synthetic procedure with 
an overall yield of 46%. Due to the unavailability of analogues ketones derivatives and the 
success obtained with the halogen-for-magnesium exchange reaction a novel three-step 
synthetic pathway for precursors 1g and 1h was developed (Scheme 39).  
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Scheme 39: General synthetic pathway to precursors 1g and 1h  
The commercially available 2-fluoro-5-iodobenzaldehyde 38 was treated with an excess 
of diiodosilane (DIS) in order to produce the diiodo derivative 39.
152
 Using commercial DIS, 
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total conversion of the starting material was achieved after 8 h and 4 equivalents of DIS were 
needed. The use of freshly prepared DIS reduced both, the reaction time to 1.5 h and the 
amount of reagent needed to 1.5 equivalents.
153
 In both cases the isolated yield of compound 
39 was about 80%. 
Freshly prepared lithium diisopropylamide (LDA) was used to generate the enolate 
derivative of Seebach´s reagent. This was coupled with compound 39 and the alkylated 
product 40 was obtained in 81% yield. 
Finally, the precursor 1g was obtained using a “one-pot two-step” reaction. In the first 
step compound 40 was reacted with i-PrMgBr in order to generate the magnesium derivative. 
The magnesium derivative was then acylated with 3,5-bis(trifluoromethyl)benzoyl chloride. 
The precursor 1g was obtained with 84% yield. Following an analogous procedure, the 
organo-magnesium derivative was reacted alternatively with trifluoroacetic anhydride. In this 
case, the precursor 1h was obtained with 62% yield. 
3.1.4 Conclusions 
Two efficient synthetic approaches have been developed for the preparation of highly 
functionalized fluoro-benzaldehydes and ketones. The first approach involves 6 steps and is 
an optimized modification of the synthesis pursued by Wagner et al.
105
 for the compounds 1a 
and 1b, in which two steps for 1a and one for 1b have been saved and the overall yields 
considerably increased from 4% for 1a and 1% for 1b to 41% and 19% respectively. The 
second approach is a novel three-step synthesis, which here has been used for the preparation 
of ketone precursors 1g and 1h. However, this attractive method can probably also be applied 
for the synthesis of aldehydes. 
In total eight different precursors have been prepared and four [
18
F]fluorophenylamino 
acids are supposed to be achievable from them. Precursors 1a, 1d and 1e will be used for the 
radiosynthesis of 2-[
18
F]F-phe via a decarbonylation reaction (Scheme 40).  
As depicted in Scheme 41, the versatile precursor 1b will be employed for the 
radiosynthesis of 2-[
18
F]Ftyr via a decarbonylation reaction as well as for the radiosynthesis 
of 6-[
18
F]FDOPA via Baeyer-Villiger oxidation. 
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Scheme 40: Precursors 1a, 1d and 1e for the radiosynthesis of 2-[
18
F]Fphe  
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Scheme 41: Precursor 1b for the radiosynthesis of 2-[
18
F]Ftyr and 6-[
18
F]FDOPA 
The last four precursors enable the radiosynthesis of 6-[
18
F]Fmtyr. It will be possible to 
comparatively evaluate the influence of the activating group in the labeling reaction as well as 
the influence of the chiral auxiliary in the enantiomeric purity (Scheme 42). 
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Scheme 42: Precursors 1c, 1f, 1g and 1g for the radiosynthesis of 6-[
18
F]Fmtyr 
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3.2 Enantioselective radiosynthesis of 2-[18F]fluoro-L-phenylalanine and 2-
[
18
F]fluoro-L-tyrosine by isotopic exchange 
As mentioned in the introduction of this work, 2-[
18
F]Fphe and 2-[
18
F]Ftyr are two 
radiopharmaceuticals that may be useful in the evaluation of the brain functions and have 
potential as diagnostics for tumors. In spite of the potential of these compounds the lack of a 
convenient radiosynthetic methodology for their preparation has limited a wider use in 
nuclear medicine practice. 
The radiosynthetic approach pursued in this section is based on the procedure followed 
by Wagner et al.
105
 for the synthesis of 6-[
18
F]FDOPA. Scheme 43 depicts the radiosynthetic 
pathway. Different to the previous radiosynthesis a major modification has been done in the 
second step where instead of the Baeyer-Villiger oxidation a decarbonylation reaction using 
Rh(PPh3)3Cl was performed, in order to obtain the target compounds. 
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Scheme 43: General radiosynthetic pathway to 2-[
18
F]Fphe and 2-[
18
F]Ftyr. 
3.2.1 Radiofluorination 
The first step of the radiosynthetic concept pursued here for labeling of the title 
compounds is an isotopic 
18
F-for-
19
F exchange. Previous work on nucleophilic aromatic 
18
F-
substitution of benzaldehydes using both, model compounds and complex precursors, have 
shown that the use of DMF as solvent and temperatures above 100 °C gave the best 
radiochemical yields.
105,154
 Table 5 summarizes the results obtained with the optimization of 
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the labeling conditions for precursor 1a under conventional heating. Entries 1 to 4 show that 
an increase of the concentration of the basic tetra-n-butylammonium hydrogen carbonate 
(TBAHCO3) as anion activator led to higher labeling yields; but also the formation of an 
additional new product was evidenced by both TLC-UV and radio-TLC analyses. In order to 
identify the side product a cold experiment was carried out and the new compound was 
isolated and analyzed by NMR. The 
1
H spectrum revealed that the new species was the 
diastereomer 42a (Scheme 44), resulting from epimerization in position 5 of the 
imidazolidinone system. An increase of the temperature to 150 ºC (entry 5) did not provide a 
better RCY but a diastereomeric 1:1 mixture of the compounds [
18
F]1a and 42a within 10 
min. Standard 
18
F-labeling conditions using Kryptofix 2.2.2
25
 (entry 6) provided the undesired 
diastereomer 42a even as major product.  
TBA18F
DMF
18F
O
N
N
Boc
O
+1 [
18F]1
R1
42a, R1= H
42b, R1= OBn  
Scheme 44: Epimerization of 1a,b during the isotopic exchange reaction. 
Table 5: Influence of temperature, time and kind of anion activation (PTC) on the RCY of 
the isotopic exchange reaction on 1a
a,b 
   10 min 20 min 
Entry PTC
c
 [μmol] Temp. 
°C 
[
18
F]1a (%) 42a (%) [
18
F]1a (%) 42a (%) 
1 TBAHCO3 [2.3] 130 28 0 39 0 
2 TBAHCO3 [5.2] 130 51 6 57 7 
3 TBAHCO3 [8.5] 130 60 10 59 14 
4 TBAHCO3 [17.0] 130 61 17 52 30 
5 TBAHCO3 [5.2] 150 26 24 - - 
6 [K222]2CO3 [13.0] 130 26 40 14 50 
aSD = ±5%. b1 mL DMF, 15 µmol 1a, conv. heating (oil bath). cPTC = phase transfer catalyst for [18F]fluorine activation. 
Based on these results, the conditions described in entry 2 of Table 5 were selected for 
further experiments for the labeling of precursor 1a under conventional heating.  
54 
Similarly, the isotopic exchange reaction with precursor 1b generates the products 
[
18
F]1b and 42b following the trends previously described for the compound 1a, i.e. the 
fluorine exchange yield increases with the increase of both, the concentration of the base and 
of the temperature, in detriment of the radiochemical purity. The best RCY of [
18
F]1b was 
59% while that of 42b was 4%. The optimal results were obtained in this case under identical 
conditions as given in entry 2, besides that 6.4 μmol of TBAHCO3 were employed. 
It was also observed that the labeling reaction of precursors 1 is very sensitive to 
humidity. The RCY dropped dramatically when not freshly dried solvents (acetonitrile for 
TBA
18
F drying process and DMF for labeling) were used. This phenomenon can be caused by 
formation of relative high concentrations of H
18
F if, due to the low concentration of the base, 
the nucleophilic halide species cannot be effectively regenerated. However, deactivation of 
the base by neutralization not only led to the observed decrease of the RCY of the desired 
products [
18
F]1 but also the occurrence of diasteromers 42 was decreased.  
In an attempt to improve the isotopic exchange process the reaction was performed using 
microwave heating. Microwave irradiation produces efficient internal heating by direct 
coupling of microwave energy with the molecules that are present in the reaction mixture 
creating an inverted temperature gradient compared to conventional thermal heating.
155
 Due 
to these characteristics microwave heated reactions are faster and in some cases more 
selective and than those under conventional heating. 
Figure 7 shows the RCY of compounds [
18
F]1a and 42a in dependence of the applied 
microwave power. It can be seen that the total RCY increases with power, however at above 
45 W the undesired diastereomer 42a starts to appear and its yield increases also with elevated 
power.  
Table 6 compares the optimized results obtained with the synthesis of [
18
F]1a and [
18
F]1b 
under conventional and microwave heating. It can be noticed that either conventional or 
microwave heating produce a rather similar RCY. The main difference is the reaction time, 
where the microwave heated reaction is ten times faster than that with heating by oil bath. 
Increasing the RCY of the compounds [
18
F]1, by extending the reaction times is limited due 
to the occurrence of the diastereomers 42. 
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Figure 7: Dependence of the RCY of [
18
F]1a and 42a as function of the microwave power. 
15 µmol 1a, TBAHCO3 5.1 µmol, 1 mL DMF, 1 min 
Table 6: Optimized RCY of labeling of 1a,b by isotopic exchange using both conventional 
and microwave heating
a 
Precursor Heating
b
 Time (min) [
18
F]1 (%) 4 2(%) 
1a CH 10 51 6 
1a MH 1 42 5 
1b CH 10 59 4 
1b MH 1 53 4 
a
SD = ±5% (CH), ±1% (MH).
 b
CH: conventional heating (oil bath), MH: microwave heating. 
3.2.2 Decarbonylation 
The removal of the activating formyl group (Scheme 43) was performed with 
Rh(PPh3)3Cl (Wilkinson´s catalyst). Using this reagent for decarbonylation, however, a 
stoichiometric reaction is required due to the formation of stable Rh(PPh3)2(CO)Cl as 
secondary product. Optimization studies were carried out using compound [
18
F]1a as starting 
material under similar conditions as those described by Plenevaux and co-workers for the 
decarbonylation of [
18
F]fluorobenzaldehydes.
156
 Dioxane was used as solvent and the reaction 
solution was magnetically stirred for 20 min in an oil bath at 150 ºC. Since the labeled 
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compound [
18
F]1a is chemically indistinguishable from the precursor 1a they can not be 
separated and the amount of the Rh complex was calculated as the molar equivalent of 1a.  
Figure 8 graphically depicts the obtained results. Using equimolar amounts of starting 
material and organometallic reagent 64 ± 5% of the desired compound 41a was observed in 
radio-HPLC analysis (see experimental, System A) as well as 21 ± 7% of the starting material 
[
18
F]1a and 15 ± 3% of an unknown compound. Increasing the amount of Wilkinson`s 
catalyst to 1.5 eq improved the conversion of the starting material to 99% and a RCY of 85 ± 
8% of the desired compound 41a (Table 7, entry 1). Further increase of the amount of catalyst 
did not cause any improvement, in constrast augmented the amount of the side product. 
 
Figure 8: Radioactivity distribution of [
18
F]1a, 41a and an unknown compound as function 
of the amount of Rh complex. 15 µmol [
18
F]1a, 1 mL dioxane, 20 min  
In 2007 Shen and coworkers published a study dealing with the decarbonylation reaction 
of poly-substituted [
18
F]fluorobenzaldehydes with Rh(PPhe3)3Cl.
11
 Also there the formation 
of an unknown polar compound was observed besides the desired product. They found a 
relationship between the occurrence of the side product and the kind of solvent, pointing out 
benzonitrile as the medium of choice for this reaction. In fact using benzonitrile as solvent at 
150 ºC for the decarbonylation of [
18
F]1a none of the unknown compound was detected while 
a mixture of the starting material and the desired compound 41a in 40:60 proportion was 
provided after 20 min reaction time (Table 7, entry 2). In order to improve the conversion, the 
temperature was raisen to 180 ºC. This time 15% of the unknown compound was detected 
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while the conversion of [
18
F]1a was still incomplete (Table 7, entry 3). On the other hand, the 
use of DMF as solvent produced the unknown compound as major product (Table 7, entry 4).  
Table 7: Solvent effect on the RCY of the decarbonylation reaction on [
18
F]1a
a,b 
Entry Solvent Rh eq. Temp °C Unkn ( %) [
18
F]1a (%) 41a (%) 
1 Dioxane 1.5 150 14 1 85 
2 Benzonitrile 2.0 150 - 40 60 
3 Benzonitrile 2.0 180 15 18 67 
4 DMF 2.0 150 62 16 22 
a
SD = ±5%.
 b
15 µmol [
18
F]1a, conventional heating, 20 min 
In further experiments using dioxane as solvent was observed that a reaction time shorter 
than 20 min decreases the conversion yields of [
18
F]1a while a longer reaction time increased 
the yield of the unknown product. Thus, the overall best conditions for decarbonylation were 
those ones described in entry 1 of the Table 7 with an almost quantitative conversion of 
[
18
F]1a and in total only 15% of other labeled compounds. 41a could easily be separated by 
use of a silica gel column and a solvent mixture of ethyl acetate in petroleum ether (30%) 
while the polar unknown compound remained attached on the stationary phase. 
A microwave heated version of the decarbonylation reaction was also developed. In this 
case compound [
18
F]1b was used for the optimization procedure and benzonitrile was 
preferred over dioxane as solvent since it shows better absorption of microwaves. The 
reaction was irradiated with 100 W during 50 s. Figure 9 shows the distribution of 
radioactivity among products formed as function of the amount of Wilkinson‟s catalyst. In 
contrast to the conventionally heated reaction both, the conversion of [
18
F]1b and the yield of 
the desired compound 41b, increased with the amount of the Rh complex.  
This could be transferred to compound 1a and when using 4 equivalents of the Rh 
complex the desired compounds 41a and 41b were obtained in yields of 83 ± 1% and 81 ± 
1%, respectively. Although neither the yields nor the selectivity of the microwave heated 
reactions were better than those via conventional heating the reproducibility and especially 
the reaction time was again considerably improved by the change to microwave heating. 
Analogously as with conventional heating, here again an optimal reaction time (50 s) was 
found, with lower RCY at shorter times but increased formation of the unknown product 
above 50 s. 
58 
 
Figure 9: Radioactivity distribution of [
18
F]1b, 41b and unknown compound as function of 
the amount of Rh complex. 15 µmol [
18
F]1b, 1 mL benzonitrile, 50 s 
The decarbonylated products were purified using a silica gel cartridge. Due to the higher 
boiling point of benzonitrile, the solvent was not evaporated, in case of microwave heating, 
but the reaction mixture rather diluted with 5 % ethyl acetate in petroleum ether and then 
passed via syringe through the column where the reaction products were retained. A second 
portion of the same solvent mixture was used in order to assure the total elution of the 
benzonitrile. The desired compound 41b was then eluted with a more polar solvent mixture as 
described above for the elution of 41a. 
3.2.3 Hydrolysis 
In previous reports the hydrolysis of imidazolidinones has been carried out with 
concentrated HI or HBr and temperatures of 200 ºC and 150 ºC, respectively.
105,157
 The need 
of such harsh conditions is due to the high stability of the amide bond.
158
 In this work here 
hydrolysis with all typical mineral acids (HI, HBr and HCl) was performed resulting in 
quantitative hydrolysis yields at 190 ºC during 30 min no matter which acid was used. Several 
experiments were performed in order to achieve satisfying results with diluted acids, e.g. 1.0 
to 7.5 N HCl, however, they were unsuccessful. Therefore for further experiments less 
hazardous concentrated HCl was used.  
The microwave heated version of this reaction gave also quantitative yields while saving 
again reaction time when the temperature/time control of the device was used in order to keep 
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the temperature at 140 ºC for 20 min. The application of high power microwaves was avoided 
with HCl because of the rapid generation of overpressure which can lead to the explosion of 
the reaction vessel. 
After the three steps the conventional heated reactions yielded the desired products 2-
[
18
F]Fphe and 2-[
18
F]Ftyr in 43% and 49% whereas 34% and 43% RCY, respectively, were 
obtained when microwave heating was applied, however, 38 min of total preparation time 
were saved with the latter. Thus considering the radioactive decay, the amounts of isolated 
radioactive products were directly comparable. Both products were obtained with good 
enantiomeric purity. The e.e. achieved for 2-[
18
F]Fphe was 88% while an e.e. of 92% was 
obtained in the case of 2-[
18
F]Ftyr. 
3.2.4 Specific activity 
 The specific activity obtained in isotopic exchange procedures is a function of both, 
the quantity of labeling precursor and starting [
18
F]fluoride activity. The maximum amount of 
carrier that can be found in 2-[
18
F]Fphe and 2-[
18
F]Ftyr preparations directly corresponds to 
the amount of precursor which in this work was 2.8 mg and 3.0 mg, respectively. Using the 
electrophilic radiofluorination by destannylation it has been reported that batches of activity 
of 1.41 GBq of 2-[
18
F]Ftyr can be obtained with a specific activity of around 74 GBq/mmol,
41
 
which corresponds to a carrier content of approximately 3.8 mg. This amount is even bigger 
than the maximum amount of carrier with the isotopic exchange procedure described here 
under developmental conditions with a low starting radioactivity of about 300 MBq per 
experiment. Thus, in production runs starting with > 10 GBq of n.c.a. [
18
F]fluoride it can be 
expected that the specific activity of the title compounds will be several times higher as 
compared to that achieved by electrophilic procedures. 
3.2.5 Dependence of the enantiomeric purity of 2-[18F]fluoro-L-phenylalanine as 
function of the protecting group of the imidazolidinone system 
Achievement of high enantiomeric purity is an important goal in the development of 
multi-step radiosyntheses of [
18
F]fluoroaromatic amino acids starting from nucleophilic 
[
18
F]fluoride. Since the use of basic conditions are needed in the first substitution step in order 
to avoid inactivation of the radioactive nucleophile, chemical modifications in the structure of 
the precursor can be valuable for protection from epimerization. 
60 
The imidazolidinone system offers the possibility of a structural change by exchange of 
the protecting group in position 1 (Scheme 45). The idea was to use a more voluminous 
protecting group in order to introduce a steric hindrance of position 5 and in this way avoid 
the access of the base for H-abstraction during labeling.  
Precursor 1d bearing a bulky benzyloxycarbonyl group instead of tert-butoxycarbonyl 
protecting group was reacted under identical conditions as precursor 1a using conventional 
heating. The radiochemical yields of all three reactions steps were similar to those obtained 
for precursor 1a. After chiral HPLC (see experimental, System D) it was determined that the 
enantiomeric purity of the 2-[
18
F]Fphe was 96 ± 3% which is comparable with the previous 
results. 
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Scheme 45: Radiosynthesis of 2-[
18
F]Fphe from precursor 1d 
Efforts to prepare derivatives of the precursor 1 bearing even bigger protecting groups 
were not successful. Therefore, a brief theoretical study on the influence of the protecting 
group on the space configuration of the precursor was then instead performed. Precursors 1a, 
1d and the analogous compound, in which the imidazolidinone is protected with a subirane 
group, were selected for comparison. A molecular modeling calculation using the software 
Chem3D Pro (MM2 job) was run in order to find the configuration of least energy. The 
graphical results can be seen in Figure 10. No matter the size of the protecting group, the 
hydrogen atom in position 5 is always available for the reaction with the base. Thus, in the 
case of the bulky subirane protecting group, this proton is located in anti-configuration to it. 
From the experimental result and the configuration calculation it can be concluded that the 
size of the protecting group in position 1 has hardly an influence in the enantiomeric purity of 
the final product. 
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Figure 10: Graphical results of the MM2 energy minimization study. Energy-minimized 
structures of labeling precursors: a) 1a, b) 1d, c) 1 bearing a bulky subirane 
protecting group in position 1 of the imidazolidinone system. The acid proton in 
position 5 of the imidazolidinone ring is in every case enclosed within the elipse. 
It can be observed that the protecting groups have minimal screening effect over 
this proton and in the case of the subirane protecting group (c) it is located in anti-
configuration to it. 
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3.2.6 Radiosynthesis of 2-[18F]fluoro-L-phenylalanine using the alternative 
Schöllkopf-precursor 1e  
It was mentioned before that precursors bearing Schöllkopf´s reagent were first used for 
the radiosynthesis of 6-[
18
F]FDOPA, however the enantiomeric purity of the final product was 
not good enough in order to establish this approach as method of choice for a nucleophilic 
preparation of this important radiopharmaceutical. In that earlier work
103
 the Kryptofix 2.2.2 
carbonate/oxalate system was used for the labeling reaction. In the present work, it has been 
shown that the use of highly basic medium is inappropriate for the labeling of Seebach 
derivatives 1 due to diasteromerization of the precursor leading to the formation of the 
undesired enantiomer of the [
18
F]fluorophenylamino acid. Because of Schöllkopf derivatives 
are easier to hydrolyze than the respective Seebach derivatives, it was interesting to re-
evaluate this kind of compounds as precursors using TBAHCO3 as base since the use of 
concentrated acid and/or high temperatures for the last hydrolysis step of the radiosynthesis 
could probably be avoided. 
Unfortunately the precursor 1e showed to be non-stable limiting the number of 
experiments which could be performed. However, using freshly prepared 1e, it was possible 
to carry out the radiosynthesis using the same conditions used for the precursor 1a (Scheme 
46). 
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Scheme 46: Radiosynthesis of 2-[
18
F]Fphe from precursor 1e 
The RCY for the isotopic exchange reaction using TBAHCO3 as base was 20%. Only one 
product was distinguished in both, the TLC and radio-TLC analysis which seems to indicate 
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that diasteromerization of the precursor was not taking place. Decarbonylation gave similar 
results as with compound [
18
F]1a with 80% RCY. Hydrolysis with concentrated HCl 
provided the desired 2-[
18
F]Fphe in quantitative yield. Chiral HPLC analysis of the final 
product, however, showed to be an enantiomeric mixture containing 10% of the undesired 2-
[
18
F]F-D-phe. 
An exhaustive analysis of the formation of the undesired 2-[
18
F]F-D-phe as function of 
the base concentration was not performed due to the limitations given by the decomposition 
of the precursor. It is not clear which processes are taking place, diasteromerization of the 
precursor or racemisation of the decarbonylated species during hydrolysis. However, the 
results showed that at least in the case of the radiosynthesis of 2-[
18
F]Fphe under equal 
reaction conditions the precursor 1a is better than the analogous 1e. 
Finally, it can be concluded that a new procedure for the radiosynthesis of 2-[
18
F]Fphe 
and 2-[
18
F]Ftyr has been developed. The three-step approach can be performed either under 
conventional or microwave heating. It was also shown that the incidence of 2-[
18
F]F-D-phe 
and 2-[
18
F]F-D-tyr in the case of the Seebach´s derivatives occurs as consequence of the 
diastereomerization of the precursor during the nucleophilic exchange reaction with 
[
18
F]fluoride and it happens independently of the size of the protecting group of the 
imidazolidinone system. Furthermore, this work is the first example of the radiosynthesis of 
18
F-labeled aromatic amino acids via a decarbonylation reaction with Rh(PPh3)3Cl. 
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3.3 Enantioselective radiosynthesis of 6-[18F]fluoro-L-m-tyrosine by isotopic 
exchange 
6-[
18
F]Fluoro-L-m-tyrosine (6-[
18
F]Fmtyr) is an imaging agent of high interest for 
measuring the activity of the enzyme AADC. However, a wider application of this probe in 
nuclear medicine practice again has been restricted by the lack of an efficient radiosynthetic 
procedure. Due to the success achieved with the three-step radiochemical synthesis of 6-
[
18
F]FDOPA,
105
 2-[
18
F]Fphe and 2-[
18
F]Ftyr, it was decided to adapt this pathway in order to 
prepare 6-[
18
F]Fmtyr following the reaction sequence: 
18
F-for-
19
F exchange, Baeyer-Villiger 
oxidation, and acid hydrolysis. 
4-Fluorobenzaldehydes derivatives have successfully been employed as precursors for the 
preparation of 6-[
18
F]FDOPA,
105
 2-[
18
F]Fphe and 2-[
18
F]Ftyr. However, the use of the 
aldehyde 1a for the radiosynthesis of 6-[
18
F]Fmtyr is not appropriate because regioselectivity 
problems can arise during the oxidation step. As depicted by Scheme 47, the Baeyer-Villiger 
oxidation mechanism involves first the addition of a peroxy acid to the carbonyl group of the 
substrate followed by a concerted migration of one of the substituents to the oxygen with 
formation of the carboxylic acid derived from the peroxy acid. Therefore, two different 
products can be generated from benzaldehydes, either benzoic acids or phenyl formates. The 
direction of reaction is largely determined by the electron density of the phenyl ring: electron 
donating substituents favor ring migration to yield the phenyl formate whereas electron 
withdrawing substituents favor hydrogen migration to yield benzoic acid.
159
 Thus, oxidation 
of 3-bromo-4-fluorobenzaldehyde leads to the aromatic carboxylic acid and not to the 3-
bromo-4-fluorophenyl formate.
160
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Scheme 47: General mechanism of the Baeyer-Villiger oxidation 
In order to avoid regioselectivity problems it was decided to include a directing group in 
the structure of the precursor for the oxidation. Asymmetric ketones undergo Baeyer-Villiger 
reaction following a well known migration pattern, where an aryl group migrates to the 
oxygen atom with preference over a methyl substituent (which has the lowest migration speed 
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among the ketones). In the light of this fact, the phenone derivatives 1c, 1f, 1g and 1h were 
employed as labeling precursors (Scheme 48). 
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Scheme 48: General radiosynthetic pathway to 6-[
18
F]Fmtyr by isotopic exchange 
3.3.1 Radiofluorination 
Table 8 lists the results obtained with labeling of precursor 1c. In the previous section it 
was shown that the use of DMF as solvent provided good labeling results, however in this 
case, attempts to carry out the reaction using DMF as reaction medium showed no formation 
of the desired labeled product (Table 8, entries 1-2). The change of solvent to DMSO 
provided better results. After 10 min reaction time at 130 °C the desired labeling product 
[
18
F]1c was obtained in 5% RCY. When the temperature was raised to 160 °C the RCY 
increased to 16%, however, at higher temperatures diasteromerization of the labeling 
precursor takes place without a further increase in the yield of the desired compound (Table 8, 
entry 5). Analogously to the aldehyde derivatives 1a and 1b an increase of the basic anion 
66 
activator concentration led to a bigger epimerization rate; as well as the use of 
kryptate/K2CO3 gave the undesired diastereoisomer as major product (Table 8, entries 6-8). 
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Scheme 49: Epimerization of 1c during the isotopic exchange reaction 
For further experiments which were carried out, therefore the conditions were used as 
described in entry 4 of Table 8. Again here the avoidance of humidity plays an important role. 
As well as for the analogous aldehyde precursors 1a and 1b just freshly dried acetronitrile 
should be used for the drying process of [
18
F]fluoride as well as dry DMSO for the labeling 
reaction. 
Table 8: Influence of temperature, time and kind of anion activation on the RCY of the 
isotopic exchange reaction on 1c
a,b
  
    10 min 20 min 
Entry Solvent PTC
c
 [μmol] Temp. °C [18F]1c (%) 42c (%) [18F]1c (%) 42c (%) 
1 DMF TBAHCO3 [7.7] 130 0 0 0 0 
2 DMF TBAHCO3 [7.7] 150 0 0 0 0 
3 DMSO TBAHCO3 [7.7] 130 5 0 7 0 
4 DMSO TBAHCO3 [7.7] 160 16 0 18 0 
5 DMSO TBAHCO3 [7.7] 180 15 2 16 3 
6 DMSO TBAHCO3 [10.3] 160 14 6 16 7 
7 DMSO TBAHCO3 [13.0] 160 21 12 20 13 
8 DMSO [K222]2CO3 [13.0] 160 4 27 5 40 
a
SD = ±3%. 
b
1 mL solvent, 15 µmol 1c, conv. heating. 
c
PTC = phase transfer catalyst for [
18
F]fluoride activation. 
Labeling of the bislactimether derivative 1f (see Scheme 48) under the conditions 
mentioned above produced similar results. The desired labeled compound [
18
F]1f was 
obtained in 15 ± 3% RCY. Following the same trend as with precursor 1c, the RCY increased 
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with the anion activatior concentration arriving to an average of 30% when 17 µmol of 
TBAHCO3 were employed for the reaction. However, contrary to [
18
F]1c both radio-TLC and 
TLC-UV analyses showed a single spot with a Rf value consistent with precursor 1f.  
Due to the success of previous labeling experiments using microwave heating, this 
method was also tried using precursor 1c. The best RYC (16 ± 2%) of the desired labeled 
compound [
18
F]1c was obtained when the reaction mixture was irradiated with 110 W 
microwaves during 1 min. Either longer irradiations times or higher power induced 
diastereomerization of the precursor while the RYC did not improve. 
Compared to aldehyde 1a, the activation of the isotopic exchange reaction in the 
acetophenone derivative 1c was weaker. On the other hand, it was also observed that 
precursor 1c tolerates better the basic conditions, because no diastereomerization was 
observed when 7.7 µmol of TBAHCO3 of base were used for the reaction in contrast to the 
maximum tolerance of the aldehyde of 5.2 µmol. However, this tendence can probably be 
attributed to deprotonation of the acidic α carbonyl methyl group more than steric or 
electronic effects of the ketone that avoids the side reaction. Deprotonation with subsequent 
deactivation of the base can also be affecting the isotopic exchange process because of the 
impossibility to regenerate the nucleophilic [
18
F]fluoride in case of protonation. Besides of 
that the enol would not be able to withdraw electrons from the aromatic ring. 
In order to corroborate the hypothesis formulated above a precursor without enolizable 
protons was radiolabeled. Precursor 1g is a benzophenone derivative analogous to 
Mulholland´s ketone.
128
 Instead of an individual protecting group for the amine and for the 
acid, 1g is bearing an imidazolidinone system. 
19
F-for-
18
F exchange with 1g was performed 
using microwave heating, after 1 min of reaction the desired compound was obtained with 
30 ± 4% RYC. Increase of the RCY confirms that in the case of the acetophenone 1c the α-
carbonyl acid protons could be the origin of a negative influence on the isotopic exchange 
reaction. 
Based on the previous experimental results a new precursor was designed where the 
second phenone substituent was a trifluoromethyl group (1h). The intention was to create a 
stronger imbalance in the electronic cloud of the aromatic ring due to the high electrophilic 
character of the trifluoromethyl group and by this way to accomplish a better activation for 
the isotopic exchange. Labeling of precursor 1h using 7.7 µmol of TBAHCO3, DMSO as 
68 
solvent and heating by 110 W microwaves for 1 min in fact generated the desired compound 
[
18
F]1h in 40 ± 5% RCY.  
3.3.2 Baeyer-Villiger oxidation and hydrolysis 
The second step in the radiochemical pathway to 6-[
18
F]Fmtyr is the conversion of the 
radiofluorinated precursor into the respective phenylester. In a cold experiment, the Baeyer-
Villiger oxidation of 1c was performed using 4 equivalents m-CPBA and an excess 
trifluoroacetic acid in chloroform at 60 °C. After 20 min the reaction was allowed to cool to 
room temperature, the reaction mixture was neutralized and extracted with dichloromethane, 
the crude product purified by flash chromatography and the isolated product analysed by 
1
H-
NMR. The spectrum showed the signals expected for compound 44c with the exception of the 
nine protons singlet belonging to the Boc protecting group. The hydrolysis of the 
corresponding imidazolidinone in acid medium led to the formation of Fmtyr. This result was 
confirmed by HPLC analysis through the comparison with a standard sample. 
Those preliminary results encouraged us to try the oxidation of the labeled compound 
[
18
F]1c. Table 8 lists the RCY of 6-[
18
F]Fmtyr obtained using different oxidizing agents after 
hydrolysis with concentrated hydroiodic acid. RCY of 6-[
18
F]Fmtyr reflected the yield 
obtained in the oxidation reaction since the hydrolysis produced quantitative results. All the 
reactions were carried out using chloroform as solvent and were stoped after 30 min. When 
m-CPBA (Table 9, entry 1) was used as oxidant only 13% RCY of 6-[
18
F]Fmtyr was 
quantified by analytic HPLC. Moreover, after hydrolysis solid residues, probably belonging to 
the organic acid, remained in the reaction vial hindering the dilution and subsequent transfer 
of the final product into the semi-preparative HPLC system. 
Table 9: Optimization of the reaction conditions for the oxidation of [
18
F]1c and RCY of 6-
[
18
F]Fmtyr after acid hydrolysis
a
  
Entry Oxidant  Yield (%)
b 
1 m-CPBA
b 
13 
2 CH3COOOH
c 
68 
3 CF3COOOH
c 
81 
a
SD = ±5%.
b
 4 mol eq, 
c 
8 mol eq, 1 mL CHCl3, 60 °C, conventional heating 30 min.  
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In order to avoid the solubility problems observed with m-CPBA, it was replaced with 
water-soluble peracetic acid. Peracetic acid is an established reagent for the Baeyer-Villiger 
oxidation, thus, it is commercially available as a 40% solution in acetic acid. When the 
reaction of compound [
18
F]1c was performed using 8 eq. excess of this reagent, the RCY of 6-
[
18
F]Fmtyr after hydrolysis was increased to 68% (Table 9, entry 2). Besides of the 
improvement of the RCY, in this case a second advantage was that a homogeneous solution of 
the final product was achieved, which can easily be transferred into the semi-preparative 
column.  
Trifluoroperacetic acid is an alternative oxidant that has shown great activity in Baeyer-
Villiger reactions. Since the earlier preparation of trifluoroperoxyacetic acid from 
trifluoroacetic anhydride and concentrated hydrogen peroxide
161
 is not possible any more as 
concentrated hydrogen peroxide is not commercially available any longer, some alternative 
procedures using different sources of H2O2 have been developed.
162,163
 In order to achieve the 
oxidation of compound [
18
F]1c, here trifluoroperacetic acid was generated in situ by the 
reaction of trifluoroacetic anhydride with sodium percarbonate. After hydrolysis of the 
intermediate 44c obtained by this oxidation method the desired 6-[
18
F]Fmtyr was obtained 
with RCY of 81 ± 5% (Table 9, entry 3). Use of this oxidation reagent not only increased the 
RCY in comparison to the other two discussed above, but it has also the advantage that the 
remaining reactive as well as the formed trifluoroacetic acid can be removed at the end of 
reaction by simple distillation while sodium carbonate is neutralized by the acid used for 
oxidation. Additionally the salt formed by neutralization of the percarbonate raises the boiling 
point of the reaction mixture for hydrolysis, which, considering the high temperatures needed 
for the reaction, constitutes a further advantage. 
Oxidation under the above optimized conditions and subsequent hydrolysis with 
concentrated HCl of the bislactimether derivative [
18
F]1f delivers the desired labeled amino 
acid in 73% RCY. Taking advantage of the higher stability of precursor 1f when compared to 
the aldehyde 1e, experiments were performed to show the dependence of the enantiomeric 
purity of the final preparation as function of the amount of TBAHCO3 used for labeling. 
Chiral HPLC analysis (see experimental, System D) of the final product generated from the 
labeling of 1f with different amounts of anion activator clearly evidenced a dependence of the 
enantiomeric purity on its concentration. As depicted in Figure 11, also with bislactimether 
derivatives the decrease of the enantiomeric purity is totally influenced by the 
diastereomerization of precursor 1f during the isotopic exchange reaction.   
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Figure 11: Radioactivity distribution of 6-[
18
F]F-L-mtyr and 6-[
18
F]F-D-mtyr as function of 
the TBAHCO3 concentration used for the isotopic exchange reaction on 
precursor 1f 
From this results it is also clear that precursors bearing the Schöllkopf´s bislactimether 
are more sensitive to the conditions of the 
18
F-for-
19
F exchange than those formed with 
Seebach´s imidazolidinone system, since preparations of 2-[
18
F]Fphe and 6-[
18
F]Fmtyr from 
1e and 1f, respectively, showed a higher fraction of the undesired D-enantiomer than those 
from 1a and 1c. 
The Baeyer-Villiger oxidation of compound [
18
F]1g with trifluoroperoxyacetic acid, 
followed by hydrolysis of the protecting groups produced the desired amino acid in an 
average RCY of 18%. The HPLC analysis of the oxidation reaction mixture showed that the 
conversion of the starting material [
18
F]1g was low (46 ± 5%) and multiple new labeled 
compounds were observed. The low reactivity of compound [
18
F]1g can probably be 
attributed to steric effects by both phenyl groups of the carbonyl function plus the 
imidazolidinone ring impeding the effective approach of the oxidant. Additionally, in spite of 
the two electron withdrawing trifluoromethyl groups attached to the secondary phenyl ring, it 
seems that the reaction is also not regioselective since the RCY of the desired amino acid is 
only 40% of the converted products. Oxidation of [
18
F]1g with 4 eq. m-CPBA in CHCl3 at 60 
°C did not provide any of the desired [
18
F]fluoroamino acid at all.  
Previous work dealing with the radiosynthesis of 4-[
18
F]fluorophenol starting from 
benzophenones derivatives via Baeyer-Villiger oxidation, reported a good or even excellent 
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RCY.
164
 In order to achieve the desired compound, the benzophenone derivatives were treated 
with peracetic acid (generated in situ from a mixture of acetic anhydride and hydrogen 
peroxide) in acetic acid at 80 °C. Therefore, compound [
18
F]1g was reacted under similar 
conditions using a commercially available solution of peracetic acid in acetic acid (40%), 
however, the radiochemical yield of the desired product was only 14%.  
Table 10 summarizes the conditions for the oxidation reaction of [
18
F]1h and the RCY of 
6-[
18
F]Fmtyr obtained after hydrolysis. Treatment of [
18
F]1h with peracetic acid and 
subsequent hydrolysis afforded the desired 6-[
18
F]Fmtyr in 33% RCY (entry 1). Oxidation 
followed by acid hydrolysis of [
18
F]1h provided a better radiochemical yield than that 
achieved with [
18
F]1g. However, it is still lower than that obtained after oxidation and 
hydrolysis of [
18
F]1c and [
18
F]1f.  
Table 10: Conditions for the Baeyer-Villiger oxidation of [
18
F]1h and RCY of 6-[
18
F]Fmtyr 
obtained after hydrolysis 
Entry Oxidant agent Solvent Temp °C RCY (%) 
1 CF3COOOH
b 
CHCl3 60 33±5 
2 m-CPBA
a 
CHCl3 reflux - 
3 m-CPBA
a 
CH2Cl2/CF3CH2OH r.t. - 
4 m-CPBA
a 
CH2Cl2/CF3CH2OH reflux 5 
5 CH3COOOH
b 
ACN 60 - 
6 CF3COOOH
b 
CF3CH2OH 60 - 
a
 4 mol eq, 
b 
8 mol eq, 1 mL solvent, 30 min 
The use of peracetic acid as oxidant for Bayer-Villiger reaction on trifluoroacetophenone 
has been previously reported.
161
 In this earlier work phenyl trifluoroacetate was obtained with 
5% yield after a reaction time of 5 h. A further paper from Kitazume and Kataoka
165
 reported 
93% yield of the same compound after 1 h reaction time using m-CPBA as oxidazing agent in 
refluxing CHCl3. Oxidation of [
18
F]1h using these conditions followed by acid hydrolysis did 
however not produce any 6-[
18
F]Fmtyr (entry 2). More recently Kobayashi and coworkers
166
 
obtained 87% yield of phenyl trifluoroacetate after 10 min reaction at r.t.. The oxidant was 
again m-CPBA, while a mixture of CH2Cl2 and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) was 
used as solvent containing additionally phosphate buffer (pH 7,6) to catalyze the reaction. The 
use of similar conditions for the oxidation of [
18
F]1h was not successful (entry 3). 6-
72 
[
18
F]Fmtyr was obtained in 5% RCY when the temperature of the reaction was increased to 60 
°C (entry 4). Further experiments using trifluoroperacetic acid in acetronitrile or peracetic 
acid in trifluoroethanol did not provided any 6-[
18
F]Fmtyr (entries 5 and 6). 
A new nucleophilic synthesis of 6-[
18
F]Fmtyr by isotopic exchange has been developed. 
The three-step radiosynthetic procedure leads to the desired amino acid in ca. 13% overall 
radiochemical yield with high enantiomeric purity of > 93% when compound 1c is used as 
precursor. It was shown that analogously to precursor 1c, compound 1f suffered epimerization 
during the isotopic exchange. A comparable overall radiochemical yield of 11% of 6-
[
18
F]Fmtyr was achieved with precursor 1f while the enantiomeric purity in this case was only 
87%. 
Precursors 1g and 1h showed relative high radiochemical yield of the 
18
F-for-
19
F 
substitution, with 30% and 40% respectively. However, it was not possible to match the RCY 
for the Baeyer-Villiger oxidation obtained for the acetophenone derivatives [
18
F]1c and 
[
18
F]1f. 6-[
18
F]Fmtyr was obtained from 1g and 1h with overall RCY of only 6% and 13%, 
respectively. However, the enantiomeric purity of the final product using any of both 
precursor was >98%. Thus, further efforts of the optimization of the Baeyer-Villiger reaction 
of these precursors seem to be justified. 
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3.4 Enantioselective radiosynthesis of 6-[18F]fluoro-DOPA by isotopic exchange 
6-[
18
F]Fluoro-DOPA (6-[
18
F]FDOPA) is one of the few established radiopharmaceuticals 
for diagnostic imaging using PET. In spite of that 6-[
18
F]FDOPA has been widely used for 
human studies, is still considered in a development stage since its availability is limited due to 
radiosynthetic constraints.
18
 As described in the introduction of this work (see Chapter 1.8.1), 
today electrophilic methods are generally applied to produce 6-[
18
F]FDOPA,
90
 however, with 
the disadvantages of relatively low specific activity and batch yields in addition to a limited 
availability of electrophilic radiofluorination established in many PET centers. Although 
nucleophilic procedures were developed for routine production of 6-[
18
F]FDOPA, they are 
difficult to implement because of the complexity of the reactions involved in built-up 
syntheses.
101,102 
Following the compromising concept as discussed above, Wagner et al.
105
 presented an 
interesting radiochemical pathway for the radiosynthesis of c.a. 6-[
18
F]FDOPA by isotopic 
exchange. Scheme 50 depicts the general pathway for this radiosynthesis. In the work 
presented here, all steps have been optimized, as was done for the precursor (see Chapter 
3.1.3.2).  
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Here, the results achieved are summarized for the optimization of every individual 
reaction together with preliminary results of the automation of this procedure using a 
commercially available synthesis module. 
3.4.1 Radiofluorination 
The results concerning the first step, which is identical with the radiosynthesis of 2-
[
18
F]Ftyr were reported above (see Chapter 3.2.1). As discussed there the isotopic exchange 
reaction on precursor 1b generates the products [
18
F]1b and 42b. The best RCY of [
18
F]1b 
was 59% while that of 42b was 4% with 15 µmol of precursor, 6.4 μmol of TBAHCO3 and 
1 mL of DMF at 130 °C for 10 min as optimal reaction conditions. 
Since a high enantiomeric purity of 6-[
18
F]FDOPA is required for its application in 
medicine it is pertinent to repeat that the isotopic exchange reaction is the critical step in order 
to achieve this objective. Once again: the structure of precursor 1b contains an acidic proton 
in position 5 of the imidazolidinone. The isotopic exchange, however, requires the use of a 
base to activate the nucleophilic species by avoiding the formation of H
18
F. The base, in this 
case TBAHCO3, is able to remove the acidic proton from 1b generating a planar carbanion. 
The carbanion can get re-protonated, but two protonation sites are now available the first 
regenerating 1b and the second producing diasteromer 42b. After oxidation and hydrolysis 
42b leads to the formation of non-wanted 6-[
18
F]F-D-DOPA. This process, like any other 
chemical reaction, depends on the concentration of the reactants and the temperature. For this 
reason, it is necessary to keep the concentration of TBAHCO3 as low as possible.  
3.4.2 Baeyer-Villiger oxidation 
The Baeyer-Villiger oxidation is applicable for the generation of a phenol from [
18
F]1b 
because the substrate is substituted with an electron-donor benzyloxy group. Previous work
105
 
reported the use of m-CPBA as oxidizing agent in dichloromethane as solvent. Although the 
reaction produced the desired compound in a good RCY after 20 min, a solid residue 
remained in the reaction vessel after hydrolysis that hinders the transfer of the reation mixture 
into the HPLC system. Alternatively, the Baeyer-Villiger oxidation can be performed either 
with trifluoroperacetic acid, generated in situ from sodium percarbonate and trifluoroacetic 
anhydride
163
 or commercially available 40% solution of peracetic acid/acetic acid, as shown 
for the radiosynthesis of 6-[
18
F]Fmtyr (see Chapter 3.3.2). The oxidation of [
18
F]1b was 
performed using 8 equivalents of the oxidizing agent, calculated from the amount of precursor 
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in 1 mL chloroform at 60 °C for 10 min. With these reagents, either trifluoroperacetic acid or 
peracetic acid, a radiochemical yield of 81 ± 5% was achieved, which is comparable with that 
obtained with m-CPBA but the reaction time could be reduced to the half. Finally 
trifloroperacetic acid is preferable over peracetic acid since reactions with the first result in a 
cleaner product and its excess as well as the formed trifluoroacetic acid can be easily removed 
under vacuo. 
3.4.3 Hydrolysis 
Seebach´s chiral auxiliary has been early employed by Lemaire et al.
100
 in a nucleophilic 
build-up synthesis of 6-[
18
F]FDOPA. The hydrolysis reaction was carried out with 
concentrated HI at 200 ºC achieving a quantitative RCY. Wagner et al.
105
 reported that 
hydrolysis under similar conditions led to a poor RCY due to the formation of several side 
products. Treatment with HBr at the same temperature did not cause any improvement. In the 
latter publication it was proposed that an oxidation of HI and HBr to elemental iodine and 
bromine, respectively, could probably be taking place due to the excess of m-CPBA. Finally 
as optimal condition the hydrolysis of the oxidazed intermediate was performed with 
concentrated HBr at 150 °C for 30 min and the desired product was obtained in 53% RCY.  
In the present work it was observed that under those conditions only a low conversion of 
the starting material is achieved. When the hydrolysis was, however, carried out in a heavy-
wall borosilicate glass tube closed with a Teflon screw cap (pressure tube) and the 
temperature raised to 200 °C, a quantitative radiochemical yield was obtained in spite of the 
excess of m-CPBA in the reaction medium. Moreover, when the oxidation step was performed 
with trifluoroperacetic acid it could be distilled off prior to hydrolysis, thus diminishing the 
risk of oxidation of the mineral acid. Analogously to the hydrolysis of the other 
[
18
F]fluoroamino acids presented in this work here, concentrated HCl provided a quantitative 
RCY. Figure 12 depicts a comparison between the HPLC analysis of a standard sample of 6-
L-FDOPA and the radio-HPLC analysis of the crude product after the hydrolysis reaction. 
From the simple comparison of both chromatograms it is easy to identify 6-[
18
F]F-L-DOPA.   
Thus, in total the nucleophilic radiosynthesis of 6-[
18
F]FDOPA by isotopic exchange has 
been optimized. The three-step radiosynthetic procedure leads to the desired amino acid in ca. 
40% overall radiochemical yield with a high enantiomeric purity of > 96%. The increase of 
the overall RCY from 22% reported by Wagner et al.
105
 is basically due to the improved RCY 
of the hydrolysis reaction. Furthermore, a better understanding of the isotopic exchange 
76 
reaction has also been accomplished. The side product-A, referred to by Wagner and 
coworkers,
105
 was here identified as diasmeromer 42b being the product of epimerization of 
position 5 of the imidazolidinone system due to the basic conditions and high temperature 
during the isotopic-exchange reaction. The Baeyer-Villiger oxidation was also optimized: 
employment of trifluoroperacetic acid allowed to reduce the time of the reaction from 20 min 
to 10 min, whereas the remaining peracid and the trifluoroacetic acid formed were easily 
removed at the end of the reaction by distillation while addition of HCl used for hydrolysis 
neutralized sodium carbonate.  
 
 
Figure 12: HPLC analysis of a standard sample of 6-L-FDOPA and the crude product after 
the hydrolysis reaction. a) UV-chromatogram of a standard solution of 6-L-
FDOPA. b) Radio-chromatogram of a sample of 6-[
18
F]FDOPA after hydrolysis 
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3.4.4 Preliminary attempts to automate the radiosynthesis of 6-[18F]fluoro-L-
DOPA 
In order to transfer the elaborated three-step radiosynthesis of 6-[
18
F]FDOPA into an 
automated synthesizer the SynChrom R&D device of Raytest GmbH controlled by GINA 
SynChrom software was chosen. Figure 13 depicts the scheme of the technical concept of this 
synthesis module. 
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Figure 13: Schematic representation of the 6-[
18
F]FDOPA synthesis module set-up 
The optimization experiments described above were performed using [
18
F]fluoride which 
was separated from the enriched water by electrochemic adsorption (see experimental). 
However, for the remote controlled radiosynthesis the [
18
F]fluoride was directly transferred 
from the cyclotron target into the synthesis module. For this reason, the first step toward 
automation of this method was to perform the separation of the enriched water. Usually this 
process is carried out by ion exchange chromatography, specifically with a cartridge 
containing an anion exchange resin (QMA light). Generally, once the radioactive species is 
trapped on the cartridge its elution is achieved using a solution of the PTC system in water or 
acetronitrile. Since it was not possible to elute the [
18
F]fluoride with only 6.4 μmol of 
TBAHCO3 and an increase of the concentration of TBAHCO3 was undesirable because of the 
occurrence of the side product 42b, it was decided to add a second tetra-n-butyl ammonium 
78 
salt containing a non-nucleophilic anion in order to facilitate the elution. A mixture of 
TBAHCO3 and tetra-n-butyl ammonium mesylate (TBAMs) in water was used for this 
purpose. With this eluent 92 ± 5% of the activity attached on the cartridge was recovered. 
Freshly dried acetonitrile was added to it and the resulting mixture distilled azeotropically to 
dryness. Control experiments showed that, as expected, the addition of TBAMs has not 
influence on the RCY of the isotopic exchange reaction. Moreover, when the 
18
F-for-
19
F 
exchange reaction was performed in the presence of TBAMs only, no formation of [
18
F]1b 
was detected. 
During the automation of the isotopic exchange reaction it was also observed that when 
the solution of precursor 1b in DMF was stored in the glass container provided with the 
synthesis device before the labeling reaction, the compound [
18
F]1b was not formed. Since it 
was already known that the presence of moisture could deactivate the isotopic exchange 
reaction, the glass containers for acetronile and the solution of the precursor were 
meticulously dried. After that, the formation of the desired compound was achieved, however, 
with a low RCY of only ≈ 10%. An alternative and more practical solution was found when 
both, the glass container housing the acetronitrile as well as the one for the precursor solution 
were replaced with disposable syringes. In this way the moisture holded by the glass 
containers and their connectors was avoided while saving time in exhaustive cleaning and 
drying procedures before every radiosynthesis. The syringe contents were dispensed into the 
reactor 1 using vacuum. Radiochemical yields between 40% and 50% were obtained by 
employing this method. 
After the isotopic exchange reaction, it was necessary to remove the polar solvent and the 
non-reacted [
18
F]fluoride from [
18
F]1b. This step was achieved by solid-phase extraction 
(SPE). A previous report
105
 suggested the addition of water to the reaction mixture, but it 
produced precipitation of the organic compounds leading to the obstruction of tubing and 
valves. A 4:1 mixture of water and acetonitrile resulted to be more proper to that end. [
18
F]1b 
was retained on the SPE cartridge and the water-soluble impurities washed out. Afterward the 
desired compound was eluted with chloroform and the eluate dried online over a column 
packed with of magnesium sulfate.  
The online drying procedure presented two advantages, first it saved time by avoiding 
azeotropic distillation and second the reactor 2 (see Figure 13) had not to be used and could 
be prepared for the Baeyer-Villiger oxidation reaction, i.e. the oxidation agent could be 
loaded in reactor 2 before starting the radiosynthesis. Pre-loading of the oxidation agent was a 
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major achievement since it made feasible the generation of trifluoroperacetic acid from a 
solution of trifluoroacetic anhydride and solid sodium percarbonate. The dry solution 
containing [
18
F]1b was thus conducted into the reactor 2 and the reaction mixture was then 
heated at 60 °C for 10 min. After that the reaction mixture was evaporated to dryness.  
The last step of the radiosynthesis also proved to be the most difficult one to automate. 
Hydrolysis of the imidazolidinone group requires a high temperature. Along the elaboration in 
the present work it turned out that optimal conditions included heating of compound 45 in 
concentrated hydrochloric acid at 200 °C for 30 min. This generates a pressure of 
approximately 8 bar in an 18 mL closed reaction vessel. This high pressure did not represent 
any problem during optimization studies since a pressure tube was used. However, the 
specifications of the valves of the synthesis module, especially those directly attached to 
reactor 2, guarantee proper function only up to 3 bar. In a first experiment the hydrolysis 
reaction was performed at 180 °C, due to safety reasons, however, it resulted in broken valves 
and leaking of the reaction mixture. 
Thus, the automatic radiosynthesis of 6-[
18
F]FDOPA became a technical challenge rather 
than a chemical one. Since the original valves were not able to manage the pressure generated 
during the hydrolysis and the dimensions of commercially available high pressure valves are 
too big to be easily installed in the device, the effort was directed toward the protection of the 
existing ones. The reaction temperature was reduced to 170 °C and the tubing distribution 
modified in order to permit the transport of a He stream against every valve connected 
directly with the reactor 2, in such a way reducing the pressure difference between both sides. 
Application of these measures allowed to perform the reaction. However, in the future the 
synthesis device should technically be improved because during some experiments small 
leakage of the reaction mixture was observed. However, HPLC analysis of a sample taken 
from reactor 2 after hydrolysis provided proof-of-principle of the formation of 6-FDOPA 
(Figure 14). 
Although further work is still needed, especially in order to overcome the technical 
problems described above, the results shown here demonstrate that the three-step 
radiochemical synthesis is feasible to be performed in an automated remote-controlled 
synthesis device.  
80 
 
Figure 14: HPLC analysis of a standard sample of 6-D,L-FDOPA and the crude product after 
automatic synthesis. a) UV-chromatogram of a standard solution of 6-D,L-
FDOPA. b) UV-chromatogram of a sample from reactor 2 after the hydrolysis 
reaction 
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4 EXPERIMENTAL 
4.1 General techniques 
All reactions sensitive to humidity were carried out under argon atmosphere, and prior to 
use, the reaction flasks were dried over night in an oven at 95 C. All liquids sensitive to 
humidity were transferred into the reaction flask, equipped with a septum, through syringes. 
All reaction mixtures were magnetically stirred.  
Spectrometric devices 
1
H, 
13
C and 
19
F NMR spectra were recorded on a on an Inova 400 MHz spectrometer 
(Varian, Germany) using CDCl3. All shifts are given in ppm using as reference the signal of 
CDCl3. HRMS spectra were obtained on an FTICR „LTQ FT Ultra‟ (Thermo Fisher 
Scientific, Germany).  
Microwave device 
Microwave heated experiments were performed using a CEM Discover (Matthews, USA) 
single-mode microwave reactor system.  
Preparative chromatography and analytic thin layer chromatography 
Flash chromatography was performed following the procedure proposed by Still
167
 on 
silica gel (Merck 60 mesh for flash chromatography). Thin layer chromatography (TLC) was 
performed on precoated plates of silica gel 60 F254 (Merck, Germany) and the compounds 
were detected at 254 nm.  
4.2 Reagents and Solvents 
Dry solvents, dichloromethane, tetrahydrofurane, dioxane and methanol were purchased 
from Fluka. Ethylether, acetone, N,N-dimethyformamide, benzonitrile and acetonitrile were 
purchased from Aldrich, Germany Ethylether, petroleum ether, acetonitrile (HPLC grade), 
ethylacetate and ethanol were purchased from Merck. All solvents were used without further 
purification. 
3-Bromo-4-fluorobenzaldehyde (2a), 1-(3-bromo-4-fluorophenyl)ethanone (2c), isoprop-
ylmagnesium chloride lithium chloride complex, [bis(trifluoroacetoxy)iodo]benzene, lithium 
82 
aluminium hydride, diisobutylaluminium hydride, carbontetrabromide, trifluoroacetic acid, 
trifluoroacetic anhydride, triphenylphosphine, diisopropylamine, (S)-Z-BMI, butyllithium, 
Wilkinson‟s catalyst, 2-fluoro-5-iodobenzaldehyde (38), isopropylmagnesium bromide, 3,5-
bis(trifluoromethyl)-benzoyl chloride, potasium carbonate, sodium sulfate, sodium thiosulfate, 
magnesium sulfate, 2-fluoro-L,D-phenylalanine, ammonium chloride, sodium hydroxide, 
sodium chloride and Dess-Martin periodinane were purchased from Aldrich. Sulfuric acid, 
iodine, sodium acetate, benzylbromide, (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine, 
1,2-ethanedithiol and ethylchloroformate from Fluka, and tributylammonium hydroxide, 
molecular bromine, (S)-BocBMI, hydroiodic and hydrobromic acids were acquired from 
Merck, Germany. 4-Fluorosalicilyc acid (30) was acquired from Alfa Aesar GmbH & Co KG. 
2-Fluoro-L-tyrosine,  6-fluoro-L-m-tyrosine and 6-fluoro-L-DOPA were acquired from ABX. 
Hydrochloric acid and sodium hydrogencarbonate were purchased from KMF Laborchemie 
Handels GmbH. Diiodosilane was prepared as described by Keinan and Perez.
153
 
4.3 Synthesis of Seebach-precursors via a dithiolane approach 
5-Bromo-4-fluoro-2-hydroxybenzoic acid (31) 
4-fluorosalicilyc acid (1.00 g, 6.4 mmol) was dissolved in methanol (10 mL). 
Sodium acetate (2.20 g, 26.88 mmol) was added and the mixture was cooled 
to -78 °C. Molecular bromine (0.33 mL, 6.4 mmol) dissolved in 10 mL of 
methanol was slowly added and the mixture was allowed to warm to room 
temperature. After 5 h the solvent was removed under vacuum and the remnants treated with a 
solution of 10% HCl. The residue was filtered under vacuum, washed with water and 
dissolved in EtOAc. After drying with Na2SO4 the solvent was removed in vacuo to give 
1.23 g (82%) of the desired product 31. M.p. 205-207 °C (Lit. 203-205 °C
168
) 
Benzyl 2-(benzyloxy)-5-bromo-4-fluorobenzoate (32)  
K2CO3 (7.06 g, 51.08 mmol) and benzylbromide (3.34 mL, 28.08 mmol) 
were added to a solution of the acid 31 (3.00 g, 12.77 mmol) in acetone 
(100 mL). The mixture was stirred under reflux. After 3 h the heating was 
suspended and the reaction was cooled down to room temperature. Water 
was added and the mixture extracted with CH2Cl2 (3 x 30 mL). The organic fractions were 
combined and washed with brine. The organic layer was separated, dried over Na2SO4 and the 
solvent removed under vacuum. The crude product was purified by flash chromatography (5% 
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EtOAc/petroleum ether) giving 4.08 g of 32 (77%). Rf= 0.33 (5% EtOAc/petroleum ether); 
M.p. 77 – 78 °C. 1H NMR (CDCl3) δ 8.07 (d, J= 8.0, 1H), 7.41-7.29 (m, 10H), 6.79 (d, J= 
10.4 Hz, 1H), 5.17 (s, 2H), 5.31(s, 2H); 
13
C NMR (CDCl3) δ 164.1, 161.9 (J= 253.4 Hz), 
159.2 (J= 10.4 Hz), 136.6 (J= 2.5 Hz) 135.7, 135.4, 128.7, 128.6, 128.3, 128.24, 128.18, 
127.1, 118.0 (J= 3.4 Hz), 102.8 (J= 26.2 Hz), 99.3 (J= 22.0), 71.2, 67.1; 
19
F NMR (CDCl3) δ  
-97.7; HRMS C21H17BrFO3 m/z [M + H]
+
 calculated 415.0345, found 415.0341. 
(2-(Benzyloxy)-5-bromo-4-fluorophenyl)methanol (22)  
3.06 g (7.36 mmol) of the ester 32 were dissolved in dry dichloromethane 
(50 ml) and cooled to 0 °C. 16.19 mL (1.0 M, 16.19 mmol) of a solution of 
DIBAL was added dropwise. The reaction was stirred during 10 min at 0 °C 
and then was allowed to warm to room temperature. After 30 min the 
reaction mixture was quenched with water. The organic layer was separated and the aqueous 
phase extracted with dichloromethane, the organic fractions were combined and washed with 
brine, separated and dried over Na2SO4. The solvent was removed and the crude product 
purified by flash chromatography (15% AcOEt/petroleum ether) to yield the product 22 in 
90%. Rf= 0.60 (20 % EtOAc/petroleum ether); M.p. 100-101 °C. 
1
H NMR (CDCl3) δ 7.47 (d, 
J= 7.8, 1H), 7.31-7.38 (m, 5H), 6.73 (d, J= 10.2 Hz, 1H), 5.09 (s, 2H), 4.65 (s, 2H), 2.08 (s, 
1H); 
13
C NMR (CDCl3) δ 158.9 (J= 245.7 Hz), 156.4 (J= 8.5 Hz), 135.6 (J= 2.5 Hz), 132.4, 
128.8, 128.4, 127.3, 127.1 (J= 4.2 Hz), 101.3 (J= 27.0 Hz), 99.1 (J= 21.1Hz), 70.7, 60.6; 
19
F 
NMR (CDCl3) δ -105.9; E.A. calculated C: 54.04, H: 3.89; found C: 53.6 H: 4.24. 
2-(Benzyloxy)-5-bromo-4-fluorobenzaldehyde (2b) 
DMP 1.50 g (3.42 mmol) was added to a solution of the alcohol 22 (0.97 g, 
3.13 mmol) in methylene chloride (20 mL) under stirring. After 20 min the 
reaction mixture was diluted with 50 mL of ether and poured into saturated 
aqueous NaHCO3 containing a seven fold excess of Na2S2O3. The mixture 
was stirred to dissolve the solid, and the layers were separated. The organic layer was washed 
with water, separated, dried over Na2SO4, filtrated and the solvent evaporated in vacuo. The 
crude product was purified by flash chromatography (5% EtOAc/petroleum ether) giving the 
desired compound in 95% of yield. Rf= 0.45 (5% EtOAc/petroleum ether); M.p. 89-91 °C. 
1
H 
NMR (CDCl3) δ 10.31 (s, 1H), 7.98 (d, J= 8.2, 1H), 7.31-7.38 (m, 5H), 6.78 (d, J= 9.9 Hz, 
1H), 5.10 (s, 2H); 
13
C NMR (CDCl3) δ 186.9, 163.3 (J= 255.9 Hz), 161.4 (J= 10.1 Hz), 134.8, 
133.5 (J= 3.4 Hz), 128.9, 128.7, 127.4, 122.9 (J= 3.4 Hz), 102.4 (J= 26.2 Hz), 101.1 (J= 22.0 
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Hz), 71.2; 
19
F NMR (CDCl3) δ -93.6; HRMS C14H11BrFO2 m/z [M + H]
+
 calculated 
308.9926, found 308.9905. 
2-(2-(Benzyloxy)-5-bromo-4-fluorophenyl)-1,3-dithiolane (33b) 
1,2-Ethanedithiol (0.29 mL, 3.55 mmol) was added to a solution of 2b 
(1.00 g, 3.23 mmol) and iodine (0.082 g, 0.32 mmol) in dichloromethane 
(10 mL) and the mixture was stirred at room temperature. After 1 h the 
reaction was quenched with NaS2O3 (0.1 M, 25 mL) and NaOH (10 %, 25 
mL). Then 25 mL of dichloromethane were added and the organic layer was 
separated, dried with MgSO4 and filtered. The solvent was removed in vacuo and the crude 
product purified by flash chromatography (3% AcOEt/petroleum ether) giving 1.21 g of 33b 
(97%). Rf= 0.49 (% EtOAc/petroleum ether); M.p. 117-118 °C. 
1
H NMR (CDCl3) δ 7.82 (d, 
J= 8.0, 1H), 7.14-7.39 (m, 5H), 6.63 (d, J= 10.2 Hz, 1H), 5.03 (s, 2H), 5.90 (s, 1H), 3.25 (m, 
2H), 3.32 (m, 2H); 
13
C NMR (CDCl3) δ 159.9 (J= 247.4 Hz), 156.8 (J= 8.9 Hz), 136.8, 133.3, 
129.9, 129.4, 128.4, 129.2 (J= 3.2 Hz), 102.4 (J= 27.0 Hz), 100.3 (J= 21.1 Hz), 72.0, 49.4, 
40.5; 
19
F NMR (CDCl3) δ -105.9; HRMS C16H15BrFOS2 m/z [M + H]
+
 calculated 384.9732, 
found 384.9726.  
2-(3-Bromo-4-fluorophenyl)-1,3-dithiolane (33a) 
Compound 33a was prepared following the procedure described for compound 
33b. Yield 97%; Rf= 0.51 (5% EtOAc/petroleum ether); M.p. 51-53 °C. 
1
H NMR 
(CDCl3) δ 7.71 (dd, J= 7.2 Hz, J= 2.2 Hz, 1H), 7.39 (ddd, J= 8.5 Hz, J= 4.5 Hz, 
J= 2.3 Hz, 1H), 7.03 (t, J= 8.2 Hz, 1H), 5.53 (s, 1H), 3.47 (m, 2H), 3.34 (m, 2H); 
13
C NMR (CDCl3) δ 158.6 (J= 248.3 Hz), 138.1 (J= 3.4 Hz), 133.0, 128.6 (J= 7.6 
Hz), 116.3 (J= 22.8 Hz), 108.9 (J= 22.0 Hz), 54.8, 40.3; 
19
F NMR (CDCl3) δ -108.4.; HRMS 
C9H9BrFS2 m/z [M + H]
+
 calculated 278.9313, found 278.9133. 
2-(3-Bromo-4-fluorophenyl)-2-methyl-1,3-dithiolane (33c) 
1,3-Ethanedithiol (0.435 mL, 5.07 mmol) was added to a solution of 1-(3-bromo-
4-fluorophenyl)ethanone (1.00 g, 4.60 mmol) and iodine (0.12 g, 0.46 mmol) in 
dichloromethane (10 mL) and the mixture was stirred under reflux. After 3.5 h 
the reaction was cooled to room temperature and quenched with NaS2O3 (0.1 M, 
25 mL) and NaOH (10%, 25 mL). Then 25 mL of dichloromethane were added 
and the organic layer was separated, dried with MgSO4 and filtered. The solvent was removed 
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in vacuo and the crude product purified by flash chromatography (3% AcOEt/petroleum 
ether) to give 33c (95%) as a pale yellow oil. Rf= 0.35 (3% EtOAc/petroleum ether); 
1
H NMR 
(CDCl3) δ 7.94 (dd, J= 6.4 Hz, J= 2.6 Hz, 1H), 7.65 (ddd, J= 8.8 Hz, J= 4.5 Hz, J= 2.5 Hz, 
1H), 7.02 (t, J= 8.5 Hz, 1H), 3.29-3.49 (m, 4H), 2.09 (s, 3H); 
13
C NMR (CDCl3) δ 157.9 (J= 
248.8 Hz), 143.8 (J= 3.3 Hz), 132.1, 127.7 (J= 7.6 Hz), 115.7 (J= 22.8 Hz), 108.3 (J= 24.7), 
67.4, 40.5, 33.6; 
19
F NMR (CDCl3) δ -110.1; HRMS C10H11BrFS2 m/z [M + H]
+
 calculated 
292.9470, found 292.9466. 
Ethyl 4-(benzyloxy)-5-(1,3-dithiolan-2-yl)-2-fluorobenzoate (34b) 
Dioxane (0.3 mL) was added to a solution of isopropylmagnesium 
chloride lithium chloride complex in THF (1.3 M, 3.14 mL 4.08 mmol) 
and the mixture was cooled to 0 °C. After 5 min 1.21 g (3.14 mmol) of 
compound 33b was added and the mixture stirred during 1.0 h at 0 °C. 
Then 0.61 mL (6.28 mmol) of ethylchloroformate was added and the 
mixture was allowed to reach room temperature. The solution was stirred for 2 h and then 
quenched with saturated aqueous NH4Cl solution (4 mL). The reaction mixture was 
partitioned in H2O:ether (30:30) the organic layer separated and the aqueous phase was 
extracted with ether (2 x 20 mL), the organic fractions were combined dried with Na2SO4 and 
concentrated in vacuo. The crude residue was purified by flash chromatography (10% 
AcOEt/petroleum ether) yielding compound 34b (77%). Rf= 0.39 (10% EtOAc/petroleum 
ether); M.p. 83-85 °C. 
1
H NMR (CDCl3) δ 8.29 (d, J= 8.4, 1H), 7.29-7.42 (m, 5H), 6.63 (d, J= 
12.1 Hz, 1H), 5.13 (s, 2H), 4.35 (q, J= 7.1 Hz, 2H), 5.95 (s, 2H), 3.30 (m, 2H), 3.38 (m, 2H), 
1.36 (s, J= 7.0 Hz, 3H); 
13
C NMR (CDCl3) δ 164.1 (J= 4.2 Hz), 162.7 (J= 260.9 Hz), 159.8 
(J= 10.1 Hz), 135.4, 131.6 (J= 2.5 Hz), 128.7, 128.4, 127.3, 126.5 (J= 3.4 Hz), 110.7 (J= 9.3 
Hz), 100.8 (J= 27.9 Hz), 70.9, 61.0, 48.4, 39.3, 14.3; 
19
F NMR (CDCl3) δ -106.4; HRMS 
C19H20FO3S2 m/z [M + H]
+
 calculated 379.0838, found 379.0830. 
Ethyl 5-(1,3-dithiolan-2-yl)-2-fluorobenzoate (34a)  
Compound 34a was prepared following the procedure described for 
compound 34b. Yield 81%; Rf= 0.42 (10% EtOAc/petroleum ether); 
1
H NMR 
(CDCl3) δ 7.67 (ddd, J= 8.4 Hz, J= 4.4 Hz, J= 2.6 Hz, 1H), 7.99 (dd, J= 6.8 
Hz, J= 2.4 Hz, 1H), 7.04 (dd, J= 8.7 Hz, J= 10.2 Hz, 1H), 4.35 (q, J= 7.1 Hz, 
2H), 5.59 (s, 1H), 3.47 (m, 2H), 3.34 (m, 2H), 2.12, 1.37 (t, J= 7.2 Hz, 3H); 
13
C NMR (CDCl3) δ 164.0 (J= 4.2 Hz), 161.4 (J= 260.9 Hz), 136.5 (J= 3.4 Hz), 133.9 (J= 9.3 
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Hz), 131.5, 118.7 (J= 10.1 Hz), 117.2 (J= 22.8 Hz), 61.4, 55.0, 40.3, 14.2; 
19
F NMR (CDCl3) 
δ -110.5. HRMS C12H14FO2S2 m/z [M + H]
+
 calculated 273.0419, found 273.0414. 
Ethyl 2-fluoro-5-(2-methyl-1,3-dithiolan-2-yl)benzoate (34c) 
Compound 34c was prepared following the procedure described for 
compound 34b. Yield 81%; Rf= 0.57 (10 % EtOAc/petroleum ether); 
1
H 
NMR (CDCl3) δ 8.26 (dd, J= 6.8 Hz, J= 2.7 Hz, 1H), 7.91 (ddd, J= 8.8 Hz, 
J= 4.5 Hz, J= 2.7 Hz, 1H), 7.04 (dd, J= 8.8 Hz, J= 10.0 Hz, 1H), 4.38 (q, J= 
7.2 Hz, 2H), 3.31 – 3.50 (m, 4H), 2.12 (s, 3H), 1.38 (t, J= 7.2 Hz, 3H); 13C 
NMR (CDCl3) δ 164.4 (J= 9 Hz), 160.8 (J= 261.3 Hz), 142.1 (J= 3.8 Hz), 133.2 (J= 9.5 Hz), 
130.3, 118.1 (J= 10.0 Hz), 116.5 (J= 22.5 Hz), 67.5, 61.4, 40.5, 33.5, 14.3; 
19
F NMR (CDCl3) 
δ -112.2. HRMS C13H16FO2S2 m/z [M + H]
+
 calculated 287.0576, found 287.0570. 
(4-(Benzyloxy)-5-(1,3-dithiolan-2-yl)-2-fluorophenyl)methanol (35b)  
1.21 mL of LiAlH4 in dry THF (2.0 M, 2.42 mmol) was added dropwise 
to a solution of the ester 34b (0.81 g, 2.42 mmol) dissolved in dry THF 
(25 ml). The reaction was stirred for 1 h at room temperature. The 
mixture was quenched with water and acidified with concentrated H2SO4 
until the solid was dissolved. The mixture was extracted with CH2Cl2, 
the organic phase separated and dried over Na2SO4. The solvent was removed and the crude 
purified by flash chromatography (25 % AcOEt/petroleum ether) yielded product 35b in 90%. 
Rf= 0.44 (30 % EtOAc/petroleum ether); M.p. 114-117 °C. 
1
H NMR (CDCl3) δ 7.73 (d, J= 
8.6, 1H), 7.32 – 7.45 (m, 5H), 6.58 (d, J= 11.5 Hz, 1H), 5.06 (s, 2H), 4.63 (s, 2H), 6.00 (s, 
1H) 3.28 (m, 2H), 3.37 (m, 2H); 
13
C NMR (CDCl3) δ 160.6 (J= 247.4 Hz), 156.1 (J= 10.1 
Hz), 136.0, 129.2 (J= 5.9 Hz), 128.6, 128.1, 127.2, 125.8 (J= 3.4 Hz), 119.5 (J= 15.2 Hz), 
100.1 (J= 26.2 Hz), 70.6, 59.2 (J= 4.0 Hz), 48.6, 39.4; 
19
F NMR (CDCl3) δ -117.8; E.A. 
calculated C: 60.69, H: 5.09, S: 19.06; found C: 60.4, H: 5.45, S: 21.1. 
(5-(1,3-Dithiolan-2-yl)-2-fluorophenyl)methanol (35a)  
Compound 35a was prepared following the procedure described for 
compound 35b. Yield 91%; Rf= 0.40 (20% EtOAc/petroleum ether); M.p. 
60-61 °C.
 1
H NMR (CDCl3) δ 7.37 (m, 1H), 7.53 (dd, J= 6.9 Hz, J= 1.9 Hz, 
1H), 6.92 (“t”, J= 9.0 Hz, 1H), 4.67 (s, 2H), 5.56 (s, 1H) 3.44 (m, 2H), 3.30 
(m, 2H); 
13
C NMR (CDCl3) δ 160.0 (J= 247.4 Hz), 136.2 (J= 3.4 Hz), 128.78 
F
BnO
S S
OH
F
S S
OH
F
S S
OEt
O
                                                                   87 EXPERIMENTAL 
 
(J= 14.3 Hz), 128.76, 127.8 (J= 15.2 Hz), 115.2 (J= 22.0 Hz), 59.2 (J= 4.2 Hz), 55.5, 40.2; 
19
F NMR (CDCl3) δ -120.6; E.A. calculated C: 52.15, H: 4.81, S: 27.84; found C: 52.0, H: 
4.95, S: 28.5. 
(2-Fluoro-5-(2-methyl-1,3-dithiolan-2-yl)phenyl)methanol (35c) 
Compound 35c was prepared following the procedure described for 
compound 34b. Yield 91%; Rf= 0.52 (20% EtOAc/petroleum ether). 
1
H NMR 
(CDCl3) δ 7.79 (dd, J= 7.0 Hz, J= 2.5 Hz, 1H), 7.66 (ddd, J= 8.2 Hz, J= 4.9 
Hz, J= 2.7 Hz, 1H), 6.95 (“t”, J= 9.0 Hz, 1H), 4,73 (s, 2H), 3.32 – 3.44 (m, 
4H), 2.12 (s, 3H); 
13
C NMR (CDCl3) δ 159.5 (J= 247.2 Hz), 142.0 (J= 3.8 
Hz), 128.0 (J= 8.2 Hz), 127.9, 127.0 (J= 14.5 Hz), 114.7 (J= 21.5 Hz), 67.9, 59.5 (J= 3.9 Hz), 
40.4, 33.9; 
19
F NMR (CDCl3) δ -112.4; E.A. calculated C: 54.07, H: 5.36, S: 26.3; found C: 
53.9, H: 5.84, S: 26.3. 
2-(2-(Benzyloxy)-5-(bromomethyl)-4-fluorophenyl)-1,3-dithiolane (36b)  
A magnetically stirred solution of the alcohol 35b (1.25 g, 3.71 mmol) 
and 1.37 g (4.09 mmol) of carbontetrabromide in 10 mL of 
dichloromethane was cooled to 0 C. A solution of triphenylphosphine 
(1.46 g, 5.57 mmol) in 5 mL of dichloromethane was added dropwise. 
After the addition the mixture was stirred for further 5 min, whereupon 
the solvent was partially removed in vacuo at room temperature. Ether (20 mL) was added 
and the mixture filtered. The filter cake was washed with ether (2 x 20 mL). The combined 
filtrates and washings were concentrated and the residue purified via flash chromatography 
giving 1.10 g (74%) of the bromide as a white solid. Rf= 0.46 (3% EtOAc/petroleum ether); 
M.p. 114-115 °C; 
1
H NMR (CDCl3) δ 7.74 (d, J= 8.7, 1H), 7.31-7.44 (m, 5H), 6.61 (d, J= 
11.2 Hz, 1H), 5.09 (s, 2H), 4.48 (s, 2H), 5.97 (s, 1H) 3.40 - 3.27 (m, 4H); 
13
C NMR (CDCl3) δ 
160.7 (J= 250.9 Hz), 156.9 (J= 9.8 Hz), 135.7, 130.5 (J= 4.9 Hz), 128.7, 128.3, 127.2, 126.5 
(J= 3.5 Hz), 116.6 (J= 14.9 Hz), 100.3 (J= 25.6 Hz), 70.7, 48.5, 39.3, 29.3 (J= 3.6 Hz); 
19
F 
NMR (CDCl3) δ -114.6; HRMS C17H17BrFOS2 [M + H]
+
 calculated 298.9888, found 
298.9708. 
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2-(3-(Bromomethyl)-4-fluorophenyl)-1,3-dithiolane (36a) 
Compound 36a was prepared following the procedure described for compound 
36b. Yield 74%; Rf= 0.49 (3% EtOAc/petroleum ether), M.p. 63-64 °C;
 1
H 
NMR (CDCl3) δ 7.59 (dd, J= 7.1 Hz, J= 2.4 Hz, 1H), 7.50 (ddd, J= 8.4 Hz, J= 
4.8 Hz, J= 2.3 Hz, 1H), 7.04 (“t”, J= 9.0 Hz, 1H), 5.63 (s, 1H), 4.53 (s, 2H) 
3.60 - 3.33 (m, 4H); 
13
C NMR (CDCl3) δ 160.2 (J= 249.7 Hz), 136.7 (J= 3.6 
Hz), 130.8 (J= 3.5 Hz), 130.2 (J= 8.4 Hz), 125.1 (J= 14.9 Hz), 115.9 (J= 21.7 Hz), 55.3, 40.3, 
25.5 (J= 4.4 Hz); 
19
F NMR (CDCl3) δ -117.7; HRMS C10H10FS2 [M + H - HBr]
+
 calculated 
213.0208, found 213.0203. 
2-(3-(Bromomethyl)-4-fluorophenyl)-2-methyl-1,3-dithiolane (36c) 
Compound 36c was prepared following the procedure described for compound 
36b. Yield 84%; Rf= 0.51 (3% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 
7.76 (dd, J= 7.1 Hz, J= 2.1 Hz, 1H), 7.66 (ddd, J= 8.0 Hz, J= 4.5 Hz, J= 2.5 
Hz, 1H), 6.95 (“t”, J= 7.5 Hz, 1H), 4,49 (s, 2H), 3.51-3.28 (m, 4H), 2.01 (s, 
3H); 
13
C NMR (CDCl3) δ 159.6 (J= 250.9 Hz), 142.4 (J= 3.4 Hz), 129.8 (J= 
3.2 Hz), 128.3 (J= 8.2 Hz), 124.3 (J= 14.6 Hz), 115.2 (J= 21.5 Hz), 67.7, 40.5, 33.7, 25.9 (J= 
4.3 Hz); 
19
F NMR (CDCl3) δ -119.5; HRMS C22H24BrF2S4 [2M + H - HBr]
+
 calculated 
532.9912, found 532.9908. 
(2S,5S)-tert-Butyl 5-(4-(benzyloxy)-5-(1,3-dithiolan-2-yl)-2-fluorobenzyl)-2-tert-butyl-3-
methyl-4-oxoimidazolidine-1-carboxylate (37b) 
A stirred solution of diisopropylamine (0.47 mL, 3.30 mmol) in 
dry THF (2 mL) was cooled down to -78 °C, then BuLi 
(2.5 M/hexane, 1.32 mL, 3.30 mmol) was added dropwise. The 
resulting solution was stirred during 15 min. A solution of (S)-
Boc-BMI (0.71 g, 2.75 mmol) in dry THF (2 mL) was added 
slowly and stirring was maintained for 40 min. The benzyl 
bromide 36b (1.10 g, 2.75 mmol) in THF (3 mL) was then 
added. The reaction mixture was allowed to warm to room temperature and stirring was 
continued over 3 h. The reaction was quenched with saturated aqueous ammonium chloride 
(10 mL), 30 mL of water were added and the reaction was extracted with CH2Cl2 (3 x 25 mL). 
The organic layer was dried over sodium sulfate and evaporated giving the crude product 
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which was purified by flash chromatography (20% EtOAc/petroleum ether) (1.19 g, 75%, 
pale yellow solid). Rf= 0.42 (25 % EtOAc/petroleum ether); M.p. 117-118 °C. 
1
H NMR 
(CDCl3) δ 7.37 (d, J= 7.2, 1H), 7.32-7.45 (m, 5H), 6.54 (d, J= 11.5 Hz, 1H), 4.95 (br, H), 5.03 
(s, 2H), 4.30 (br, 1H), 5.99 (s, 1H), 3.29 (m, 2H), 3.41 (m, 2H), 2.89 (s, 3H), 1.34 (s, 9H), 
3.18 (d, J= 15.8 Hz, 1H), 3.60 (br, 1H), 0.95 (s, 9H); 
13
C NMR (CDCl3) δ 171.5, 160.9 (J= 
246.6 Hz), 154.8 (J= 10.1 Hz), 152.8 (br), 136.3, 129.3 (J= 4.3 Hz), 128.6, 128.0, 127.2, 
125.0 (br), 115.1 (J= 16.0 Hz), 100.0 (J= 27.0 Hz), 81.0, 80.9, 70.5, 58.9 (J= 4.0 Hz), 48.7, 
40.9, 39.4, 39.4, 39.2, 32.3, 28.0, 26.5, 26.6; 
19
F NMR (CDCl3) δ -113.6; HRMS 
C30H40FN2O4S2 [M + H]
+
 calculated 575.2414, found 575.2413. 
(2S,5S)-tert-Butyl 5-(5-(1,3-dithiolan-2-yl)-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoi-
midazolidine-1-carboxylate (37a) 
Compound 37a was prepared following the procedure described for 
compound 37b. Yield 84%; Rf= 0.33 (25% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.19-7.26 (m, 2H), 6.87 (“t”, J= 9.3 Hz, 1H), 
4.90 (br, 1H), 4.32 (br, 1H), 5.52 (s, 1H), 3.70 (br, 1H), 3.24 (d, J= 
15.1 Hz, 1H), 3.46 (m, 2H), 3.30 (m, 2H), 2.88 (s, 3H), 1.33 (s, 9H), 
0.93 (s, 9H); 
13
C NMR (CDCl3) δ 171.5, 160.7 (J= 247.4 Hz), 152.7 
(br), 135.2 (br), 129.7, 127.5 (J= 8.7 Hz), 123.8 (J= 15.8 Hz), 115.0 (J= 23.4 Hz), 81.2, 81.0, 
58.8, 55.9, 40.9, 40.0, 40.1, 32.2, 28.0, 27.0 (br), 26.5; 
19
F NMR (CDCl3) δ -116.3; HRMS 
C23H34FN2O3S2 m/z [M + H]
+
 calculated 469.1995, found 469.1994.  
(2S,5S)-tert-Butyl 2-tert-butyl-5-(2-fluoro-5-(2-methyl-1,3-dithio-lan-2-yl)benzyl)-3-me-
thyl-4-oxoimidazolidine-1-carboxylate (37c)  
Compound 37c was prepared following the procedure described for 
compound 37b. Yield 89%; Rf= 0.52 (25% EtOAc/petroleum ether); 
M.p. 103-105 °C; 
1
H NMR (CDCl3) δ 7.51 (ddd, J= 8.6 Hz, J= 4.9 
Hz, J= 2.7 Hz, 1H), 7.37 (dd, J= 7.0 Hz, J= 2.3 Hz, 1H), 6.88 (“t”, J= 
9.4 Hz, 1H), 5.04 (br, 1H), 4.33 (br, 1H) 3.25-3.41 (m, 4H), 3.27 (br, 
2H), 2.03 (s, 3H), 2.97 (s, 3H), 1.25 (s, 9H), 0.96 (s, 9H); 
13
C NMR 
(CDCl3) δ 171.6, 154.9(J= 248.6 Hz), 152.9 (br), 141.6 (br), 127.7 (br), 126.3 (J= 8.0 Hz), 
123.0 (J= 15.1 Hz), 114.5 (J= 23.1 Hz), 81.0, 80.9, 68.6 (br), 58.2 (br), 40.8, 40.0, 39.9 (br), 
33.7 (br), 32.4, 27.9, 26.7 (br), 26.5; 
19
F NMR (CDCl3) δ -118.5. HRMS C24H36FN2O3S2 m/z 
[M + H]
+
 calculated 483.2151, found 483.2148. 
F
S S
N
N
O
O
O
F
S S
N
N
O
O
O
90 
(2S,5S)-Benzyl 5-(5-(1,3-dithiolan-2-yl)-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoimi-
dazolidine-1-carboxylate (37d) 
A stirred solution of diisopropylamine (0.27 mL, 2.68 mmol) in 
dry THF (2 mL) was cooled down to -78 °C, then BuLi (2.5 
M/hexane, 1.10 mL, 2.68 mmol) was added dropwise. The 
resulting solution was stirred during 15 min. A solution of (S)-Z-
BMI (0.65 g, 2.23 mmol) in dry THF (2 mL) was added slowly 
and stirring was maintained for 40 min. The benzyl bromide 36a 
(0.66 g, 2.23 mmol) in THF (2 mL) was then added. The reaction 
mixture was allowed to warm to room temperature and stirring was continued over 3 h. The 
reaction was quenched with saturated aqueous ammonium chloride (10 mL). Then 30 mL of 
water were added and the reaction was extracted with CH2Cl2 (3 x 25 mL). The organic layer 
was dried over sodium sulfate and evaporated giving the crude product which was purified by 
flash chromatography (20% EtOAc/petroleum ether) (0.87 g, 78%, pale yellow solid). Rf= 
0.30 (25% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.39-7.29 (m, 7H), 6.93 (“t”, J= 9.3 
Hz, 1H), 5.55 (s, 1H), 5.31-4.99 (dd, J= 53.7 Hz, J= 12.0 Hz, 2H), 4.87 (br, 1H), 4.44 (br, 
1H), 3.79 (m, 1H), 3.57-3.32 (m, 4H), 3.16 (m, 1H), 2.90 (s, 3H), 0.95 (s, 9H); 
13
C NMR 
(CDCl3) δ 170.9, 165.0, 135.8, 131.0 (J= 4.8 Hz), 132.5, 130.9, 128.5, 128.3, 128.1, 128.0, 
115.2 (J= 23.7 Hz), 81.2, 67.5, 59.6, 55.61, 41.0, 40.26, 40.25, 32.2, 26.5; 
19
F NMR (CDCl3) 
δ -116.9;  
 (2S,5S)-tert-Butyl 5-(4-(benzyloxy)-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-methyl-4-ox-
oimidazolidine-1-carboxylate (1b) 
[Bis(trifluoroacetoxy)iodo]benzene (1.37 g, 3.09 mmol) was 
added in one portion to 1.19 g of 37b (2.06 mmol) dissolved in 
10 mL of 9:1 MeOH:H2O. The reaction mixture was stirred at 
room temperature during 5 min. The reaction was quenched 
with saturated aqueous NaHCO3 (20 mL). The product was 
extracted with CH2Cl2 (3 x 25 mL). The combined organic 
layers were washed with brine, dried over Na2SO4, filtered, and concentrated. Purification by 
flash chromatography (30% EtOAc/petroleum ether) yields the desired aldehyde 1b in 92%. 
Rf= 0.42 (25% EtOAc/petroleum ether); M.p. 90-92 °C;
 1
H NMR (CDCl3) δ 10.36 (s, 1H), 
7.51 (d, J= 8.8, 1H), 7.32-7.39 (m, 5H), 6.67 (d, J= 11.5 Hz, 1H), 4.88 (br, 1H), 5.10 (s, 2H), 
4.29 (br, 1H), 2.98 (s, 3H), 3.28 (d, J= 14.9 Hz, 1H), 3.60 (br, 1H), 1.33 (s, 9H), 0.95 (s, 9H); 
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13
C NMR (CDCl3) δ 187.9, 171.7, 165.8 (J= 256.7, Hz), 160.9 (J= 11.0 Hz), 152.5 (br), 
135.4, 130.1 (J= 8.4 Hz), 128.8, 128.4, 127.2, 121.4 (br), 117.0 (J= 18.1 Hz), 100.9 (J= 27.0 
Hz), 81.2, 81.1, 70.7, 58.4 (br), 40.9, 32.1, 29.7, 27.9, 26.5; 
19
F NMR (CDCl3) δ -101.2; 
HRMS C28H36FN2O5 [M + H]
+
 calculated 499.2608, found 499.2602. 
(2S,5S)-tert-Butyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-4-oxoimidazolidine-
1-carboxylate (1a)  
Compound 1a was prepared following the procedure described for 
compound 1b. Yield 93%; Rf= 0.34 (25% EtOAc/petroleum ether); 
M.p. 92-93 °C; 
1
H NMR (CDCl3) δ 9.81 (s, H), 7.69 (m, 1H), 7.58 
(dd, J= 7.0 Hz, J= 1.4 Hz, 1H), 7.10 (“t”, J= 9.2 Hz, 1H), 4.84 (br, 
1H), 4.33 (br, 1H), 3.65 (br, 1H), 3.41 (d, J= 15.2 Hz, 1H), 2.92 (s, 
3H), 1.34 (s, 9H), 0.94 (s, 9H); 
13
C NMR (CDCl3) δ 190.5, 171.4, 
165.0 (J= 257.0 Hz), 152.5 (br), 132.5, 132.3 (J= 6.2 Hz), 130.2 (J= 10.0 Hz), 125.4 (J= 16.7 
Hz), 116.2 (J= 24.4 Hz), 81.3, 81.1, 58.5, 40.9, 32.2, 28.0, 27.6 (br), 26.5; 
19
F NMR (CDCl3) 
δ -104.3; HRMS C21H30FN2O4 m/z [M + H]
+
 calculated 393.2190, found 393.2183. 
(2S,5S)-tert-Butyl 5-(5-acetyl-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-
1-carboxylate (1c) 
Compound 1c was prepared following the procedure described for 
compound 1b. Yield 91%; Rf= 0.29 (25% EtOAc/petroleum ether); 
M.p. 76-78 °C; 
1
H NMR (CDCl3) δ 7.76 (ddd, J= 8.4 Hz, J= 5.2 Hz, 
J= 2.4 Hz, 1H), 7.66 (dd, J= 7.4 Hz, J= 2.3 Hz, 1H), 6.88 (“t”, J= 8.7 
Hz, 1H), 4.85 (br, 1H), 4.34 (br, 1H), 3.68 (br, 1H), 3.38 (d, J= 14 Hz, 
1H), 2.94 (s, 3H), 2.52 (s, 3H), 1.33 (s, 9H), 0.96 (s, 9H); 
13
C NMR 
(CDCl3) δ 196.6, 171.6, 164.3(J= 255.7 Hz), 152.7 (br), 130.9 (J= 5.4 Hz), 128.8 (J= 9.0 Hz), 
124.3 (J= 14.4 Hz), 115.5, 113.0 (J= 3.0 Hz), 81.3, 81.1, 58.5, 40.9, 32.2, 27.9, 26.6, 26.5; 
19
F 
NMR (CDCl3) δ -107.4. HRMS C22H32FN2O4 m/z [M + H]
+
 calculated 469.1995, found 
469.1994. 
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(2S,5S)-Benzyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-4-oxoimidazolidine-1-
carboxylate (1d) 
Compound 1d was prepared following the procedure described 
for compound 1b. Yield 90%; Rf= 0.22 (25% EtOAc/petroleum 
ether); 
1
H NMR (CDCl3) δ 9.86 (s, 1H), 7.79-7.65 (m, 2H), 7.14 
(“t”, J= 9.5 Hz, 1H), 5.30-4.96 (dd, J = 56.3, J= 12.0) 4.89 (br, 
1H), 4.48 (br, 1H), 3.80 (m, 1H), 3.47 (m, 1H), 2.93 (s, 3H), 0.96 
(s, 9H); 
13
C NMR (CDCl3) δ 190.6, 171.0, 165.0, 135.5, 133.4 
(J= 6.2 Hz), 132.5, 130.0 (J= 10.0 Hz), 128.7, 128.6, 128.4, 128.2 
(J= 16.7 Hz), 116.0 (J= 24.4 Hz), 81.2, 67.6, 58.1, 40.9, 32.0, 26.4; 
19
F NMR (CDCl3) δ -
105.4.  
4.4 Synthesys of Schöllkopf-precursors via a dithiolane approach 
(2S,5R)-2-(5-(1,3-Dithiolan-2-yl)-2-fluorobenzyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydro-
pyrazine (37e) 
(R)-2,5-Dihydro-3,6-dimethoxy-2-isopropylpyrazine (0.23 ml, 
1.23 mmol) was dissolved in 2 ml of dry THF. The solution was 
cooled down to -78 °C and BuLi (2.5 M/hexane, 0.49 ml, 1.23 
mmol) was added under stirring. After 15 min, compound 36a 
(0.36 g, 1.23 mmol) in 2 mL THF was added and the reaction 
mixture was allowed to warm to room temperature and stirring was continued over 3 h. The 
reaction was quenched with water (20 mL) and extracted with ether (3x15 mL). The organic 
extracts were combined, dried over sodium sulfate and the solvent evaporated giving the 
crude product which was purified by flash chromatography (5% EtOAc/petroleum ether) 
(0.35 g, 71%, colorless oil); Rf= 0.45 (10% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.63 
(m, 2H), 6.93 (“t”, J= 9.2 Hz, 1H), 5.60 (s, 1H), 4.35 (m, 1H), 3.75 (s, 3H), 3.70 (s, 3H), 3.47 
(t, J= 2.3 Hz, 1H), 3.34-3.49 (m, 4H), 2.97-3.29 (m, 2H), 2.23 (m, 1H), 1.01 (d, J= 6.8 Hz, 
3H), 0.66 (d, J= 6.8 Hz, 3H); 
13
C NMR (CDCl3) δ 162.5 (J= 196.3 Hz), 162.4, 135.1 (J= 3.8 
Hz), 131.9 (J= 4.9 Hz), 127.7 (J= 8.4 Hz), 124.7 (J= 16.4 Hz), 115.3 (J= 23.3 Hz), 60.3, 55.8, 
52.5, 40.1, 33.9, 33.2, 31.2, 26.5, 19.0, 16.5; 
19
F NMR (CDCl3) δ -117.9. 
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(2S,5R)-2-(2-Fluoro-5-(2-methyl-1,3-dithiolan-2-yl)benzyl)-5-isopropyl-3,6-dimethoxy-
2,5-dihydropyrazine (37f) 
Compound 37f was prepared following the procedure described for 
compound 37e. Yield 77%; Rf= 0.55 (10% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.58 (m, 1H), 6.93 (“t”, J= 9.2 Hz, 1H), 4.40 (m, 
1H), 3.78 (s, 3H), 3.73 (s, 3H), 3.54-3.23 (br, 6H), 3.11-3.02 (m, 1H), 
2.18 (m, 1H), 2.11 (s, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.64 (d, J= 6.8 
Hz, 3H);
 13
C NMR (CDCl3) δ 163.0, 162.4, 131.2, 130.9 (J= 3.2 Hz), 130.0 (J= 9.6 Hz), 126.8 
(J= 8.2 Hz), 114.3 (J= 23.0 Hz), 60.1, 56.1, 52.5, 40.3, 33.9, 33.1, 31.0, 19.1, 16.4; 
19
F NMR 
(CDCl3) δ -119.5. 
4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)benzal-
dehyde (1e) 
Compound 1e was prepared following the procedure described for 
compound 1b. Yield 71%; Rf= 0.34 (5 % EtOAc/petroleum ether); 
1
H 
NMR (CDCl3) δ 9.95 (s, H), 7.76 (m, 1H), 7.17 (“t”, J= 8.5 Hz, 1H), 
4.36 (m, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 3.57 (t, J= 3.4 Hz, 1H), 3.04-
3.40 (m, 2H), 2.20 (m, 1H), 1.00 (d, J= 6.8 Hz, 3H), 0.67 (d, J= 6.8 Hz, 3H); 
1-(4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)phe-
nyl)ethanone (1f) 
Compound 1f was prepared following the procedure described for 
compound 1b. Yield 70%; Rf= 0.30 (10% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.84 (m, 1H), 7.10 (“t”, J= 9.1 Hz, 1H), 4.34 (m, 
1H), 3.77 (s, 3H), 3.69 (s, 3H), 3.41 (t, J= 3.4 Hz, 1H), 3.03-3.35 (m, 
2H), 2.59 (s, 3H), 2.18 (m, 1H), 0.99 (d, J= 6.8 Hz, 3H), 0.66 (d, J= 6.8 Hz, 3H); 
13
C NMR 
(CDCl3) δ 196.2, 167.0 (J= 253.1 Hz), 162.4, 133.2 (J= 6.5 Hz), 132.9 (J= 3.2 Hz), 129.0 (J= 
9.6 Hz), 125.2 (J= 16.8 Hz), 115.3 (J= 23.6 Hz), 60.5, 55.8, 52.5, 33.2, 31.5, 26.5, 19.0, 16.5; 
19
F NMR (CDCl3)δ -109.1. 
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4.5 Synthesis of fluorophenone derivatives of Seebach-precursors 1g and 1h via a 
Grignard approach 
1-Fluoro-4-iodo-2-(iodomethyl)benzene (39) 
2-Fluoro-5-iodobenzaldehyde (1.00 g, 4.0 mmol) was dissolved in 25 mL 
dichloromethane. Diiodosilane (0.6 mL, 6.0 mmol) was added and the mixture 
stirred at roon temperature during 1.5 h. The reaction was quenched with a 
saturated solution of NaHCO3 (20 mL) and 10 % aqueous Na2S2O3 (20 mL). 
The organic phase was separated, dried over Na2SO4 and the solvent removed in vacuo. The 
residue was purified by flash chromatography (1% AcOEt:P.E.). The desired product was 
obtained as white solid in 80% yield. Rf= 0.50 (1% EtOAc/petroleum ether); 
1
H NMR 
(CDCl3) δ 7.70 (dd, J= 7.0 Hz, J= 2.4 Hz, 1H), 7.57 (ddd, J= 8.6 Hz, J= 4.8 Hz, J= 2.3 Hz, 
1H), 6.82 (“t”, J= 8.8 Hz, 1H), 4,37 (s, 2H); 13C NMR (CDCl3) δ 162.8 (J= 249.6 Hz), 139.3 
(J= 3.1 Hz), 138.7 (J= 8.0 Hz), 129.4 (J= 15.6 Hz), 118.1 (J= 21.9 Hz), 87.1 (J= 3.7 Hz); 
19
F 
NMR (CDCl3) δ -117.3. 
(2S,5S)-tert-Butyl 2-tert-butyl-5-(2-fluoro-5-iodobenzyl)-3-methyl-4-oxoimidazolidine-1-
carboxylate (40) 
A stirred solution of diisopropylamine (0.27 mL, 1.87 mmol) in dry 
THF (1.0 mL) was cooled down to -78 °C, then BuLi (2.5 M/hexane, 
0.75 mL, 1.87 mmol) was added dropwise. The resulting solution was 
stirred during 15 min. A solution of (S)-Boc-BMI (0.40 g, 1.56 mmol) 
in dry THF (1.5 mL) was added slowly and stirring was maintained 
for 40 min. The benzyl iodide 39 (0.56 g, 1.56 mmol) in THF (2.0 
mL) was then added. The reaction mixture was allowed to warm to room temperature and 
stirring was continued over 3 h. The reaction was quenched with saturated aqueous 
ammonium chloride (10 mL), 30 mL of water were added, and the reaction was extracted with 
ether (3 x 25 mL). The organic layer was dried over sodium sulfate and evaporated to give the 
crude product which was purified by flash chromatography (20% EtOAc/petroleum ether) 
(0.62 g, 81%, white solid).
 
Rf= 0.48 (20% EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.44 
(m, 1H), 7.38 (dd, J= 6.8 Hz, J= 2.2 Hz, 1H), 6.78 (“t”, J= 8.6 Hz, 1H), 4.86 (s, 1H), 4.33 (br, 
1H), 3.65 (br, 1H), 3.30 (dd, J= 15.1 Hz, J= 2.4 1H), 2.97 (s, 3H), 1.44 (s, 9H), 0.99 (s, 9H); 
13
C NMR (CDCl3) δ 171.4, 163.7 (J= 246.3 Hz), 152.0, 139.4 (J= 4.1 Hz), 136.8 (J= 8.1 Hz), 
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126.6 (J= 16.1 Hz), 117.4 (J= 24.0 Hz), 86.6 (J= 3.7 Hz), 81.3, 81.2, 58.8, 41.0, 32.0, 28.1, 
26.6; 
19
F NMR (CDCl3) δ -116.1. 
(2S,5S)-tert-Butyl 5-(5-(3,5-bis(trifluoromethyl)benzoyl)-2-fluorobenzyl)-2-tert-butyl-3-
methyl-4-oxoimidazolidine-1-carboxylate (1g) 
Isopropylmagnesium bromide (2.9 M, 0.42 mL, 
1.22 mmol) was placed through syringe in a dry and argon 
flushed round bottom flask, 1.0 mL of dry THF and the 
solution was cooled to 0 °C. A solution of compound 40 
(0.30 g, 0.61 mmol) in 1.0 mL dry THF was added and the 
mixture stirred during 1.0 h at 0 °C. Then, 0.23 mL 
(1.22 mmol) of 3,5-bis(trifluoromethyl)-benzoyl chloride 
was added and the mixture was allowed to reach room 
temperature. The reaction mixture was stirred for 2 h and was then quenched with saturated 
aqueous NH4Cl solution (4 mL). The mixture was partitioned in H2O:ether (30:30) the 
organic layer separated and the aqueous phase was extracted with ether (2 x 20 mL), the 
organic fractions were combined, dried with Na2SO4, and concentrated in vacuo. The crude 
residue was purified by flash chromatography (25% AcOEt/petroleum ether) yielding 
compound 1g (84%). Rf= 0.29 (10% EtOAc/petroleum ether). Rf= 0.74 (25% 
EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 8.24 (br, 2H), 8.13 (br, 1H), 7.64 (m, 2H), 7.18 
(“t”, J= 8.6 Hz, 1H), 4.98 (s, 1H), 4.40 (m, 1H), 3.60 (m, 2H), 2.98 (s, 3H), 1.41 (s, 9H), 1.01 
(s, 9H); 
13
C NMR (CDCl3) δ 192.3, 171.6, 163.0, 139.4, 133.2 (J= 6.1 Hz), 132.4, 131.6 (J= 
3.2 Hz), 130.6 (J= 9.7 Hz), 129.7 (br), 125.6 (br), 125.4 (J= 11.0 Hz), 120.2, 115.8 (J= 23.9 
Hz), 81.4, 81.1, 58.3, 40.9, 31.9, 28.0, 26.5; 
19
F NMR (CDCl3) δ -105.9, -62.8.  
(2S,5S)-tert-Butyl 2-tert-butyl-5-(2-fluoro-5-(2,2,2-trifluoroacetyl)benzyl)-3-methyl-4-
oxoimidazolidine-1-carboxylate (1h).  
Compound 1h was prepared following the procedure described for 
compound 1g but using trifluoroacetic anhydride. Yield 62%. Rf= 
0.32 (25 % EtOAc/petroleum ether); 
1
H NMR (CDCl3) δ 7.40 (m, 
1H), 7.16 (m, 2H), 4.85 (s, 1H), 4.36 (m, 1H), 3.75 (m, 1H), 3.01 (m, 
1H), 2.90 (s, 3H), 1.16 (s, 9H), 0.94 (s, 9H); 
13
C NMR (CDCl3) δ; 
19
F NMR (CDCl3)δ -82.8, -116.3. 
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4.6 Radiochemistry 
4.6.1 Preparation of tetrabutylammonium [18F]fluoride 
N.c.a. [
18
F]fluoride was produced by the 
18
O(p,n)
18
F nuclear reaction with bombardment 
of an isotopically enriched [
18
O]water target with 17 MeV protons at the JSW cyclotron BC 
1710 (FZ Jülich).
169
 The produced 
18
F-fluoride was isolated from the irradiated water through 
electrochemically supported adsorption on a Sigradur-Anode (HTW Hochtemperatur-
Werkstoffe GmbH) and desorption into 500 mL of pentadistilled water after recovery of the 
18
O enriched water.
24
 An aliquot of the [
18
F]fluoride solution was added to 17.5-130 µL (2.6-
17.0 µmol) of a 0.13 M tetrabutylammonium bicarbonate solution (TBAHCO3). The mixture 
was diluted with 1.0 mL of dry acetonitrile and transferred by syringe into a reaction flask. 
The solvent was evaporated under a stream of nitrogen at 80 °C and 650 mbar. The azeotropic 
evaporation was repeated twice with 1.0 mL of acetonitrile and afterwards the vial was 
evacuated for 5 min at 20-30 mbar. 
4.6.2 General procedure for the radiosynthesis of 2-[18F]fluoro-L-phenylalanine 
and 2-[
18
F]fluoro-L-tyrosine under conventional heating 
A solution of 10-15 µmol of the corresponding amino acid-precursor in 1.0 mL DMF was 
added to the dried residue of TBA
18
F. The mixture was heated at 130 ºC for 10 min. After 
labeling, the DMF solution was diluted with water (15 mL), and passed through a pre-
conditioned LiChrolut RP-18e cartridge (Merck, Germany). The product was eluted from the 
cartridge with 2.0 mL acetonitrile and then the solvent evaporated at 80 °C and 650 mbar. A 
solution of 1.5 eq. of Wilkinson´s catalyst in 1 mL dioxane was added to the dry residue and 
the mixture was stirred for 20 min at 150 ºC. The dioxane was distilled off, the residue 
suspended in 1 mL of a solution of ethyl acetate in petroleum ether (30% AcOEt/P.E.) and 
then filtered through a silica gel plug (650 mg silica gel in a 3 mL polyethylene filtration 
tube). The reaction vial was washed with an extra portion of the solution (1 mL) and the 
compound was then eluted with 4 mL of the same mixture. The solvent mixture was 
evaporated and 250 µL of hydrochloric acid were added and the reaction was heated to 200 
°C and stirred for 30 minutes.  
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4.6.3 General procedure for the radiosynthesis of 2-[18F]fluoro-L-phenylalanine 
and 2-[
18
F]fluoro-L-tyrosine under microwave heating 
A solution of 10-15 µmol of the corresponding amino acid-precursor in 1.0 mL DMF was 
added to the dried residue of TBA
18
F. The mixture was irradiated with 50 W microwaves 
during 1 min. The purification of the labeled compound was carried out using the same 
procedure described above. A solution of 4.0 eq. of Wilkinson´s catalyst in 1 mL benzonitrile 
was added and the mixture was irradiated with 100 W microwaves during 50 s. The reaction 
mixture was diluted with 10 mL of a solution of ethyl acetate in petroleum ether (5% 
AcOEt/P.E.) and then passed through a silica gel column (see above). The desired compound 
was then eluted from the column with 5 mL of a solution of 30% AcOEt/P.E. After the 
solvent mixture was evaporated, 250 µL of hydrochloric acid were added and the reaction 
mixture was heated with microwaves to 140 ºC for 20 min (Ramp: 150 W, 15 s, Hold: 20 
min).  
4.6.4 General procedure for the radiosynthesis of 6-[18F]fluoro-L-m-tyrosine 
A solution of 10-15 µmol of the precursor in 1.0 mL DMSO was added to the dried 
residue of TBA
18
F. The mixture was heated at 160 ºC for 10 min. After labeling, the DMSO 
solution was diluted with water (10 mL), and passed through a pre-conditioned LiChrolut RP-
18e cartridge; the product was eluted from the cartridge with 2.0 mL chloroform and the 
eluate was dried using a column packed with Na2SO4. 45 µmol of the oxidant agent was 
added, and the mixture was stirred for 30 min at 60 ºC. After the reaction was completed the 
chloroform was evaporated at 60 °C and 750 mbar. 1 mL of hydrochloric acid (32 %) was 
added to the residue and the solution was heated at 200 ºC for 30 min.  
4.6.5 General procedure for the radiosynthesis of 6-[18F]fluoro-L-DOPA 
A solution of 10-15 µmol of the precursor in 1.0 mL DMF was added to the dried residue 
of TBA
18
F. The mixture was heated at 130 ºC for 10 min. After labeling, the DMF solution 
was diluted with water (10 mL), and passed through a pre-conditioned LiChrolut RP-18e 
cartridge; the product was eluted from the cartridge with 2.0 mL chloroform and the eluate 
was dried using a column packed with Na2SO4. 45 µmol of the oxidant agent was added, and 
the mixture was stirred for 10 min at 60 ºC. After the reaction was completed the chloroform 
was evaporated at 60 °C and 750 mbar. 1 mL of hydrochloric acid (32 %) was added to the 
residue and the solution was heated at 200 ºC for 30 min. 
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4.6.6 Automated radiosynthesis of 6-[18F]FDOPA 
Synthesis device 
The automated device used for a remote-controlled radiosynthesis of 6-[
18
F]FDOPA 
device was a SynChrom R&D (Raytest GmbH, Germany) controlled by GINA SynChrom 
software. For a schematic sketch of the set-up see Figure 13. 
[
18
F]Fluoride fixation and desorption 
[
18
F]Fluoride was separated from the irradiated 
18
O-enriched water by an anion exchange 
resin (QMA light). The elution of the activity was achieved with 0.3 ml of a mixture of tetra-
n-butyl ammonium hydrogencarbonate (6.4 µmol) and tetra-n-butyl ammonium mesylate (25 
µmol) in water. Azeotropic drying was then repeatedly performed with acetonitrile (DNA 
quality, 3 x 1 mL). 
Radiofluorination 
(2S,5S)-tert-Butyl 5-(4-(benzyloxy)-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-methyl-4-o-
xoimidazolidine-1-carboxylate 1b (5 mg, 14.8 mmol) dissolved in 1 ml of dry DMF was 
added to the TBA
18
F residue and heated at 130 °C for 10 min. Afterwards, the solution was 
diluted with 10 mL of a mixture 4:1 of water and acetonitrile. 
Purification of the intermediate compound [
18
F]1b 
The solution containing [
18
F]1b was passed through a C-18 cartridge and afterward the 
cartridge was washed with 10 mL water. The desired compound was eluted with 1.5 mL 
chloroform and the eluate was driven through a column containing 700 mg of sodium sulfate.  
Baeyer-Villiger oxidation and Hydrolysis 
The dry solution was transferred to the second reactor where 120 mg of sodium 
percarbonate and 100 µL of trifluoroacetic anhydride in 0.5 mL dry chloroform were 
previously loaded. The reaction mixture was then heated at 60 °C for 10 min. After the time 
was over the reaction mixture was evaporated to dryness at the under a stream He at 
650 mbar. Concentrated hydrochloric acid (1 mL) was added to the dry residue and the 
reaction mixture heated to 170 °C for 30 min. Afterward the mixture was cooled down to 
40 °C and diluted with 1 mL water. 
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4.6.7 Radioanalytic procedures 
The analysis and isolation of the 
18
F-labeled products was performed by either thin layer 
chromatography (TLC) or high-performance liquid chromatography (HPLC). 
Radio-thin layer chromatography  
Analytical radio-thin layer chromatography (radio-TLC) was carried out in order to 
determine the RCY of the products of the isotopic exchange reaction. This was performed on 
precoated plates of silica gel 60 F254. In practice, 2 μl of the sample solution was applied on 
the TLC plates and developed in the appropriate solvent mixture. The [
18
F]fluorine could 
easily be identified since, under the elution conditions, it remained on the origin of the TLC 
plate. Radioactivity on the TLC plate was detected simultaneously using an Instant ImagerTM 
(Packard Instruments). The RCY then was calculated dividing the activity of the compound of 
interest by the total activity deposited on the TLC plate, multiplied by 100. 
Table 11: Rf –values and eluent system of the compounds labeled by isotopic exchange 
Compound Solvent system (% AcOEt/P.E.) Rf value 
[
18
F]1a 25 0.34 
42a 25 0.28 
[
18
F]1b 25 0.42 
42b 25 0.36 
[
18
F]1c 25 0.29 
45c 25 0.25 
[
18
F]1d 30 0.35 
42d 30 0.28 
[
18
F]1e 5 0.34 
[
18
F]1f 10 0.30 
[
18
F]1g 10 0.29 
[
18
F]1h 25 0.35 
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Radio-high performance liquid chromatography 
High performance liquid chromatography (HPLC) separations were achieved with a 
Knauer pump, a Knauer K-2500 UV/VIS detector, two manual Rheodyne injectors (20 µL 
loop), the first located before the chromatography column and the second after it, and an 
NaI(Tl) well-type scintillation detector (EG&G Ortec; model 276 Photomultiplier Base) with 
an ACE Mate Amplifier and BIAS supply (Ortec) for radioactivity detection. Data acquisition 
and interpretation were performed with Gina software (Raytest Germany). 
In practice, the radioactive sample was injected into the column using the first injector, 
and after the elution of the last radioactive component three aliquots of the sample were 
introduced into the system through the second injector. The RCY of the product was 
determined using the Equation 1 by multiplying the activity of the desired compound (Ap), by 
100 and the correction factor for decay (λ is the decay constant of fluorine-18 and “t” is the 
time difference between the retention time of the peak of interest and the standard), and 
dividing by the total activity of the sample (A0). 
       
    
       
  
 
Equation 1: Determination of the RCY  
HPLC-Systems: 
A: Analysis of 
18
F-labelled compound was performed with a reverse-phase Kromasil 100-
5 C18 column (250-4.6 mm; CS Chromatographieservice GmbH). Elution was performed at a 
constant flow rate of 1 mL/min with acetonitrile:water (70:30). 
B: Analysis was performed with an analytic reverse-phase Synergi 4µ Hydro-RP 80A 
column (250-4.6 mm; Phenomenex). The mobile phase was aqueous acetic acid (0.1%) used 
at a flow rate of 1 mL/min. 
C: Preparative separations were carried out with a Synergi 4µ Hydro-RP 80A column 
(250 - 10 mm; Phenomenex). The mobile phase was aqueous ethanol (2%), and the flow rate 
was 4 mL/min. 
D: The enantiomeric purity of the 
18
F-labeled compounds was determined by HPLC 
using a Crownpak CR (1) 5µ column (150-4 mm; Daicel Chemical Industries) and aqueous 
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HClO4 (0.025 M) as eluent at a flow rate of 1 mL/min. Peak recording was achieved by UV 
detection at 261 nm. 
Table 12: k´-values of the samples analyzed by HPLC  
Compound/HPLC 
system 
A B C D (L/D enant.) 
[
18
F]1a 3.7 - - - 
[
18
F]1b 11.2 - - - 
[
18
F]1c 3.8 - - - 
[
18
F]1g 25 - - - 
[
18
F]1h 2.7 - - - 
41a 4.7 - - - 
41b 14.3 - - - 
44c 4.2 - - - 
2-[
18
F]Fphe - 5.4 5.1 6.0/4.4 
2-[
18
F]Ftyr - 3.0 2.7 5.2/3.6 
6-[
18
F]Fmtyr - 6.3 6.0 6.8/4.3 
6-[
18
F]FDOPA - 5.4 5.1 6.0/4.4 
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5 SUMMARY 
Aromatic [
18
F]fluoroamino acids have been developed as potential probes for the 
diagnosis of different pathologies in nuclear medicine. The most representative of this class of 
compounds is 6-[
18
F]fluoro-L-DOPA (6-[
18
F]FDOPA), one of the few established radio-
pharmaceuticals for positron emission tomography (PET), which is routinely used for the 
diagnosis of central motor disorders and also of brain and peripheral endocrine tumors. On the 
other hand, there are some other aromatic [
18
F]fluoroamino acids which have already 
preliminary been tested that showed also interesting properties as diagnostic tracers. 2-
[
18
F]Fluoro-L-phenylalanine (2-[
18
F]Fphe) has proven to be a useful radiopharmaceutical for 
the study of neutral amino acid transport at the blood brain barrier in vivo in humans. 2-
[
18
F]Fluoro-L-tyrosine (2-[
18
F]Ftyr), unlike other halogenated amino acids, is almost 
quantitatively incorporated into proteins lending it as interesting tracer for imaging of protein 
synthesis in vivo. Thus the accumulation of 2-[
18
F]Fphe and 2-[
18
F]Ftyr enables to distinguish 
tumors from normal tissue, and positron emission tomography studies of their uptake are of 
special clinical value for the diagnosis of brain tumors. 6-[
18
F]Fluoro-L-m-tyrosine (6-
[
18
F]Fmtyr) is another interesting compound that has potential as analogous imaging agent of 
6-[
18
F]FDOPA measuring the dopaminergic function in the brain in both animals as well as 
humans using PET.  
In spite of all the possible applications of these compounds their availability so far has 
been limited due to radiosynthetic constraints. Two general pathways have been developed for 
the radiofluorination of arene-derivatives of high electron density. The electrophilic approach 
is applicable because many of those compounds have a low toxicity and therefore they can be 
used in c.a. form. Due to the necessary generation of elemental [
18
F]fluorine for this approach, 
however, the currently used methods for routine preparation are limited to rather low amounts 
of activity at high costs. Alternatively developed nucleophilic syntheses using the advantage 
of large scale production of [
18
F]fluoride, however, result either in insufficient enantiomeric 
purity or in need of multi-step syntheses that are difficult to automate, due to their complexity. 
Recently, a nucleophilic isotopic exchange approach made the radiosynthesis of 6-
[
18
F]FDOPA available in three steps. In this radiochemical process the precursor (2S,5S)-tert-
butyl 5-(4-(benzyloxy)-2-fluoro-5-formylbenzyl)-2-tert-butyl-3-methyl-4-oxoimidazolidine-
1-carboxylate (1b) was radiofluorinated by an isotopic exchange reaction. Subsequently the 
formyl group was converted into the formate derivative by Baeyer-Villiger oxidation. Finally, 
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an acid hydrolysis allowed the cleavage of the protecting groups of the catechol function and 
unmasked the amino acid producing 6-[
18
F]FDOPA.  
In the present work this three-step procedure has been optimized allowing not only an 
improved radiosynthesis of 6-[
18
F]FDOPA but also, starting from the identical precursor, 2-
[
18
F]Ftyr could be prepared by a modified procedure in which a decarbonylation reaction was 
performed instead of the Baeyer-Villiger oxidation. Additionally, using analogous precursors, 
6-[
18
F]Fmtyr was prepared via the oxidative approach while 2-[
18
F]Fphe was obtained, again 
by the decarbonylation route. The specific activity of the radiotracers prepared in this work 
under developmental conditions was already as high as compared to that achieved by 
electrophilic procedures and can be expected to increase several times under production 
conditions with high starting activity of [
18
F]fluoride. 
A modified efficient synthetic approach was employed for the preparation of highly 
functionalized fluoro-benzaldehydes while a new one was developed for the preparation of 
fluoro-benzophenones, which were used as labeling precursors. The first involved six steps 
and allowed the synthesis of the already reported (2S,5S)-tert-butyl 2-tert-butyl-5-(2-fluoro-5-
formylbenzyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (1a) and 1b in overall yields of 
41% and 19%, respectively. Additionally, using the same synthetic approach the new 
precursors (2S,5S)-tert-butyl 5-(5-acetyl-2-fluorobenzyl)-2-tert-butyl-3-methyl-4-oxoimidazo-
lidine-1-carboxylate (1c), (2S,5S)-benzyl 2-tert-butyl-5-(2-fluoro-5-formylbenzyl)-3-methyl-
4-oxoimidazolidine-1-carboxylate (1d), 4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazin-2-yl)methyl)benzaldehyde (1e) and 1-(4-fluoro-3-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)phenyl)ethanone (1f) could also successfully be 
prepared in yields of 48%, 37%, 27% and 32%, respectively.  
Preparation of precursor 1b required the prior synthesis of 2-(benzyloxy)-5-bromo-4-
fluorobenzaldehyde, which was accomplished in four steps. On the other hand, the synthesis 
of compounds 1a, 1d, and 1e started from 3-bromo-4-fluorobenzaldehyde while that of 1c and 
1f required 1-(3-bromo-4-fluorophenyl)ethanone; both those starting materials were 
commercially available.  
In the first step, the carbonyl function of those starting compounds was protected as the 
1,3-dithiolane derivatives 33. From those, compounds 34 were achieved using a “two-step 
one-pot” coupling reaction by a Br-for-Mg exchange between 33 and a diisopropylmagnesium 
chloride lithium chloride complex followed by coupling with ethyl chloroformate. Reduction 
104 
of 34 with LiAlH4 provided the benzyl alcohols 35 in yields of about 92%. The conversion of 
the benzyl alcohols to the benzyl bromides 36 was performed using the Appel reaction, again 
with good yields of 74% to 84%. Freshly prepared lithium diisopropylamide (LDA) generated 
the enolate derivative of the chiral auxiliaries (S)-(-)-1-BOC-2-tert-butyl-3-methyl-
imidazolidin-4-one (Seebach´s reagent) and (S)-(-)-1-Z-2-tert-butyl-3-methyl-imidazolidin-4-
one while butyl-lithium was used with (R)-2,5 dihydro-3,6-dimethoxy-2-isopropylpyrazine. 
Afterwards they were coupled to the corresponding benzyl bromides producing the alkylated 
products 37 in a range of 70-89% yield. By deprotection of the 1,3-dithiolane with 
[bis(trifluoroacetoxy)iodo]benzene the desired compounds 1a-f were achieved.  
The second approach, which was developed here for the preparation of the ketone 
precursors (2S,5S)-tert-butyl 5-(5-(3,5-bis(trifluoromethyl)benzoyl)-2-fluorobenzyl)-2-tert-
butyl-3-methyl-4-oxoimidazolidine-1-carboxylate (1g) and (2S,5S)-tert-butyl 2-tert-butyl-5-
(2-fluoro-5-(2,2,2-trifluoroacetyl)benzyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (1h) 
represents a novel three-step synthesis. In summary, the procedure went like this: 
commercially available 2-fluoro-5-iodobenzaldehyde 38 was treated with an excess of 
diiodosilane yielding the diiodo derivative 39 with 80%. Freshly prepared lithium diiso-
propylamide (LDA) was used here again to generate the enolate derivative of Seebach´s 
reagent. This was coupled with compound 39 achieving product 40 in 81% yield. From this, 
precursors 1g and 1h were obtained using a “one-pot two-step” reaction. In the first step 
compound 40 was reacted with i-PrMgBr in order to generate the magnesium derivative. This 
was then acylated with 3,5-bis(trifluoromethyl)benzoyl chloride producing 1g in 84% yield. 
Alternatively the organo-metallic species was reacted with trifluoroacetic anhydride 
generating 1h in 62% yield. The overall yields of 1g and 1h were 54% and 40%, respectively. 
The radiosynthesis of 2-[
18
F]Fphe and 2-[
18
F]Ftyr was achieved using precursors 1a and 
1b, respectively. Optimization studies on the isotopic exchange reaction using conventional 
heating (oil bath) showed that an increase of the concentration of the basic TBAHCO3 anion 
activator led to higher labeling yields; but also to the formation of additional new products 
which were identified as diasteromers of the desired compounds [
18
F]1a and [
18
F]1b. An 
increase of the temperature from 130 to 150 ºC did not provide a better RCY but increased the 
production of the diastereomer while standard 
18
F-labeling conditions using Kryptofix 2.2.2 
provided the undesired compound even as major product. The use of microwave heating for 
isotopic exchange delivered similar RCY than those obtained with conventional heating but 
saving 9 min reaction time. It was observed that an elevated power of the microwave 
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produced higher RCY of the desired product but also of the non-wanted diastereomer. 
Additionally, reaction times under 10 min and 50 s for conventional and microwave heating, 
respectively, produced low RCY of both the desired compounds and the diastereomers, while 
extended reaction times increased only the production of the diastereomers. 
After optimization of the three steps of the radiosynthetic pathway the conventional 
heated reactions yielded the desired products 2-[
18
F]Fphe and 2-[
18
F]Ftyr in 43% and 49%, 
whereas 34% and 43% RCY were obtained, respectively, when microwave heating was 
applied. However, 38 min of total preparation time were saved with the latter. Thus 
considering the radioactive decay, the amounts of isolated radioactive products obtained with 
both methods were directly comparable. Both products were obtained with good enantiomeric 
purity. The e.e. achieved for 2-[
18
F]Fphe was 88% while an e.e. of 92% was obtained in the 
case of 2-[
18
F]Ftyr. It was also shown that the incidence of 2-[
18
F]F-D-phe and 2-[
18
F]F-D-tyr 
in the case of the Seebach´s derivatives occurred as consequence of the diastereomerization of 
the precursors during the nucleophilic exchange reaction with [
18
F]fluoride. Experiments 
performed using the bulky precursor 1d showed that diastereomerization occurred 
independently of the size of the protecting group of the imidazolidinone system. 
Radiosynthesis of 2-[
18
F]Fphe starting from the labeling precursor 1e resulted only in a low 
RCY; moreover, the instability of this precursor limited the number of experiments which 
could be performed. 
A new nucleophilic synthesis of 6-[
18
F]Fmtyr by isotopic exchange was also developed. 
In this case, DMSO resulted to be more suitable than DMF for the 
18
F-for-
19
F exchange 
reaction. Also a higher temperature was required for labeling of the precursor 1c, while the 
RCY was low compared to the analogous aldehyde 1a. The three-step radiosynthetic 
procedure led to the desired amino acid in 13% overall radiochemical yield with a high 
enantiomeric purity of > 93% when the Seebach-precursor 1c was employed. A comparable 
overall radiochemical yield of 11% of 6-[
18
F]Fmtyr was achieved with the Schöllkopf-
precursor 1f while the enantiomeric purity in this case was only 87%. These results 
demonstrated that Schöllkopf´s derivatives were more sensitive to the labeling conditions than 
Seebach´s ones. Precursors 1g and 1h in contrast to 1c and 1f showed a relative high 
radiochemical yield of the 
18
F-for-
19
F substitution, with 30% and 40% respectively, but it was 
not possible to match the RCY of the Baeyer-Villiger oxidation obtained with the 
acetophenone derivatives [
18
F]1c and [
18
F]1f. Therefore, 6-[
18
F]Fmtyr was obtained from 1g 
and 1h with an overall RCY of only 6% and 13%, respectively. However, the enantiomeric 
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purity of the final product using any of the latter precursors was > 98%. Thus, further efforts 
of the optimization of the Baeyer-Villiger reaction of these precursors seem to be justified. 
The nucleophilic radiosynthesis of 6-[
18
F]FDOPA by isotopic exchange could also be 
improved. In comparison to the overall RCY of 22% reported earlier the here optimized three-
step radiosynthetic procedure led to the desired amino acid in approximately 40% overall 
radiochemical yield with high a enantiomeric purity of > 96%. This was largely due to the 
increased RCY of the hydrolysis reaction. Furthermore, a better understanding of the isotopic 
exchange reaction was attained. The side product-A, as referred to by Wagner et al., was 
identified as diasmeromer 42b being produced by the epimerization of position 5 of the 
imidazolidinone system due to the basic conditions and high temperature during the isotopic 
exchange reaction. Further, the Baeyer-Villiger oxidation was also optimized by the use of 
trifluoroperacetic acid which reduced the time of reaction from 20 min to 10 min.  
Preliminary studies on the automation of the radiosynthesis of 6-[
18
F]FDOPA using a 
commercially available remote-controlled synthesis module showed that this is principally 
feasible for the three-step radiochemical procedure as developed here. However, further work 
is still needed, especially in order to overcome the technical problems (high pressure) 
originated from the harsh conditions needed to hydrolyze the imidazolidinone group.  
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ABBREVIATIONS 
 
(S)-Boc-BMI  (S)-(-)-1-Boc-2-tert-butyl-3-methyl-4-imidazolidinone 
(S)-Z-BMI  (S)-benzyl 2-tert-butyl-4-oxoimidazolidine-1-carboxylate 
2-[
18
F]Fphe  2-[
18
F]fluoro-L-phenylalanine 
2-[
18
F]Ftyr  2-[
18
F]fluoro-L-tyrosine 
6-[
18
F]FDOPA 3,4-Dihydroxy-6-[
18
F]fluoro-L-phenylalanine 
6-[
18
F]Fmtyr  6-[
18
F]Fluoro-L-m-tyrosine 
AA   amino acid 
AADC   aromatic L-amino acid decarboxylase 
ACN    acetonitrile 
Bq    Becquerel 
BTI   [bis(trifluoroacetoxy)iodo]benzene 
BuLi   butyllithium 
c.a.    carrier added 
CA   catecholamines 
CH   conventional heating 
CNS    central nervous system 
COMT  catechol-O-methyl transferase 
d    doublet (NMR) 
DA   dopamine 
DBH   dopamine β-hydroxylase 
DEA   diethylamine 
DIBAL-H  diisobutylaluminium hydride 
DIPA    diisopropylamine 
DIS   diiodosilane 
DMF    N,N-dimethylformamide 
DMP   Dess-Martin periodinane 
DMSO   dimethylsulfoxide 
DOPA   dihydroxyphenylalanine 
e.e.   enantiomeric excess 
EOB   end of bombardment 
EP   epinephrine 
FDG    2-[
18
F]fluorodeoxyglucose 
HFIP   1,1,1,3,3,3-hexafluoro-2-propanol 
HPLC    high performance liquid chromatography 
IMT   3-[
123
I]iodo-α-methyl-L-tyrosine 
Kryptofix 2.2.2 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane 
LDA   lithium diisopropylamine 
m    multiplet (NMR) 
M.p.    melting point 
MAOA  monoamine oxidase 
m-CPBA  m-chloroperoxybenzoic acid 
MET   [
11
C-methyl]-L-methionine 
MH   microwave heating 
MRI   magnetic resonance imaging 
n.c.a.   no-carrier-added 
NE   norepinephrine 
NET   neuroendocrine tumors 
NMR    nuclear magnetic resonance 
PD   Parkinson´s disease 
PET    positron emission tomography 
PH   phenylalanine hydroxylase 
PNMT   phenylethanolamine N-methyltransferase 
PSR   protein synthesis  
q    quartet (NMR) 
RCY    radiochemical yield 
s    singlet (NMR) 
SPECT  single photon emission computed tomography 
t   triplet (NMR) 
TBA   tetrabutylammonium 
TFA   trifluoroacetic acid 
THP   tetrahydropyranylether 
TLC    thin layer chromatography 
TMSDAM  trimethylsilyldiazomethane 
US   ultrasound 
VTA   ventral tegmental area 
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